Download full issue
ORIGINAL RESEARCH
REVIEWS
PRACTICAL EXPERIENCE
DURING THE IMPOSING OF THE NUMBER
___
ORIGINAL RESEARCH
УДК: 616.615.3-053.2-097:616.44-008.61 DOI: 10.20969/VSKM.2026.19(2).7-17
Clinico-immunological features of glomerulonephritis in children with thyroid hyperfunction
Abdurayim Sh. Arzikulov1, Umida A. Arzibekova1, Abdikadir G. Arzibekov1, Mariya A. Daminova2, Khusan S. Kadirov1 Feruza Kh. Sultanova1, Khakimakhon F. Makhsudova1, Kamoliddin Z. Salakhiddinov1, GulhayoA. Mamatkhujayeva1
1 Andijan State Medical Institute, 1 Atabekov str., 170100 Andijan, Uzbekistan
2 Kazan (Volga Region) Federal University, 74 Karl Marx str., 420012 Kazan, Russia
Abstract. Introduction. Children with chronic kidney disease often develop alterations of their endocrine system. The deficiency of thyroid hormones can lead to a worse prognosis in glomerulonephritis because these hormones influence the immune response and inflammatory processes in the kidneys. Aim. To study the influence of thyroid hyperfunction on the clinical manifestations of glomerulonephritis in children living in the Fergana Valley of the Republic of Uzbekistan, a region that was formerly endemic for goiter. Materials and Methods. This prospective study was based on clinical observations of children with glomerulonephritis and hyperthyroidism aged 3 to 15 years (n = 60) who were hospitalized in the nephrology department in the years of 2020–2024. Clinical-laboratory, instrumental, biochemical and immunological methods were used. The study assessed thyroid and renal functional parameters and immunological shifts. The data are presented as means (M) and standard deviations (SD), and as absolute (n) and relative (%) frequencies. Student’s t-test was used to determine the significance of differences between two mean values; qualitative variables were analyzed with Pearson’s χ2 test (differences were considered significant at p < 0.05). Results and Discussion. Among children with thyroid hyperfunction, there were acute glomerulonephritis with nephritic syndrome (41.9%) and the hematuric form of chronic glomerulonephritis (22.5%) identified. Correlation analysis showed a direct relationship between thyroid function indices and general and specific renal function parameters in children with glomerulonephritis and thyroid hyperfunction: Proteinuria correlated with free T3 (fT3), free T4 (fT4), and protein-bound iodine (PBI); hematuria correlated with fT3, fT4, and PBI; azotemia correlated with fT3, fT4, and PBI; daily urine output correlated with fT3, fT4, and PBI; and glomerular filtration correlated with fT3, fT4, and PBI. A direct correlation was also observed between immunological status indicators and thyroid status – namely between immunoglobulin classes and CD3+, CD4+ and CD8+ lymphocytes and fT3, fT4 and PBI – indicating the effect provided by thyroid on the immune reactivity of children with the nephrotic form of chronic glomerulonephritis. Conclusions. A significant influence of thyroid hormones on renal function was identified, suggesting that the thyroid gland was involved in the pathogenesis of glomerulonephritis. Given the identified characteristics of glomerulonephritis in children living in a goiter-endemic area, in cases of acute severe course, prognostically unfavorable clinical variants, persistent prolonged disease, or failure of therapy, thyroidal influence on disease progression should be considered.
Keywords: glomerulonephritis, hyperthyroidism, children, kidneys, thyroid gland, thyroid hormones.
For citation: Arzikulov, A.Sh.; Arzibekova, U.A.; Arzibekov, A.G.; et al. Clinico-immunological features of glomerulonephritis in children with thyroid hyperfunction. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 7-17. DOI: 10.20969/VSKM.2026.19(2).7-17.
REFERENCES
1. Арзибеков А.A., Арзикулов А.А., Арзибекова У.A. Клинико-функциональная характеристика больных детей с гломерулонефритом и повышенной функцией щитовидной железы // Международный журнал научной педиатрии. – 2023. – Т. 2, Вып. 6. – С. 244-248. Arzibekov AA, Arzikulov AA, Arzibekova UA. Kliniko-funktsional’naya kharakteristika bol’nykh detey s glomerulonefritom i povyshennoy funktsiyey shchitovidnoy zhelezy [Clinical and functional characteristics of children with glomerulonephritis and hyperthyroidism]. Mezhdunarodnyy zhurnal nauchnoy pediatrii [International Journal of Scientific Pediatrics]. 2023; 2 (6): 244-248. (In Russ.) DOI: 10.56121/2181-2926-2023-2-6-244-248
2. Карзакова Л.М., Автономова О.И., Кудряшов С.И., [и др.]. О связи клинических проявлений гломерулонефрита с особенностями тиреоидного статуса больных // Проблемы Эндокринологии. – 2020. – Вып. 66, № 2. – С.13-23. Karzakova LM, Avtonomova OI, Kudryashov SI, et al. O svyazi klinicheskikh proyavleniy glomerulonefrita s osobennostyami tireoidnogo statusa bol’nykh [On the relationship between clinical manifestations of glomerulonephritis and the characteristics of the thyroid status of patients].Problemy Endokrinologii [Problems of Endocrinology]. 2020; 66 (2): 13-23. (In Russ.) DOI: 10.14341/probl11825
3. Iglesias P, Bajo MA, Selgas R, Diez HJ. Thyroid dysfunction and kidney disease: an update. Rev Endocr Metab Disr. 2017; 18(1): 131-144. DOI: 10.1007/s11154-016-9395-7
4. Anderson JL, Gruppen EG, van Tienhoven-Wind L, et al. Glomerular filtration rate is related to free triiodothyronine in euthyroid patients: comparison of different equations for estimating renal function and creatinine clearance. Eur J Intern Med. 2018; 48: 94-99. DOI: 10.1016/j.ejim.2017.10.009
5. Agahee S, Amuzegar A, Honarvar M, et al. Relationship between thyroid hormones and kidney function decline. Review article. Thyroid Res. 2024; 17: 14. DOI: 10.1186/s13044-024-00201-y
6. Dousdampanis P, Trigka K, Vagenakis G, Fortunas K. Thyroid and kidneys: a complex interaction between health and disease. Int J Artif Organs. 2014; 37(1): 1-12. DOI: 10.5301/ijao.5000300
7. Наниева А.Р., Хутугова И.А., Джиоев И.Г. Функционально-морфологическое состояние почек при гипо- и гипертиреозе // Современные проблемы науки и образования. – 2023. – № 5. Naniyeva AR, Khutugova IA, Dzhioyev IG. Funktsional’no-morfologicheskoye sostoyaniye pochek pri gipo- i gipertireoze [Functional and morphological state of the kidneys in hypo- and hyperthyroidism]. Sovremennyye problemy nauki i obrazovaniya [Modern problems of science and education]. 2023; 5. (In Russ.) URL: https://science-education.ru/ru/article/view?id=32939 DOI: 10.17513/spno.32939
8. Калишевская М. А., Хамнуева Л. Ю., Орлова Г.М. Поражение почек при патологии щитовидной железы // Байкальский медицинский журнал. – 2011. – № 103 (4). – С.17-21. Kalishevskaya MA, Khamnuyeva LYU, Orlova GM. Porazheniye pochek pri patologii shchitovidnoy zhelezy [Kidney damage in thyroid pathology]. Baykal’skiy meditsinskiy zhurnal [Baikal Medical Journal]. 2011; 103 (4): 17-21. (In Russ.)
9. Мельник А.А. Дисфункция щитовидной железы и заболевания почек // Почки. - 2019. – Т. 8, № 1. – С. 68-78. Mel’nik AA. Disfunktsiya shchitovidnoy zhelezy i zabolevaniya pochek [Thyroid dysfunction and kidney disease]. Pochki [Kidneys]. 2019; 8 (1): 68-78. (In Russ.) DOI: 10.22141/2307-1257.8.1.2019.157798
10. Болотова Е.В., Дудникова А.В., Кияницкая И.С. Хроническая болезнь почек у пациентов с нарушением функции щитовидной железы // Клиническая нефрология. – 2020. – № 12 (4). – C.70–74. Bolotova YEV, Dudnikova AV, Kiyanitskaya IS. Khronicheskaya bolezn’ pochek u patsiyentov s narusheniyem funktsii shchitovidnoy zhelezy [Chronic kidney disease in patients with thyroid dysfunction]. Klinicheskaya nefrologiya [Clinical nephrology]. 2020; 12 (4): 70–74. (In Russ.) DOI: 10.18565/nephrology.2020.4.70-74
11. Салахова А.И., Абдусагатова Ш.Ш., Яхяева К.З. Изменения показателей гормонов щитовидной железы у детей с хроническим гломерулонефритом нефротической формой // Медицина: теория и практика. – 2019. – № 4 (S). – C. 489-489. Salakhova AI, Abdusagatova SHSH, Yakhyayeva KZ. Izmeneniya pokazateley gormonov shchitovidnoy zhelezy u detey s khronicheskim glomerulnefritom nefroticheskoy formoy. [Changes in thyroid hormone levels in children with chronic nephrotic glomerulonephritis]. Meditsina: teoriya i praktika [Medicine: Theory and Practice]. 2019; 4 (S): 489-489. (In Russ.)
12. Gu Qh, Cao X, Mao Xm, et al. Significance of thyroid dysfunction in the patients with primary membranous nephropathy. BMC Nephrol. 2022; 23: 398. DOI: 10.1186/s12882-022-03023-y
13. Arzikulov ASh, Abdumukhtarova MZ, Mamajanov ZA, et al. Comparative study of the resistance level of the organism in schoolchildren with socio-psychological disadaptation among Uzbek population studying in different conditions. BIO Web of Conferences. 2024; 84: 03029. DOI: 10.1051/bioconf/20248403029
14. Исмаилов С.И., Рашитов М.М. Прогресс в области профилактики йододефицитных заболеваний в Республике Узбекистан (1998–2016) // Клиническая и экспериментальная тиреоидология. – 2016. – № 12(3). – С.20-24. Ismailov SI, Rashitov MM. Progress v oblasti profilaktiki yododefitsitnykh zabolevaniy v Respublike Uzbekistan (1998–2016) [Progress in the Field of Prevention of Iodine Deficiency Disorders in the Republic of Uzbekistan (1998–2016)]. Klinicheskaya i eksperimental’naya tireoidologiya [Clinical and Experimental Thyroidology]. 2016;12(3):20-24. (In Russ.) DOI: 10.14341/ket2016320-24
15. Казакова Р. Распространенность эндемического зоба в Республике Узбекистан и его профилактика // Молодые ученые. – 2023. – № 1(13). – С.38–40. Kazakova R. Rasprostranennost’ endemicheskogo zoba v Respublike Uzbekistan i yego profilaktika [Prevalence of Endemic Goiter in the Republic of Uzbekistan and its Prevention]. Molodyye uchenyye [Young Scientists]. 2023; 1(13):38–40. (In Russ.)
16. Соловьев В.Б., Кальянов М.В. Йоддефицит и его профилактика: современное состояние проблемы // Современные проблемы науки и образования. – 2025. – № 3. Solov’yev VB, Kal’yanov MV. Yoddefitsit i yego profilaktika: sovremennoye sostoyaniye problemy [Deficiency and Its Prevention: Current State of the Problem]. Sovremennyye problemy nauki i obrazovaniya Iodine [Modern Problems of Science and Education]. 2025; 3. (In Russ.) URL: https://science-education.ru/ru/article/view?id=34051 DOI: 10.17513/spno.34051
17. Jain D, Aggarwal HK, Pawan Kumar YM, Jain P. Evaluation of thyroid dysfunction in patients with nephrotic syndrome. Med Pharm Rep. 2019; 92(2): 139-144. DOI: 10.15386/mpr-1091
УДК 615.036 DOI: 10.20969/VSKM.2026.19(2).18-23
Analysis of the range of antacid medications approved for use in pediatric practice
Tatiana A. Bredikhina1, Sergey S. Popov1, Elena V. Mikhailova1, Diana V. Shilnikova1
1 Voronezh State Medical University, 10 Studencheskaya str., 394036 Voronezh, Russia
Abstract. Introduction. Developing a reasonable range of medications is an important component of ensuring the quality of pharmaceutical care in pharmacies. Antacid medications are a popular group for treating gastrointestinal diseases in children. Aim. To analyze the range of antacid medications approved for use in pediatric practice, available on the country-wide and regional pharmaceutical markets in Russia. Materials and Methods. The range of antacid medications was analyzed using data from the Unified Register of Medicines of the Eurasian Economic Union and the pharmacy product search and reservation website “yaVapteke.ru” (Voronezh, Russia). The following methods were used: Content analysis, structural analysis, comparison, and grouping methods. Results and Discussion. Russian pharmaceutical market offers nine different formulations of antacids approved for pediatric use, comprising the active ingredients of 49 trade names. Voronezh pharmacies offer all formulations of medications registered in Russia, and the majority (59.2%) of trade names. Domestic medications, primarily in liquid dosage forms, such as suspension and gel, predominate in the product range of the Russian country-wide and regional pharmaceutical markets. Only three formulations of the medications in this group are included in clinical guidelines describing the treatment regimens for children and adolescents. Age-specific differences have been established in antacid use, as outlined in clinical guidelines and the general characteristics of the medications. Conclusion. Pharmaceutical counseling plans for pharmacy customers purchasing antacid medications for children and adolescents must consider the age restrictions outlined in clinical guidelines. The current trend in improving the quality of pharmaceutical care is to develop a reasonable product range and counseling plans that provide recommendations for the selection and use of medications for children of various age groups.
Keywords: antacid medications, general characteristics of drugs, assortment, pediatrics, gastritis, gastroesophageal reflux disease
For citation: Bredikhina, T.A.; Popov, S.S.; Mikhailova, E.V.; Shilnikova, D.V. Analysis of the range of antacid medications approved for use in pediatric practice. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 18-23. DOI: 10.20969/VSKM.2026.19(2).18-23.
REFERENCES
1. Единый реестр зарегистрированных лекарственных средств Евразийского экономического союза. Ediny`j reestr zaregistrirovanny`x lekarstvenny`x sredstv Evrazijskogo e`konomicheskogo soyuza [Unified Register of Registered Medicines of the Eurasian Economic Union]. (In Russ.) Режим доступа [URL]:https://pharma.eaeunion.org/pharma/registers/26/ru/register
2. Клинические рекомендации «Гастрит и дуоденит у детей. 2024». – 88 c. Klinicheskie rekomendacii «Gastrit i duodenit u detej - 2024» [Clinical guidelines «Gastritis and duodenitis in children - 2024»]. 2024; 88 p. (In Russ.) Режим доступа [URL]: https://cr.minzdrav.gov.ru/preview-cr/837_1
3. Клинические рекомендации «Гастроэзофагеальная рефлюксная болезнь у детей. 2025». – 68 c. Klinicheskie rekomendacii «Gastroe`zofageal`naya reflyuksnaya bolezn` u detej. 2025» [Clinical guidelines «Gastroesophageal reflux disease in children. 2025»]. 2025; 68 p. (In Russ.) Режим доступа [URL]: https://cr.minzdrav.gov.ru/preview-cr/402_2
4. Педиатрический и неонатальный формуляр лекарственных средств (детский многопрофильный стационар) : методические рекомендации для организаторов здравоохранения и врачей / под ред. А.К. Хаджидиса. – СПб. : СПбГЭУ, 2020 – 382 с. Pediatricheskij i neonatal`ny`j formulyar lekarstvenny`x sredstv (detskij mnogoprofil`ny`j stacionar) : metodicheskie rekomendacii dlya organizatorov zdravooxraneniya i vrachej pod redakciey AK Xadzhidisa [Pediatric and neonatal drug formulary (children’s multidisciplinary hospital): guidelines for healthcare organizers and physicians, ed AK Xadzhidis]. SPb : SPbGEU [St Petersburg: SPbGEU]. 2020; 382 р. (In Russ.)
5. Радциг Е.Ю., Константинов Д.И. Внепищеводные проявления гастроэзофагеальной рефлюксной болезни: взгляд оториноларинголога // Терапевтический архив. – 2021. – Т. 93, №4. – С. 521-525. Radcig EYu, Konstantinov DI. Vnepishhevodny`e proyavleniya gastroe`zofageal`noj reflyuksnoj bolezni: vzglyad otorinolaringologa [Extraesophageal manifestations of gastroesophageal reflux disease: an otolaryngologist’s perspective]. Terapevticheskij arxiv [Therapeutic archive]. 2021; 93, (4): 521-525. (In Russ.) DOI: 10.26442/00403660.2021.04.200814
6. Решение Совета Евразийской экономической комиссии от 3 ноября 2016 г. N 88 «Об утверждении требований к инструкции по медицинскому применению лекарственного препарата и общей характеристике лекарственного препарата для медицинского применения». Reshenie Soveta Evrazijskoj e`konomicheskoj komissii ot 3 noyabrya 2016 goda N 88 «Ob utverzhdenii trebovanij k instrukcii po medicinskomu primeneniyu lekarstvennogo preparata i obshhej xarakteristike lekarstvennogo preparata dlya medicinskogo primeneniya» [Decision of the Council of the Eurasian Economic Commission of November 3, 2016 # 88 «On approval of requirements for instructions for medical use of a medicinal product and general characteristics of a medicinal product for medical use»]. 2016. (In Russ.) Режим доступа [URL]: https://eec.eaeunion.org/comission/department/deptexreg/formirovanie-obshchikh-rynkov/akty-v-sfere-ls.php
7. Российский национальный педиатрический формуляр / Союз педиатров России; гл. ред. А.А. Баранов. – М.: ГЭОТАР-Медиа, 2009. – 908 с. Soyuz pediatrov Rossii [Union of Pediatricians of Russia]; AA Baranov, ed. Rossijskij nacional`ny`j pediatricheskij formulyar [Russian National Pediatric Formulary]. Moskva: GEOTAR-Media [Moscow: GEOTAR-Media]. 2009; 908 р. (In Russ.)
8. Росстат. Здравоохранение. Заболеваемость населения по основным классам болезней. Rosstat. Zdravooxranenie; Zabolevaemost` naseleniya po osnovny`m klassam boleznej [Healthcare; Population Morbidity by Major Disease Classes]. (In Russ.) Режим доступа [URL]: https://rosstat.gov.ru/folder/13721
9. Смирнова А.А., Токтогулова Н.А., Атабаева Л.И. [и др.] Систематический обзор клинических рекомендаций по лечению гастроэзофагеальной рефлюксной болезни // Бюллетень науки и практики. – 2024. – Т. 10, № 2. – С. 155-171. Smirnova AA, Toktogulova NA, Atabaeva LI, et al. Sistematicheskij obzor klinicheskix rekomendacij po lecheniyu gastroe`zofageal`noj reflyuksnoj bolezni [A systematic review of clinical guidelines for the treatment of gastroesophageal reflux disease]. Byulleten` nauki i praktiki [Bulletin of Science and Practice]. 2024; 10 (2): 155-171. (In Russ.)
10. Шихнабиева Э.Д., Шихнебиев Д.А., Кишев М.М., Абуков Р.М. Внутриротовые проявления гастроэзофагеальной рефлюксной болезни у лиц подросткового возраста // Вестник новых медицинских технологий. – 2020. – № 5. – С. 65-69. Shixnabieva ED, Shixnebiev DA, Kishev MM, Abukov RM. Vnutrirotovy`e proyavleniya gastroe`zofageal`noj reflyuksnoj bolezni u licz podrostkovogo vozrasta [Intraoral manifestations of gastroesophageal reflux disease in adolescents]. Vestnik novy`x medicinskix texnologij [Bulletin of New Medical Technologies]. 2020; (5): 65-69. (In Russ.) DOI: 10.24411/2075-4094-2020-16656
11. ЯвАптеке: Лекарства и цена в аптеках. YavApteke: Lekarstva i cena v aptekax [YavApteke: Medicines and prices in pharmacies]. (In Russ.) Режим доступа [URL]: https://yavapteke.ru/
УДК: 615.31 DOI: 10.20969/VSKM.2026.19(2).24-30
Studying the local manufacturing content of pharmaceutical substances used in inhalation drugs
Anastasia V. Kabanova1, Svetlana N. Egorova1, Elmira A. Serikbayeva2
1Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia
2 Kazakh National Medical University named after S.D. Asfendiyarov, 94 Tole bi str., 050012 Almaty, Kazakhstan
Abstract. Introduction. Drug safety is a part of national security. An important task is to develop a full-cycle domestic pharmaceutical manufacture, including the production of local pharmaceutical substances. Aim. To study the local manufacturing content of pharmaceutical substances included in inhalation drugs. Materials and Methods. The study objects were data from the Common Register of the Authorized Medicinal Products registered within the EAEU, the State Register of Medicines, and scientific literature data. To identify the ratio of shares of domestic and foreign inhalation drugs and their dependence on the raw material origin, a methodology was used to assess the degree of the local content of drug production considering the country of origin of the pharmaceutical substance. Results and Discussion. The study showed that about 50% of domestic inhalation drugs are made from imported pharmaceutical substances, while 40% are fully imported. An analysis of data on the registration of inhalation drugs since 2022 has revealed that 86% of the brand names were registered for the first time. The main suppliers of pharmaceutical substances are India (66%) and Italy (22%). Only 3% of pharmaceutical substances are produced by domestic enterprises. A Pareto analysis has shown that 5 countries (India, Italy, the United Kingdom, Germany, and Switzerland) supply 78% of pharmaceutical substances. 61% of international non-proprietary names of pharmaceutical substances are registered in both the State Register of Medicines and the Common Register of the Authorized Medicinal Products registered within the EAEU. Conclusions. About 90% of inhalation drugs are manufactured from imported pharmaceutical substances, while only 1% of drugs are produced domestically from local pharmaceutical substances. A high demand was identified for establishing our local manufacturing content pharmaceutical substances to address the issue of import substitution.
Keywords: inhalation drugs, pharmaceutical substances.
For citation: Kabanova, A.V.; Egorova, S.N.; Serikbayeva, E.A. Studying the local manufacturing content of pharmaceutical substances used in inhalation drugs. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 24-30. DOI: 10.20969/VSKM.2026.19(2).24-30.
REFERENCES
1. Об утверждении Стратегии развития фармацевтической промышленности Российской Федерации на период до 2020 года: приказ Минпромторга РФ от 23.10.2009 N 965 Ob utverzhdenii Strategii razvitiya farmacevticheskoj promyshlennosti Rossijskoj Federacii na period do 2020 goda: prikaz Minpromtorga RF ot 23/10/2009 N 965 [On approval of the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period up to 2020: Order of the Government of the Russian Federation of 23/10/2009 N 695]. (In Russ.) Режим доступа [URL]: https://www.consultant.ru/document/cons_doc_LAW_94066/c50c8e04fc20b142c896bee42b5e3cf279f47baa/
2. Об утверждении Стратегии развития фармацевтической промышленности Российской Федерации на период до 2030 года : распоряжение Правительства РФ от 07/06/2023 N 1495-р (ред. от 21.10.2024) Ob utverzhdenii Strategii razvitiya farmacevticheskoj promyshlennosti Rossijskoj Federacii na period do 2030 goda: rasporyazhenie Pravitel’stva RF ot 07.06.2023 N 1495-r (redakciya ot 21/10/2024) [On approval of the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period up to 2030: Order of the Government of the Russian Federation of 07.06.2023 N 1495-r (ed of 21.10.2024)]. (In Russ.) Режим доступа [URL]: https://www.consultant.ru/document/cons_doc_LAW_449976/f62ee45faefd8e2a11d6d88941ac66824f848bc2/
3. Костин К.Б., Шанава Л.А. Ключевые тенденции развития российского фармацевтического рынка в условиях неопределенности // Экономика, предпринимательство и право. – 2022. – Т.12, № 5. – С. 1639-1658. Kostin KB, Shanava LA. Klyuchevye tendencii razvitiya rossijskogo farmacevticheskogo rynka v usloviyah neopredelennosti [Key trends in the development of the Russian pharmaceutical market amidst uncertainty]. Ekonomika, predprinimatel’stvo i parvo [Journal of Economics, Entrepreneurship and Law]. 2022; 12(5): 1639–1658. (In Russ.) DOI: 10.18334/epp.12.5.114635
4. Пронузо Д.О. Обоснование выбора стратегии развития инноваций в фармацевтических организациях в условиях импортозамещения // Экономика: вчера, сегодня, завтра. – 2024. –Т. 14, № 7А. – С. 403-408. Pronuzo DO. Obosnovanie vybora strategii razvitiya innovatsii v farmatsevticheskikh organizatsiyakh v usloviyakh importozameshcheniya [Foundation of the choice of a strategy for the development of innovations in pharmaceutical organizations in the context of import substitution]. Ekonomika: vchera, segodnya, zavtra [Economics: Yesterday, Today and Tomorrow]. 2024; 14 (7А): 403-408. (In Russ.)
5. Новская H.C. Локальное производство как способ снижения внешнеэкономических рисков в фармацевтической промышленности // KANT. – 2025. – Т. 54, № 1. – С. 122-128. Novskaya HC. Lokal’noe proizvodstvo kak sposob snizheniya vneshneekonomicheskih riskov v farmacevticheskoj promyshlennosti. [Local production as a way to reduce foreign economic risks in the pharmaceutical industry]. KANT [KANT]. 2025; 54(1): 122-128. (In Russ.) DOI: 10.24923/2222-243Х.2025-54.18
6. Галимзянова Р.Ю., Пестерникова Н.Н., Хисамиева Д.Р., Галлямов Э.Р. Сравнение мнения населения о зарубежных и отечественных лекарственных препаратах // Научный альманах. – 2017. – Т.35, № 9-2. – С. 54-56. Galimzyanova RYu, Pesternikova NN, Hisamieva DR, Gallymov ER. Sravnenie mneniya naseleniya o zarubezhnyh i otechestvennyh lekarstvennyh preparatah [A comparison of public opinion on foreign and domestic medication]. Nauchnyj al’manah [Science Almanac]. 2017; 35(9-2): 54-56. (In Russ.) DOI: 10.17117/na.2017.09.02.054
7. Информационные бюллетени ВОЗ // Неинфекционные заболевания. – 2024. Informacionnye byulleteni VOZ [Fact sheets WHO]. Neinfekcionnye zabolevaniya [Noncommunicable diseases]. 2024. (In Russ.) Режим доступа [URL]: https://www.who.int/ru/news-room/fact-sheets/detail/noncommunicable-diseases
8. Линник С.А, Авдеев С.Н., Туменко Е.Е. Влияние динамики стоимости лекарственных препаратов для лечения пациентов с бронхообструктивными заболеваниями на доступность лекарственного лечения в Российской Федерации // Менеджер здравоохранения. – 2025. – № 1. – С. 66-75. Linnik SA, Avdeev SN, Tumenko EE. Vliyanie dinamiki stoimosti lekarstvennyh preparatov dlya lecheniya pacientov s bronhoobstruktivnymi zabolevaniyami na dostupnost’ lekarstvennogo lecheniya v rossijskoj federacii [The influence of the dynamics of the cost of drugs for the treatment of patients with broncho-obstructive diseases on the availability of drug treatment in the Russian Federation]. Menedzher zdravoohraneniya [Manager Zdravoochranenia]. 2025; 1: 66-75. (In Russ.) DOI: 10.21045/1811-0185-2025-1-66-75
9. Министерство здравоохранения Российской Федерации. Клинические рекомендации «Бронхиальная астма» – 2024. Ministerstvo zdravoohraneniya Rossijskoj Federacii [Ministry of Health of the Russian Federation]. Klinicheskie rekomendacii «Bronhial’naya astma» [Clinical Recommendations «Bronchial asthma»]. 2024. (In Russ.) Режим доступа [URL]: https://cr.minzdrav.gov.ru/view-cr/359_3
10. Министерство здравоохранения Российской Федерации. Клинические рекомендации «Хроническая обструктивная болезнь лёгких» – 2024. Ministerstvo zdravoohraneniya Rossijskoj Federacii [Ministry of Health of the Russian Federation]. Klinicheskie rekomendacii «Hronicheskaya obstruktivnaya bolezn’ lyogkih » [Clinical Recommendations «Chronic obstructive pulmonary disease »]. 2024. (In Russ.) Режим доступа [URL]: https://cr.minzdrav.gov.ru/view-cr/603_3
11. Об утверждении перечня жизненно необходимых и важнейших лекарственных препаратов, а также перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи : распоряжение Правительства РФ от 12.10.2019 № 2406-р (ред. от 09.06.2023) Ob utverzhdenii perechnya zhiznenno neobhodimyh i vazhnejshih lekarstvennyh preparatov, a takz he perechnej lekarstvennyh preparatov dlya medicinskogo primeneniya i minimal’nogo assortimenta lekarstvennyh preparatov, neobhodimyh dlya okazaniya medicinskoj pomoshchi : rasporyazhenie Pravitel’stva RF ot 12/10/2019 № 2406-r (red. ot 09/06/2023) [On approval of the list of vital and essential medicines, as well as lists of medicines for medical use and the minimum range of medicines needed for medical care: Order of the Government of the Russian Federation of 12/10/2019 № 2406-r (ed. of 09/06/2023)]. (In Russ.). Режим доступа [URL]: www.consultant.ru/document/cons_doc_LAW_335635/
12. Мельников А.М., Петров А.Ю. Вопросы практического применения ABC анализа // Современные проблемы здравоохранения и медицинской статистики. – 2024. – № 3. – С. 81-94. Mel’nikov AM, Petrov AYu. Voprosy prakticheskogo primeneniya ABC analiza [Issues of practical application of ABC analysis]. Sovremennye problemy zdravoohraneniya i medicinskoj statistiki [Current problems of health care and medical statistics]. 2024; 3: 81-94. (In Russ.) DOI: 10.24412/2312-2935-2024-3-81-94
13. Халимова А.А., Орлов А.С., Таубэ А.А. Анализ локализации производства биотехнологических лекарственных препаратов в России с учетом происхождения активных фармацевтических субстанций // Ведомости Научного центра экспертизы средств медицинского применения. Регуляторные исследования и экспертиза лекарственных средств. – 2024. – Т.14, № 1. – С. 53–61. Halimova AA, Orlov AS, Taube AA. Analiz lokalizacii proizvodstva biotekhnologicheskih lekarstvennyh preparatov v Rossii s uchetom proiskhozhdeniya aktivnyh farmacevticheskih substancij [Analysis of Biopharmaceutical Manufacturing Localisation in Russia Considering the Country of Origin of Active Pharmaceutical Ingredients]. Vedomosti Nauchnogo centra ekspertizy sredstv medicinskogo primeneniya. Regulyatornye issledovaniya i ekspertiza lekarstvennyh sredstv [Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation.]. 2024; 14(1): 53–61. (In Russ.) DOI: 10.30895/1991-2919-2024-14-1-53-61
14. Единый реестр зарегистрированных лекарственных средств Евразийского экономического союза. Edinyj reestr zaregistrirovannyh lekarstvennyh sredstv Evrazijskogo ekonomicheskogo soyuza [Unified Register of medical devices registered within the EAEU]. (In Russ.)]. Режим доступа [URL]: https://pharma.eaeunion.org/pharma/registers/26/ru/register
15. Государственный реестр лекарственных средств. Gosudarstvennyj reestr lekarstvennyh sredstv [State Register of Medicines]. (In Russ.) Режим доступа [URL]: http://grls.rosminzdrav.ru
УДК 616.311.2–002 DOI: 10.20969/VSKM.2026.19(2).31-36
Dental status with the clinical, immunological and microbiological parameters of the mouth in alcohol-dependent patients, based on their treatment regimens
Anastasia V. Kirtaeva1, Alena V. Nikolaeva2, Mikhail A. Kulikov1
1 I. N. Ulyanov Chuvash State University, 15 Moscow Ave., 428000 Cheboksary, Russia
2 Beautiful Dent, 30/1 Gagarin str., 428022 Cheboksary, Russia
Abstract. Introduction. Long-term regular alcohol abuse leads to a non-specific inflammatory reaction in the mouth of and to some systemic diseases in the macroorganism. Aim. To evaluate the dental status with clinical, immunological and microbiological parameters of the mouth in alcohol-dependent patients undergoing various treatment regimens. Materials and Methods. Dental statuses were assessed in two study groups (n=42) with microbiome analysis using the Dentoscreen test system and cellular immunity indicators. Levels of lymphocytes, neutrophils and macrophages/monocytes were evaluated based on the following treatment schemes: Braunodin+Prontosan and Braunodin+Emalan. Complaints, such as edema, hyperemia, pain, etc., and clinical data on GI, PMA, SBI, and CPITN indices were evaluated. Results and Discussion. Patients with alcohol dependence syndrome are characterized by a pronounced inflammatory picture (SBI index 50.0 (16.7; 5.0)) with a shift in immunological and microbiological parameters: Their levels of neutrophils increased (from 94.0 (89.0;97.0) to 99.0 (97.0;100.0) per 100 cells), the level of monocytes/macrophages decreased 5-fold and lymphocytes 2-fold compared with reference values, Porphyromonas gingivalis prevailing with a high clinically significant titer (102000.0 (77000.0;136000.0) GE/ml. After treatment, the best results were observed 30 days later in both groups. Bleeding decreased from 7.0 (7.0;8.0) and 5 (4.0;6.0) days in groups 1 and 2, respectively (p<0.0001). PMA level decreased from 39 to 7%, SBI from 37.91 to 7%, GI from 1.8 to 0.35 points, CPITN from 2.7 to 1 point. Immunological and microbiological indicators decreased to reference values in both study groups. Conclusions. Thus, the effect of alcohol on the oral cavity contributes to the activation of immune system cells, changes in the level of P. gingivalis, which manifests itself in clinical signs of inflammation. At the same time, the treatment schemes Braunodin+Prontosan and Braunodin+Emalan show good results. However, according to clinical signs, the Braunodin+Emalan treatment scheme showed the best results.
Keywords: microbiome, oral cavity, periodontal disease, Dentoscreen, inflammation, alcohol dependence.
For citation: Kirtaeva, A.V.; Nikolaeva, A.V.; Kulikov, M.A. Dental status with the clinical, immunological and microbiological parameters of the mouth in alcohol-dependent patients, based on their treatment regimens. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 31-36. DOI: 10.20969/VSKM.2026.19(2).31-36.
REFERENCES
1. Гажва С.И., Киртаева А.В. Синдром алкогольной зависимости в регионе (анализ проблемы) // Международный научно-исследовательский журнал. – 2021. – № 4–2 (106). – С. 103–107. Gazhva SI, Kirtaeva AV. Sindrom alkogol`noj zavisimosti v regione (analiz problemy`) [Alcohol dependence syndrome in the region (problem analysis)]. Mezhdunarodny`j nauchno-issledovatel`skij zhurnal [International Scientific Research Journal]. 2021; 106(4): 103–107. (In Russ.)
2. Горячев Д.Н. Челюстно-лицевые маркеры хронического алкоголизма // Неврологический вестник. – 2011. – № 12(2). – С. 58–61. Goryachev DN. Chelyustno-licevy`e markery` xronicheskogo alkogolizma [Maxillofacial markers of chronic alcoholism]. Nevrologicheskij vestnik. [Neurological Bulletin]. 2011;12(2):58–61. (In Russ.) DOI: 10.17816/nb13680
3. Копенкин М.А., Полушина Л.Г., Семенцова Е.А., [и др.] Изменение химических параметров ротовой жидкости при возраст-ассоциированных стоматологических заболеваниях // Уральский медицинский журнал. – 2024. – № 23(3). – С. 46–58. Kopenkin MA, Polushina LG, Sementsova EA, et al. Izmenenie ximicheskix parametrov rotovoj zhidkosti pri vozrast-associirovanny`x stomatologicheskix zabolevaniyax [Changes in the chemical parameters of the oral fluid in age-associated dental diseases]. Ural`skij medicinskij zhurnal [Ural Medical Journal]. 2024;23(3):46–58. (In Russ.) DOI: 10.52420/umj.23.3.46
4. Янушевич О.О., Ахмедов Г.Д., Панин А.М., [и др.]. Микроэкология полости рта и инфекционно–воспалительные осложнения в хирургической стоматологии: монография. – Москва: Практическая медицина, 2019. – 192 с. Yanushevich OO, Akhmedov GD, Panin AM, et al. Mikroe`kologiya polosti rta i infekcionno–vospalitel`ny`e oslozhneniya v xirurgicheskoj stomatologii: monografiya [Microecology of the oral cavity and infectious and inflammatory complications in surgical dentistry: a monograph]. Moskva: Prakticheskaya meditsina [Moscow: Practical Medicine]. 2019; 192 p. (In Russ.)
5. Балмасова И.П., Царев В.Н., Янушевич О.О., [и др.]. Микроэкология пародонта: монография. – Москва: Практическая медицина, 2021. – 264 с. Balmasova IP, Tsarev VN, Yanushevich OO, et al. Mikroe`kologiya parodonta: monografiya [Microecology of periodontal disease: monograph]. Moskva: Prakticheskaya meditsina [Moscow: Practical Medicine]. 2021; 264p. (In Russ.)
6. Усманова И.Н. [и др.] Роль условно–патогенной микрофлоры полости рта в развитии воспалительных заболеваний пародонта и слизистой полости рта (обзор литературы) // Вестник Южно-уральского государственного университета. – 2015. – № 15(2). – С. 37–44. Usmanova IN et al. Rol` uslovno–patogennoj mikroflory` polosti rta v razvitii vospalitel`ny`x zabolevanij parodonta i slizistoj polosti rta (obzor literatury`) [The role of conditionally pathogenic microflora of the oral cavity in the development of inflammatory periodontal diseases and oral mucosa (literature review)]. Vestnik Yuzhno-ural`skogo gosudarstvennogo universiteta [Bulletin of the South Ural State University]. 2015;15(2):37–44. (In Russ.)
7. Янушевич О.О., Вавилова Т.П., Островская И.Г. Десневая жидкость: учебное пособие. – Москва: “ГЭОТАР-Медиа”, 2019. – 152 с. Yanushevich OO, Vavilova TP, Ostrovskaya IG. Desnevaya zhidkost`: uchebnoe posobie [Gingival fluid: a textbook]. Moskva: GEOTAR–Media [Moskow: GEOTAR–Media]. 2019; 152 р. (In Russ.)
8. Baker JL, Bor B, Agnello M, et al. Ecology of the oral microbiome: beyond bacteria. Trends in microbiology: electronic journal. 2017; 25(5):362–374. DOI: 10.1016/j.tim.2016.12.012
9. Fan X, Alekseyenko AV, Wu J, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population–based nested case–control study. Gut: electronic journal. 2018; 67(1):120–127. DOI: 10.1136/gutjnl 2016.312580
10. Jabbour Z, Nascimento C, Kotake BGS. Assessing the oral microbiota of healthy and alcohol–treated rats using whole–genome DNA probes from human bacteria. Archives of oral biology: electronic journal. 2013; 58(3):317–323. DOI: 10.1016//j.archoralbio.2012.07.017
11. Kirtaeva AV, Gazhva SI. Estimation of mast cells in the rat gingiva mucous membrane in the normal condition and under the conditions of experimental alcohol intoxication [Electronic source] Indo American Journal of Pharmaceutical Sciences: electronic journal. 2020; 7(2): 530–536.
12. Slocum C, Kramer C, Genco CА. Immune dysregulation mediated by the oral microbiome: potential link to chronic inflammation and atherosclerosis. Journal of internal medicine: electronic journal. 2016; 280(1):114–128. DOI: 10.1111//joim.12476
УДК 618.3 DOI: 10.20969/VSKM.2026.19(2).37-43
Using a vaginal trainer in the treatment of pelvic organ prolapse after vaginal birth
Pavel A. Koshulko1,2, Vasilissa V. Levitina3, Ilona A. Bulygina4, Yulia O. Lukina4, Alina R. Dmitrieva4, Aidan N. Mamedova4
1 Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Sq., 603005 Nizhny Novgorod, Russia
2 City Hospital No. 28 of the Moscow District in Nizhny Novgorod, 7 Chaadaev str., 603035 Nizhny Novgorod, Russia
3 City Clinical Hospital No. 7, 81 Votkinsk Highway, 426039, Izhevsk, Udmurt Republic, Russia
4 Ryazan State Medical University named after Academician I. P. Pavlov, 9 Vysokovoltnaya str., 390026 Ryazan, Russia
Abstract. Introduction. Pelvic organ prolapse is a common manifestation of pelvic floor dysfunction in women, associated with anatomical displacement of pelvic organs. Aim. To evaluate the effectiveness of conservative treatment of pelvic organ prolapse after spontaneous vaginal delivery using the Elise 2 vaginal electrical stimulator (TensCare). Materials and Methods. The study included 200 women aged 18–35 years, examined 5 months after delivery. The study group (n=100) received electrical stimulation therapy, while the control group (n=100) was observed. The groups were comparable in terms of age, anthropometric parameters, and comorbidities (p>0.05). The treatment lasted 6 months. Effectiveness was assessed using POP-Q, perineometry, and the PFDI-20 questionnaire. The data were processed statistically using the licensed software package Statistica 14. Differences were considered statistically significant at p<0.05. Results and Discussion. After 3 months, pelvic floor muscle strength increased by 18–22% (p<0.05), while stress urinary incontinence decreased by 40% and foreign body sensation by 55%. After 6 months, perineometry values were higher in the study group (50.39±1.62 and 54.43±1.5 mmHg) compared to controls (43.47±1.6 and 49.86±1.72 mmHg; p<0.05). PFDI-20 scores decreased more than twofold. A negative correlation between muscle strength and symptom severity was identified (r = -0.62; p<0.05). Conclusions. The use of the Elise 2 vaginal electrical stimulator improves pelvic floor function, reduces prolapse symptoms, and enhances quality of life, confirming its effectiveness in the postpartum period.
Keywords: pelvic organ prolapse, Elise 2 vaginal stimulator (TensCare), spontaneous vaginal delivery, stress urinary incontinence
For citation: Koshulko, P.A.; Levitina, V.V.; Bulygina, I.A.; et al. Using a vaginal trainer in the treatment of pelvic organ prolapse after vaginal birth // The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 37-43. DOI: 10.20969/VSKM.2026.19(2).37-43.
REFERENCES
1. Пролапс тазовых органов у женщин молодого возраста // Российский вестник акушера-гинеколога. – 2023. – Т. 23, вып. (6-2). – С. 142-148. Prolaps tazovyh organov u zhenshchin molodogo vozrasta [Pelvic organ prolapse in young women]. Rossijskij vestnik akushera-ginekologa [Russian Bulletin of Obstetrics and Gynecology]. 2023;23(6-2):142-148. (In Russ.)
2. Hilde G, Stær-Jensen J, Siafarikas F, et al. Postpartum pelvic floor muscle training, levator ani avulsion and levator hiatus area: a randomized trial. Int Urogynecol J. 2023; 34(2):413-423. DOI:10.1007/s00192-022-05406-z
3. Zhang R, Barakat R, et al. Influence of pelvic floor muscle training alone or in general physical activity programs during pregnancy on urinary incontinence, episiotomy, and severe perineal tears: systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2024; 103(6):1015-1027. DOI:10.1111/aogs.14744
4. Bø K, Sherburn M. Evaluation of pelvic floor muscle strength and endurance using vaginal devices. Neurourol Urodyn. 2022; 41(2): 345–353. DOI: 10.1002/nau.24834
5. Schütze S, Heinloth M, Uhde M, et al. The effect of pelvic floor muscle training on pelvic floor function and sexual function in primiparous women: randomized study. Archives of Gynecology and Obstetrics. 2022; 306(3): 785-793. DOI: 10.1007/s00404-022-06542-z
6. Huang Y, Huang Z, Ou Y, et al. Meta-analysis of the therapeutic effect of electrical stimulation combined with pelvic floor muscle exercise on female pelvic floor dysfunction. European Journal of Medical Research. 2024; 29 (1): 380. DOI:10.1186/s40001-024-01979-1
7. Sartore A, Scalia MS, Mangino FP, et al. Pelvic floor function after third and fourth degree perineal lacerations: a case-control study on quality of life. BMC Womens Health. 2024; 24(1):12. DOI: 10.1186/s12905-023-02739-9
8. You C, Zhao Y, Zhang C, et al. Pelvic floor parameters predict postpartum stress urinary incontinence: a prospective MRI study. Insights Imaging. 2023; 14 (1):160. DOI:10.1186/s13244-023-01488-5
9. Chen R, et al. Intravaginal electrical stimulation for the treatment of pelvic floor dysfunction: systematic review and meta-analysis. Frontiers in Neurology. 2024; 15: 1378494. DOI: 10.3389/fneur.2024.1378494
10. Лазута Г.С., Гурин А.Л. Применение вагинальных тренажёров в консервативной терапии генитального пролапса на разных стадиях // Медицинский журнал РУДН. – 2023. – Вып. 1. – С. 69-76. Lazuta GS, Gurin AL. Primenenie vaginal’nyh trenazhyorov v konservativnoj terapii genital’nogo prolapsa na raznyh stadiyah [Use of vaginal exercise devices in conservative therapy for genital prolapse at different stages]. Medicinskij zhurnal RUDN [RUDN Medical Journal]. 2023; 1: 69-76. (In Russ.)
11. Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment for urinary incontinence in women: Cochrane Review. 2022; 10(10):CD005654. DOI: 10.1002/14651858.CD005654.pub3
12. Hagen S, Elders A, Stratton S, et al. Effectiveness of pelvic floor muscle training with and without electromyographic biofeedback for urinary incontinence in women: multicentre randomized controlled trial. BMJ. 2020; 371:m3719. DOI: 10.1136/bmj.m3719
13. Frawley H, Shelly B, Morin M, et al. An International Continence Society (ICS) report on the terminology for pelvic floor muscle assessment. Neurourol Urodynam. 2021; 40(5): 1217–1260. DOI:10.1002/nau.24658
14. Scaldazza C, Morosetti C, Giampieretti R, et al. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. Int Braz J Urol. 2017;43(1):121–126. DOI: 10.1590/S1677-5538.IBJU.2015.0719
15. Mundet L, Rofes L, Ortega O, et al. Kegel exercises, biofeedback, electrostimulation, and peripheral neuromodulation improve clinical symptoms of fecal incontinence and affect specific physiological targets: an randomized controlled trial. J Neurogastroenterol Motil. 2021; 27(1): 108–18. DOI:10.5056/jnm20013
УДК: 616.12-005.4-07:616.132.2 DOI: 10.20969/VSKM.2026.19(2).44-54
Analysis of the predictive potential of hematological parameters for obstructive coronary artery disease in patients with stable ischemic heart disease
Vera V. Mostovaya1, Anna S. Pogiba1, Boris I. Geltser1,2, Karina I. Shakhgeldyan1,2, Aleksandra B. Krieger2, Mikhail M. Tsivanyuk1,3, Shalva Z. Siprashvili4
1 Far Eastern Federal University, 10 Ajax Village, Bldg. 25, Russky Island, 690922 Vladivostok, Russia
2 Vladivostok State University, 41 Gogol str., 690014 Vladivostok, Russia
3Vladivostok Clinical Hospital No. 1, 22 Sadovaya str., 690078 Vladivostok, Russia
4 Primorsky Regional Clinical Hospital No. 1, 57 Aleutskaya str., 690091 Vladivostok, Russia
Abstract. Introduction. Low frequency of obstructive coronary artery disease (OCAD) detection during invasive coronary angiography in patients with stable ischemic heart disease (30–58 %) indicates the need to improve preoperative risk stratification methods using available hematological parameters. Aim. To analyze the predictive potential of hematological parameters for developing prognostic models of obstructive coronary artery disease in patients with stable ischemic heart disease. Materials and methods. A single-center retrospective cohort study was conducted in 1,005 patients (687 men and 318 women) with stable ischemic heart disease, median age 65.2 [60;72] years, who have had invasive coronary angiography. We analyzed 53 demographic, clinical and laboratory parameters, including hematological indices of inflammatory response (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and neutrophil-to-eosinophil ratio), metabolic indices (atherogenic index of plasma, triglyceride-glucose index, etc.), and hemostasis parameters. Mathematical statistics methods, such as Mann-Whitney test, chi-square test, Fisher’s exact test, and univariate logistic regression, and machine learning methods, such as multivariate logistic regression, were used to develop prognostic models. The study endpoint was represented by the hemodynamically significant (>50%) narrowing of the epicardial coronary artery lumen. Results and Discussion. Obstructive coronary artery disease was detected in 774 (77%) patients, and non-obstructive lesions in 231 (23%) patients. Statistically significant differences between groups were identified for 17 parameters, among which the following demonstrated the greatest predictive potential: Neutrophil-to-high-density-lipoprotein-cholesterol ratio >2.38 (odds ratio = 3.2), eosinophils 0.85–2.5% (odds ratio = 2.8), fibrinogen-to-international-normalized-ratio >3.63 (odds ratio = 2.44), and neutrophil-to-eosinophil ratio <74.4 (odds ratio = 2.42). A prognostic model including 8 categorical features (being a male aged 40–67 years, eosinophils 0.85–2.5%, neutrophils >53%, white blood cells >6.23×109/L, fibrinogen >3.52 g/L, high-density lipoprotein cholesterol <1.33 mmol/L, and prothrombin time <13.1 s) demonstrated high predictive accuracy (area under the curve = 0.778, sensitivity = 0.721, specificity = 0.728). Conclusions. Prognostic models based on a combination of hematological parameters allow for the acceptable risk stratification of obstructive coronary artery disease in patients with stable ischemic heart disease. Using them may help optimize patient selection for elective coronary angiography and reduce the number of undue invasive procedures.
Keywords: obstructive coronary artery disease, risk stratification, prognostic models, hematological parameters, stable ischemic heart disease.
For citation: Mostovaya, V.V.; Pogiba, A.S.; Geltser, B.I.; et al. Analysis of the predictive potential of hematological parameters for obstructive coronary artery disease in patients with stable ischemic heart disease. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 44-54. DOI: 10.20969/VSKM.2026.19(2).44-54.
REFERENCES
1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396 (10258): 1204–1222. DOI: 10.1016/S0140-6736(20)30925-9
2. Федеральная служба государственной статистики (Росстат). Причины смерти населения Российской Федерации в 2023 году: статистический сборник. – Москва. 2024. – 145 с. Federal’naya sluzhba gosudarstvennoy statistiki (Rosstat) [Federal State Statistics Service (Rosstat)]. Prichiny smerti naseleniya Rossiyskoy Federatsii v 2023 godu: statisticheskiy sbornik [Causes of death of the population of the Russian Federation in 2023: statistical collection]. Moskva [Moscow]. 2024; 145 p. (In Russ.)
3. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41 (3): 407–477. DOI: 10.1093/eurheartj/ehz425
4. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010; 362 (10): 886–895. DOI: 10.1056/NEJMoa0907272
5. National Institute for Health and Care Excellence (NICE). Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis. Clinical guideline CG95. Updated 2016. URL: https://www.nice.org.uk/guidance/cg95
6. British Cardiovascular Intervention Society (BCIS). National Audit of Percutaneous Coronary Interventions Annual Public Report 2018–2019. London. 2019. URL: https://www.bcis.org.uk/resources/audit-results
7. Гельцер Б.И., Циванюк М.М., Шахгельдян К.И., [и др.]. Факторы кардиометаболического риска в прогнозировании обструктивного поражения коронарных артерий у больных с острым коронарным синдромом без подъема сегмента ST // Российский кардиологический журнал. – 2021. – № 26 (11). – С.94-101. Geltser BI, Tsivanyuk MM, Shakhgeldyan KI, et al. Faktory kardiometabolicheskogo riska v prognozirovanii obstruktivnogo porazheniya koronarnykh arteriy u bolnykh s ostrym koronarnym sindromom bez podyema segmenta ST [Cardiometabolic risk factors in predicting obstructive coronary artery disease in patients with non-ST elevation acute coronary syndrome]. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2021; 26 (11): 94-101. (In Russ.) DOI: 10.15829/1560-4071-2021-4494
8. Циванюк М.М., Гельцер Б.И., Шахгельдян К.И., [и др.]. Показатели клинического анализа крови, липидного спектра и их соотношений в прогнозировании обструктивного поражения коронарных артерий у больных с острым коронарным синдромом без подъема сегмента ST // Российский кардиологический журнал. – 2022. – № 27 (8). – С.66-74. Tsivanyuk MM, Geltser BI, Shakhgeldyan KI, et al. Pokazateli klinicheskogo analiza krovi, lipidnogo spektra i ikh sootnosheniy v prognozirovanii obstruktivnogo porazheniya koronarnykh arteriy u bolnykh s ostrym koronarnym sindromom bez podyema segmenta ST [Clinical blood count, lipid profile parameters and their ratios in predicting obstructive coronary artery disease in patients with non-ST elevation acute coronary syndrome]. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2022; 27 (8): 66-74. (In Russ.) DOI: 10.15829/1560-4071-2022-5079
9. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008; 102 (6): 653–657. DOI: 10.1016/j.amjcard.2008.05.006
10. Undas A, Brummel-Ziedins KE. Fibrin clot properties and their modulation in thrombotic disorders. Thromb Haemost. 2014; 112 (1): 32–42. DOI: 10.1160/TH14-01-0032
11. Kurtul A, Murat SN, Yarlioglues M, et al. Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes. Am J Cardiol. 2014; 114 (7): 972–978. DOI: 10.1016/j.amjcard.2014.07.005
12. Yang YL, Wu CH, Hsu PF, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 2020; 50 (5): e13230. DOI: 10.1111/eci.13230
13. Dobiášová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001; 34 (7): 583–588. DOI: 10.1016/s0009-9120(01)00263-6
14. Гельцер Б.И., Шахгельдян К.И., Пак Р.Л., [и др.]. Индикаторы системного воспалительного ответа и их взаимосвязь с фибрилляцией предсердий у больных инфарктом миокарда с подъёмом сегмента ST после чрескожного коронарного вмешательства // Российский кардиологический журнал. – 2025. – № 30 (5). – С.91-98. Geltser BI, Shakhgeldyan KI, Pak RL, et al. Indikatory sistemnogo vospalitelnogo otveta i ikh vzaimosvyaz s fibrillyatsiey predserdiy u bolnykh infarktom miokarda s podyemom segmenta ST posle chreskozhnogo koronarnogo vmeshatelstva [Indicators of systemic inflammatory response and their relationship with atrial fibrillation in patients with ST-elevation myocardial infarction after percutaneous coronary intervention]. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2025; 30 (5): 91-98. (In Russ.) DOI: 10.15829/1560-4071-2025-6175
15. Huang Y, Liu A, Liang L, et al. Diagnostic value of blood parameters for community-acquired pneumonia. Int Immunopharmacol. 2018; 64: 10–15. DOI: 10.1016/j.intimp.2018.08.022
16. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008; 6 (4): 299–304. DOI: 10.1089/met.2008.0034
17. Zhao S, Yu S, Chi C, et al. Association between macro- and microvascular damage and the triglyceride glucose index in community-dwelling elderly individuals: the Northern Shanghai Study. Cardiovasc Diabetol. 2019; 18 (1): 95. DOI: 10.1186/s12933-019-0898-x
18. Liu Y, Guo W, Zhang J, et al. Serum uric acid-to-creatinine ratio and coronary artery disease severity in patients with acute coronary syndrome. Lipids Health Dis. 2020; 19 (1): 200. DOI: 10.1186/s12944-020-01379-w
19. Гельцер Б. И., Шахгельдян К. И., Шекунова О. И., [и др.]. ДВФУ «База данных пациентов с ИБС, прошедших коронароангиографию в условиях стационара». Св-во № 2025623882 РФ, заявка № 2025623043 от 09.07.2025; опубл. 18.09.2025. Gel’tser BI, Shakhgel’dyan KI, Shekunova OI, et al. DVFU “Baza dannykh patsiyentov s IBS, proshedshikh koronaroangiografiyu v usloviyakh statsionara”; Svidetelstvo № 2025623882 RF, zayavka № 2025623043 ot 09/07/2025; opublikovano 18/09/2025 [FEFU “Database of patients with coronary heart disease who underwent coronary angiography in a hospital setting”; Certificate No 2025623882 of the Russian Federation, application No 2025623043 dated 07/09/2025; published 09/18/2025]. 2025. (In Russ.)
20. Bittencourt MS, Hulten E, Polonsky TS, et al. European Society of Cardiology-Recommended Coronary Artery Disease Consortium Pretest Probability Scores More Accurately Predict Obstructive Coronary Disease and Cardiovascular Events Than the Diamond and Forrester Score: The Partners Registry. Circulation. 2016; 134 (3): 201–211. DOI: 10.1161/CIRCULATIONAHA.116.023396
21. Lim KKY, Chia KYG, Chin CWL, et al. Evaluating the Coronary Artery Disease Consortium Model and the Coronary Artery Calcium Score in Predicting Obstructive Coronary Artery Disease in a Symptomatic Mixed Asian Cohort. J Am Heart Assoc. 2022; 11 (8): e022697. DOI: 10.1161/JAHA.121.022697
22. Kunadian V, Chieffo A, Camici PG, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation. Eur Heart J. 2020; 41 (37): 3504–3520. DOI: 10.1093/eurheartj/ehaa503
23. Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2006; 47 (3 Suppl): S21–S29. DOI: 10.1016/j.jacc.2004.12.084
24. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010; 62 (2): 170–180. DOI: 10.1002/acr.20065
УДК: 616.344-002-031.84 DOI: 10.20969/VSKM.2026.19(2).55-61
Comparative analysis of ultrasound scores for assessing ileitis activity in Crohn’s disease
Dilyara D. Mukhametova1, Olga E. Tabakchi1, Natalia Yu. Savushkina2, Alfiya Kh. Odintsova2, Diana D. Abdulganieva1,2
1 Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia
2 Republican Clinical Hospital, 138 Orenburg Tract str., 420124 Kazan, Russia
Abstract. Introduction. Intestinal ultrasound is a noninvasive tool used for monitoring disease activity in patients with Crohn’s disease, due to its low cost, safety, and availability. Although several ultrasound indices have been developed to assess activity, none have yet been fully validated. Aim. To evaluate the diagnostic value of ultrasound scores for determining ileitis activity in Crohn’s disease. Material and Methods. The study included 43 patients with ileitis in Crohn’s disease, including 33 (77%) in the acute stage and 10 (23%) in remission. Transabdominal ultrasound examination of the intestine was performed using a Sonoscape S2N device; the normal intestinal wall thickness was 3 mm. To assess Crohn’s disease ultrasonic activity, two indices were used: International Index of Ultrasound Segmental Activity of Intestinal Inflammation (IBUS-SAS) and the Simple Index of Ultrasound Activity of Crohn’s Disease (SUS-CD). Results and Discussion. During exacerbation of Crohn’s disease, the intestinal wall thickness (4.5 [3.73; 6] mm) was greater than in remission (3.05 [2.2; 3.6] mm, p=0.004). IBUS-SAS ultrasound index was higher during exacerbation of Crohn’s disease (43.2 [27.4; 71]) than the remission index (12.22 [8.8; 21.4], p=0.0006) and correlated with endoscopic activity (r=0.49; p<0.05) and fecal calprotectin level (r=0.68; p<0.05). IBUS-SAS index was a statistically significant predictor of Crohn’s disease activity for distinguishing between exacerbation and remission (AUC = 0.949; 95% CI: 0.836 – 0.993, p<0.0001) with a sensitivity of 88.2% and a specificity of 88.9%. SUS-CD index was higher in Crohn’s disease exacerbation (3 [2; 5]) than in remission (0 [0; 1], p=0.00006) and correlated with the IBUS-SAS index (r=0.97; p<0.05), endoscopic activity (r=0.54; p<0.05), and fecal calprotectin level (r=0.65; p<0.05). SUS-CD index was also a statistically significant predictor of Crohn’s disease activity for distinguishing between exacerbation and remission (AUC = 0.933; 95% CI: 0.813 - 0.987, p < 0.0001), with a cutoff value of 1, with the sensitivity of 76.5% and the specificity of 100%. Conclusions. A quantitative approach to assessing Crohn’s disease activity is provided by using the IBUS-SAS and SUS-CD ultrasound indices. Statistically significant differences in the values of these indices were found in the remission and exacerbation groups of Crohn’s disease; both indices correlated with endoscopic activity and the fecal calprotectin levels, the diagnostic value of the IBUS-SAS index being higher.
Keywords: Crohn’s disease, activity, intestinal ultrasound, international bowel ultrasound segmental activity score, simple ultrasound activity score for Crohn’s disease
For citation: Mukhametova, D.D.; Tabakchi, O.E.; Savushkina, N.Yu.; et al. Comparative analysis of ultrasound scores for assessing ileitis activity in Crohn’s disease. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 55-61. DOI: 10.20969/VSKM.2026.19(2).55-61.
REFERENCES
1. Шелыгин Ю.А., Ивашкин В.Т., Ачкасов С.И., [и др.]. Клинические рекомендации. Болезнь Крона (К50), взрослые // Колопроктология. – 2023. – №22(3). – С.10–49. Shelygin YuA, Ivashkin VT, Achkasov SI, et al. Klinicheskiye rekomendatsii: Bolezn’ Krona (K50), vzroslyye [Clinical guidelines: Crohn’s disease (К50), adults]. Koloproktologia [Proctology]. 2023; 22(3): 10-49. (In Russ.) DOI: 10.33878/2073-7556-2023-22-3-10-49
2. Бакулин И.Г., Расмагина И.А., Машевский Г.А., [и др.]. Искусственный интеллект в диагностике воспалительных заболеваний кишечника: фокус на клинико-лабораторные показатели // Колопроктология. – 2025. – №24(2). – С.33–41. Bakulin IG, Rasmagina IA, Mashevskiy GA, et al. Iskusstvennyy intellekt v diagnostike vospalitel’nykh zabolevaniy kishechnika: fokus na kliniko-laboratornyye pokazateli [Artificial intelligence in the diagnosis of inflammatory bowel diseases: focus on clinical and laboratory markers]. Koloproktologia [Proctology.]. 2025;24(2):33–41. (in Russ.) DOI:10.33878/2073-7556-2025-24-2-33-41
3. Nylund K, Maconi G, Hollerweger A, et al. EFSUMB Recommendations and Guidelines for Gastrointestinal Ultrasound – Part 1: Examination Techniques and Normal Findings (Short version). Ultraschall in Med. 2017; 38(3): 1–15. DOI:10.1055/s-0042–115853
4. Sturm A, Maaser C, Calabrese E, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. Journal of Crohn’s & colitis. 2019; 13(3): 273–284. DOI: 10.1093/ecco-jcc/jjy114
5. Novak KL, Nylund K, Maaser C. Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn’s disease. Journal of Crohn’s and Colitis. 2021; 15(4): 609–616. DOI: 10.1093/ecco-jcc/jjaa216
6. Sævik F, Eriksen R, Eide GE, et al. Development and Validation of a Simple Ultrasound Activity Score for Crohn’s Disease. J Crohns Colitis. 2021; 15(1): 115-124. DOI: 10.1093/ecco-jcc/jjaa112
7. Maconi G, Nylund K, Ripolles T, et al. EFSUMB Recommendations and Clinical Guidelines for Intestinal Ultrasound (GIUS) in Inflammatory Bowel Diseases. Ultraschall Med. 2018;39(3):304–317. DOI: 10.1055/s-0043–125329
8. Krugliak CN, St-Pierre J, Kellar A, Rubin DT. Clinical Application of Intestinal Ultrasound in Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2024; 26(2): 31-40. DOI: 10.1007/s11894-024-00915-x
9. Stenczel ND, Purcarea MR, Tribus LC, Oniga GH. The role of the intestinal ultrasound in Crohn’s disease diagnosis and monitoring. J Med Life. 2021; 4(3): 310-315. DOI: 10.25122/jml-2021-0067
10. Allocca M, D’Amico F, Fiorino G, et al. Systematic review on definitions of intestinal ultrasound treatment response and remission in inflammatory bowel disease. J Crohns Colitis. 2025; 19(2): jjaf011. DOI: 10.1093/ecco-jcc/jjaf011
11. Nagarajan KV, Yelsangikar A, Nagar A, Bhat N. External validation of Intestinal Ultrasound score: IBUS-SAS with clinical (CDAI), biomarkers and endoscopic scoring system (SES-CD). Journal of Crohn’s and Colitis. 2024; 18: i517–i518. DOI: 10.1093/ecco-jcc/jjad212.0329
12. Freitas M, de Castro FD, Macedo SV, et al. Ultrasonographic scores for ileal Crohn’s disease assessment: Better, worse or the same as contrast-enhanced ultrasound? BMC Gastroenterol. 2022; 22: 252. DOI: 10.1186/s12876-022-02326-6
13. Dragoni G, Gottin M, Innocenti T, et al. Correlation of ultrasound scores with endoscopic activity in Crohn’s disease: a prospective exploratory study. Journal of Crohn’s and Colitis. 2023; 17(9): 1387-1394. DOI: 10.1093/ecco-jcc/jjad068
14. Zhao JY, Ju JY, Luo Y, Zhuang H. Validation of intestinal ultrasound scores in assessing endoscopic activity of colonic and small intestinal Crohn’s disease in a southwest Chinese cohort: a retrospective cross-sectional study. Quant Imaging Med Surg. 2024; 14(12): 8374-8386. DOI: 10.21037/qims-24-742
15. Frias-Gomes C, Torres J, Palmela C. Intestinal Ultrasound in Inflammatory Bowel Disease: A Valuable and Increasingly Important Tool. GE Port J Gastroenterol. 2021; 29(4): 223-239. DOI: 10.1159/000520212
УДК: 616.12-008.313.2 DOI: 10.20969/VSKM.2026.19(2).62-73
Prediction of new-onset atrial fibrillation in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention based on preprocedural and intraprocedural predictors
Regina L. Pak1,3, Boris I. Geltser1,2, Karina I. Shakhgeldyan1,2, Nikita S. Kuksin1,2, Evgenii A. Kokarev1,3, Vladislav U. Rublev1,3
1 Far Eastern Federal University, 10 Ajax Bay, Russky Island, 690922 Vladivostok, Russia
2 Vladivostok State University, 41 Gogol str., 690014 Vladivostok, Russia
3 Regional Clinical Hospital No.1, 57 Aleutskaya str., 690091 Vladivostok, Russia
Abstract. Introduction. New-onset atrial fibrillation in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention worsens short-term outcomes of the disease. Currently, no universally accepted tools exist for assessing the risk of this complication. Aim. To develop predictive models for new-onset atrial fibrillation in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention based on pre- and intraprocedural predictors. Materials and Methods. This single-center prospective study included 796 patients with ST-segment elevation myocardial infarction, who were divided into two groups: 68 (8.5%) patients with new-onset atrial fibrillation after percutaneous coronary intervention and 728 (91.5%) patients without arrhythmia. The feature selection algorithm involved statistical analysis, data categorization, predictive model development using CatBoost and multivariate logistic regression, and assessment of predictor importance via Shapley Additive explanations. Efficacy of percutaneous coronary intervention was assessed using the Thrombolysis in Myocardial Infarction (TIMI) score. Results and Discussion. Predictive models for new-onset atrial fibrillation after percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction were developed based on a multistep analysis of pre- and intraprocedural variables. The model with the best performance metrics (AUC = 0.808) included 12 categorical predictors. The most significant and comparable impact on the NOAF development was observed for TIMI < 3 and Killip class > II. Substantial contributions were also noted for blood urea > 8.9 mmol/L, fibrinogen > 5.54 g/L, and chronic heart failure (NYHA class II–III). Less pronounced associations were observed for age > 66 years, monocyte-to-lymphocyte ratio ≥ 0.52, lactate>1.7 mmol/L, neutrophil-to-eosinophil ratio ≥ 48, and systolic blood pressure < 131.5 mmHg. The weakest associations were found for Cl⁻ < 106.5 mmol/L and total cholesterol < 5.4 mmol/L. Conclusions. A multifactorial predictive model for new-onset atrial fibrillation in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention, incorporating pre- and intraprocedural categorical predictors, demonstrated high accuracy and may serve as a useful tool for predicting the risks for this complication.
Keywords: ST-segment elevation myocardial infarction, percutaneous coronary intervention, atrial fibrillation, risk prediction, machine learning.
For citation: Pak, R.L.; Geltser, B.I.; Shakhgeldyan, K.I.; et al. Prediction of new-onset atrial fibrillation in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention based on preprocedural and intraprocedural predictors. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 62-73. DOI: 10.20969/VSKM.2026.19(2).62-73.
REFERENCES
1. Зыков М. В., Барбараш О.Л. Патогенетические и клинические аспекты фибрилляции предсердий при инфаркте миокарда // Российский кардиологический журнал. – 2021. – № 26(2). – С.134-140. Zykov MV, Barbarash OL. Patogeneticheskie i klinicheskie aspekty fibrillyacii predserdij pri infarkte miokarda [Pathogenetic and clinical aspects of atrial fibrillation in myocardial infarction]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2021; 26(2): 134-140. (In Russ.) DOI: 10.15829/1560-4071-2021-43073
2. Шишкина Е.А., Хлынова О.В., Лебедева Ю.И., [и др.]. Фибрилляция предсердий и инфаркт миокарда:клинико-патогенетические взаимосвязи и влияние на прогноз // Доктор. Ру. – 2023. - № 22 (8). – С.23-28. Shishkina EA, Khlynova OV, Lebedeva UI, et al. Fibrillyaciya predserdij i infarkt miokarda: kliniko-patogeneticheskie vzaimosvyazi i vliyanie na prognoz [Atrial Fibrillation and Myocardial Infarction: Clinical and Pathogenic Correlations and Impact for the Prognosis]. Doctor.Ru. 2023; 22 (8): 23–28. (In Russ.) DOI: 10.31550/1727-2378-2023-22-8-23-28
3. Галяутдинов Г.С., Горелкин И.В., Ибрагимова К.Р., [и др.]. Впервые возникшая фибрилляция предсердий в условиях острого коронарного синдрома. Актуальные вопросы // Рациональная Фармакотерапия в Кардиологии. – 2018. – №14 (3). – С. 451-457. Galyautdinov GS, Gorelkin IV, Ibragimova KR, et al. Vpervye voznikshaya fibrillyaciya predserdij v usloviyah ostrogo koronarnogo sindroma. Aktual’nye voprosy [New-Onset Atrial Fibrillation in Settings of Acute Coronary Syndrome. Current Issues]. Racional’naya Farmakoterapiya v Kardiologii [Rational Pharmacotherapy in Cardiology]. 2018;14(3):451-457. (In Russ.) DOI: 10.20996/1819-6446-2018-14-3-451-457
4. Болдуева С. А., Соловьева М. В., Облавацкий Д. В., [и др.]. Инфаркт миокарда у больных с фибрилляцией предсердий // Кардиология. – 2020. – №60 (1). – С. 53–61. Boldueva SA, Solov’eva MV, Oblavackij DV, et al. Infarkt miokarda u bol’nyh s fibrillyaciej predserdij [Myocardial Infarction in the Group of Patients With Atrial Fibrillation]. Kardiologiya [Cardiology]. 2020; 60(1):53-61. (In Russ.) DOI:10.18087/cardio.2020.1.n620
5. Kea B, Alligood T, Manning V, et al. A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome. Curr Emerg Hosp Med Rep. 2016 Jul 6;4(3):107–118. DOI: 10.1007/s40138-016-0105-2
6. Пак Р. Л., Гельцер Б. И., Шахгельдян К. И., [и др.]. Эффективность прогностических шкал в оценке риска впервые возникшей фибрилляции предсердий у больных инфарктом миокарда с подъемом сегмента ST после чрескожного коронарного вмешательства // Российский кардиологический журнал. – 2024. – №29(12). – C.72-78. Pak RL, Geltser BI, Shahgeldyan KI, et al. Effektivnost’ prognosticheskih shkal v ocenke riska vpervye voznikshej fibrillyacii predserdij u bol’nyh infarktom miokarda s pod”emom segmenta ST posle chreskozhnogo koronarnogo vmeshatel’stva [Efficiency of prognostic scores in predicting the new-onset atrial fibrillation in patients with ST-elevation myocardial infarction after percutaneous coronary intervention]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2024;29(12):72-78. (In Russ.) DOI: 10.15829/1560-4071-2024-6125
7. Shakhgeldyan K, Kuksin N, Domzhalov I, et al. Interpretable machine learning for in-hospital mortality risk prediction in patients with ST-elevation myocardial infarction after percutaneous coronary interventions. Computers in Biology and Medicine. 2024; 170: 107953. DOI:10.1016/j.compbiomed.2024.107953
8. Nohara Y, Matsumoto K, Soejima H, Nakashima N. Explanation of machine learning models using shapley additive explanation and application for real data in hospital. Comput Methods Programs Biomed. 2022;214:106584. DOI: 10.1016/j.cmpb.2021.106584
9. Al-Obaidi F, Al-Kinani T, Al-Ali MH, Al-Myahi MH. New-onset atrial fibrillation in the post-primary PCI setting: a systematic review. Acta Medica Bulgarica. 2019; 46(2):62-70. DOI: 10.2478/amb-2019-0021
10. Wu N, Li J, Xu X, et al. Prediction Model of New Onset Atrial Fibrillation in Patients with Acute Coronary Syndrome. International Journal of Clinical Practice. 2023;23:3473603. DOI: 10.1155/2023/3473603
11. Шахгельдян К.И., Куксин Н.С., Домжалов И.Г., [и др.]. Анализ эффективности прогностических моделей внутригоспитальной летальности у больных инфарктом миокарда с подъемом сегмента ST на основе предикторов в категориальной и непрерывной формах // Современные технологии в медицине. – 2024. – №16 (1). – С. 15. Shakhgeldyan KI, Kuksin NS, Domzhalov IG, et al. Analiz effektivnosti prognosticheskih modelej vnutrigospital’noj letal’nosti u bol’nyh infarktom miokarda s pod”emom segmenta ST na osnove prediktorov v kategorial’noj i nepreryvnoj formah [Performance of the Models Predicting In-Hospital Mortality in Patients with ST-segment Elevation Myocardial Infarction with Predictors in Categorical and Continuous Forms]. Sovremennye tekhnologii v medicine [Modern Technologies in Medicine]. 2024;16(1):15. (In Russ.) DOI:10.17691/stm2024.16.1.02
12. Бородашкина СЮ, Протасов КВ. Клинико-патогенетические особенности инфаркта миокарда у больных фибрилляцией предсердий // Сибирское медицинское обозрение. – 2020. – №5. – С. 31-39. Borodashkina SU, Protasov KV. Kliniko-patogeneticheskie osobennosti infarkta miokarda u bol’nyh fibrillyaciej predserdij. [Clinical and pathogenetic features of myocardial infarction in patients with atrial fibrillation]. Sibirskoe medicinskoe obozrenie [Siberian Medical Review]. 2020;(5):31-39. (In Russ.) DOI: 10.20333/2500136-2020-5-31-39
13. Гельцер Б. И., Шахгельдян К. И., Пак Р.Л., [и др.]. Индикаторы системного воспалительного ответа и их взаимосвязь с фибрилляцией предсердий у больных инфарктом миокарда с подъемом сегмента ST после чрескожного коронарного вмешательства // Российский кардиологический журнал. – 2025. – №30(5). – C.91-98. Geltser BI, Shakhgeldya KI, Pak RL, et al. Indikatory sistemnogo vospalitel’nogo otveta i ih vzaimosvyaz’ s fibrillyaciej predserdij u bol’nyh infarktom miokarda s pod”emom segmenta ST posle chreskozhnogo koronarnogo vmeshatel’stva [Parameters of the systemic inflammatory response and their relationship with atrial fibrillation in patients with ST-elevation myocardial infarction after percutaneous coronary intervention]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2025; 30(5): 91-98. (In Russ.) DOI: 10.15829/1560-4071-2025-6175
14. Băghină R-M, Cris an S, Luca S, et al. Association between Inflammation and New-Onset Atrial Fibrillation in Acute Coronary Syndromes. J Clin Med. 2024; 13: 5088. DOI: 10.3390/jcm13175088
15. Liu L, Liu X, Ding X, et al. Lipid Levels and New-Onset Atrial Fibrillation in Patients with Acute Myocardial Infarction. J Atheroscler Thromb. 2023; 30: 515-530. DOI: 10.5551/jat.63574
16. Xue Y, Zhou Q, Shen J, et al. Lipid Profile and New-Onset Atrial Fibrillation in Patients With Acute ST-Segment Elevation Myocardial Infarction (An Observational Study in Southwest of China). Am J Cardiol. 2019;124(10):1512-1517. DOI: 10.1016/j.amjcard.2019.07.070
17. Пак Р.Л., Гельцер Б.И., Шахгельдян Б.И., [и др.]. Показатели клинического анализа крови в прогнозировании фибрилляции предсердий у больных инфарктом миокарда с подъемом сегмента ST после чрескожного коронарного вмешательства // Вестник современной клинической медицины. – 2025. – №18 (1). – С. 48-56. Pak RL, Geltser BI, Shakhgeldyan KI, et al. Pokazateli klinicheskogo analiza krovi v prognozirovanii fibrillyacii predserdij u bol’nyh infarktom miokarda s pod”emom segmenta ST posle chreskozhnogo koronarnogo vmeshatel’stva [Complete blood count parameters as prognostic factor of new-onset atrial fibrillation in patients with st-segment elevation myocardial infarction after percutaneous coronary intervention]. Vestnik sovremennoj klinicheskoj mediciny [The Bulletin of Contemporary Clinical Medicine]. 2025;18(1):48-56. (In Russ.) DOI:10.20969/VSKM.2025.18(1).48-56
18. Lazzeri C, Valente S, Chiostri M, et al. Clinical significance of lactate in acute cardiac patients. World J Cardiol. 2015; 7(8): 483-489. DOI: 10.4330/wjc.v7.i8.483
19. Lan Q, Zheng L. The Value of Blood Urea Nitrogen in the Prediction of Risks of Cardiovascular Disease in an Older Population. Frontiers in Cardiovascular Medicine. 2021; 8: 614117. DOI: 10.3389/fcvm.2021.614117
20. Zebir R, Tekkesin A, Haykir N, et al. Peak troponin I level predicts new-onset atrial fibrillation in patients with myocardial infarction. Clin Invest Med. 2016; 39 (6): E213-E219. DOI: 10.25011/cim.v39i6.27489
21. Raczkowska-Golanko M, Raczak G, Gruchala M, et al. Comprehensive Use of Routine Clinical Parameters to Identify Patients at Risk of New-Onset Atrial Fibrillation in Acute Myocardial Infarction. J Clin Med. 2021; 10(16): 3622. DOI: 10.3390/jcm10163622
22. Ulus T, Isgandarov K, Yilmaz A, et al. Predictors of new-onset atrial fibrillation in elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention. Aging Clinical and Experimental Research. 2018; 30(12): 1475-1482. DOI: 10.1007/s40520-018-0926-9
23. Liu J, Hu X. Association between glucose-to-lymphocyte ratio and in-hospital mortality in acute myocardial infarction patients. PLoS ONE. 2023; 18 (12): e0295602. DOI: 10.1371/journal.pone.0295602
УДК: 617.54-089.844-06 DOI: 10.20969/VSKM.2026.19(2).74-81
Autologous deepithelialized skin in plastic surgery of complex postoperative ventral hernias: An innovative step in the prospect of complex hernia repair?
Andrey M. Topchiev1, Andrey V. Protasov2, Andrey YU. Anisimov3, Mikhail A. Topchiev1
1 Astrakhan State Medical University, 121 Bakinskaya str., 414000 Astrakhan, Russia
2 Peoples’ Friendship University of Russia named after Patrice Lumumba, 21 Miklukho-Maklay str., Bldg 3, 117198 Moscow, Russia
3 Kazan (Volga) Federal University, 74 A Karl Marx str., 420012 Kazan, Russia
Abstract. Introduction. According to recent publications, the use of biological tissues in the repair of postoperative ventral hernias is a growing trend. Some researchers use autologous skin as a plastic material that, by preserving its tensimetric properties based on its pre-implantation preparation, integrates well with tissues and eliminates the negative consequences in the repair area, characteristic of allografts. Aim. To analyze the effectiveness of using deepithelialized autodermis prepared in an oxygenated perfluorane solution with an antibiotic before implantation, for strengthening the anatomical structures of the anterior abdominal wall in complex hernia repair. Materials and Methods. A chronic model of postoperative median hernia was experimentally created to test autodermis for inflammatory response and collagen formation. The prepared autodermis was tested for antimicrobial resistance to hospital strains of microorganisms. 35 patients with postoperative or recurrent hernias M1-M5 and W2-W3 were operated using deepithelialized autodermis. Age of the operated patients varied from 45 to 74 years. There were 14 men and 21 women. The area of the excised autologous skin graft after preparation and prior to implantation ranged within 525–1705 cm². Intraabdominal pressure was measured via a Foley urethral catheter. Computed tomography of the anterior abdominal wall was performed both before and after surgery. Results and Discussion. The created chronic model of median hernia after 30 days corresponded to a W3 hernia having an average diameter of 13.14 ± 1.33 cm (M ± m). The experiment showed that macroscopically, the implanted autologous skin is difficult to distinguish from the aponeurotic structures of the anterior abdominal wall. Histologically, after 30 days, lymphocytic infiltration was found at the autodermis implantation site, as well as fragmentation of collagen fibers and immature connective tissue with the formation of immature type III collagen. After 60 days, only isolated lymphocytic clusters remain. Under polarized light with Sirius Red staining, the transplant exhibits a red glow, indicating the formation of mature type I collagen. Out of 35 operated patients, complications were registered in 1 case (hematoma). CT monitoring from 1 to 24 months showed a tissue reaction ranging from mild infiltration to scar formation while preserving the anatomy of the anterior abdominal wall. The average length of stay was 8.5 ± 1.6 days. The time to return to work was 25.12 ± 2.1 days. No disease recurrence was observed within 5 years. Conclusions. The use of deepithelialized autodermis prepared as pre-implantation in an oxygenated perfluorane solution with an antibiotic, reduces the inflammatory process in the repair area, ensures the formation of type I collagen that promotes connective tissue formation, and reduces postoperative complications and disease recurrence.
Keywords: postoperative ventral hernia, abdominal wall reconstruction, autoclave transplantation, autodermis, hernioplasty, perfluorocarbon emulsion.
For citation: Topchiev, A.M.; Protasov, A.V.; Anisimov, A.Yu.; Topchiev, M.A. Autologous deepithelialized skin in plastic surgery of complex postoperative ventral hernias: An innovative step in the prospect of complex hernia repair? The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 74-81. DOI: 10.20969/VSKM.2026.19(2).74-81.
REFERENCES
1. Eriksson A, Rosenberg J, Bisgaard T. Surgical treatment for giant incisional hernia: a qualitative systematic review. Hernia. 2014; 18 (1): 31-38. DOI: 10.1007/s10029-013-1066-y
2. Maloney SR, Schlosser KA, Prasad T, et al. Twelve years of component separation technique in abdominal wall reconstruction. Surgery. 2019; 166 (4): 435-444. DOI: 10.1016/j.surg.2019.05.043
3. Klosterhalfen B, Klinge U. Retrieval study at 623 human mesh explants made of polypropylene--impact of mesh class and indication for mesh removal on tissue reaction. J Biomed Mater Res B ApplBiomater. 2013; 101(8): 1393-1399. DOI: 10.1002/jbm.b.32958
4. Poulose BK, Shelton J, Phillips S, et al. Epidemiology and cost of ventral hernia repair: making the case for hernia research. Hernia. 2012; 16 (2): 179-183. DOI:10.1007/s10029-011-0879-9
5. Näsvall P, Rutegård J, Dahlberg M, et al. Parastomal hernia repair with intraperitoneal mesh. Surg Res Pract. 2017; 2017: 6. DOI: 10.1155/2017/8597463
6. Olavarria OA, Bernardi K, Dhanani NH, et al. Synthetic versus Biologic Mesh for Complex Open Ventral Hernia Repair: A Pilot Randomized Controlled Trial. Surgical Infections. 2021; 22(5): 496-503. DOI: 10.1089/sur.2020.166D
7. Hiles M, Record Ritchie RD, Altizer AM. Are biologic grafts effective for hernia repair?: a systematic review of the literature. SurgInnov. 2009; 16(1): 26–37. DOI: 10.1177/1553350609331397
8. Topchiev MA, Parshin DS, Nurmagomedov AG, et al. Tensometric characteristics of de-epithelized skin graft and polypropylene mesh implant used in hernioplasty. Archiv Euromedica. 2019; 9(3): 55-57. DOI: 10.35630/2199-885X/2019/9/3.18
9. Simón-Allué R, Hernández-Gascón B, Lèoty L, et al. Prostheses size dependency of the mechanical response of the herniated human abdomen. Hernia. 2016; 20(6): 839-848. DOI: 10.1007/s10029-016-1525-3
10. Hodgdon I, Cook M, Yoo A, et al. The use of autologous fenestrated cutis grafts in hernia repair: surgical outcomes and cost analysis of 97 consecutive patients. AmSurg. 2020; 86(7): 819–25. DOI: 10.1177/0003134820933261
11. Holmdahl V, Strigard K, Gunnarsson U. Autologous full-thickness skin in the repair of complex ventral hernias: an innovative step into the future of complex hernia repair? Front Surg. 2023 Dec 15; 10: 1301702. DOI: 10.3389/fsurg.2023.1301702
12. Kaufmann R, Halm JA, Eker HH, et al. Mesh versus suture repair of umbilical hernia in adults: a randomised, double blind, controlled, multicentre trial. Lancet (London, England). 2018; 391: 860–9. DOI: 10.1016/s0140-6736(18)30298-8
13. Collaboration EHT. Mesh compared with non-mesh methods of open groin hernia repair: systematic review of randomized controlled trials. Br J Surg. 2000; 87 (7): 854–9. DOI: 10.1046/j.1365-2168.2000.01539.x
14. Hiles M, Record Ritchie RD, Altizer AM. Are biologic grafts effective for hernia repair?: a systematic review of the literature. Surg Innov. 2009; 16(1): 26–37. DOI: 10.1177/1553350609331397
15. Rozen WM, Kapila S, Enajat M, et al. Autologous dermal grafts for rectus sheath reconstruction and application in closure of ventral myofascial defects. UpdatesSurg. 2012; 64(3): 203–10. DOI: 10.1007/s13304-012 0167-y
16. Hodgdon I, Cook M, Yoo A, et al. The use of autologous fenestrated cutis grafts in hernia repair: surgical outcomes and cost analysis of 97 consecutive patients. Am Surg. 2020; 86 (7): 819–25. DOI: 10.1177/ 0003134820933261
17. ÖzkayaMutlu Ö, Egemen O, Akan A, et al. The use of dermal automesh for incidental hernia repair in abdominoplasty: clinical, biochemical, and radiological results. J Plast Surg Hand Surg. 2015; 49(3): 172–6. DOI: 10.3109/2000656x.2014.976571
18. Holmdahl V, Strigård K and Gunnarsson U. Autologous full-thickness skin in the repair of complex ventral hernias: an innovative step into the future of complex hernia repair? Front Surg. 2023; 10: 1301702. DOI: 10.3389/fsurg.2023.1301702
УДК 616.314-002-084-053.4:316.362.3 DOI: 10.20969/VSKM.2026.19(2).82-89
Scientific rationale for medico-social prevention of dental caries in preschool children by family type
Madina N. Khadyeva1,3, Afgat N. Galiullin2,Rinat A. Saleev1,Liana M. Khamidullina4, Dinara R. Khairutdinova1
1 Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia
2 Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 74 Karl Marx str., 420012 Kazan, Russia
3 UniDent – Dental Clinic Chain, 79 Chistopolskaya str. and 2 Orenburg Tract str., 420066 Kazan, Russia
4 City Polyclinic No.18, 72 Karbyshev str., 420087 Kazan, Russia
Abstract. Introduction. Dental diseases are widespread among all ages and strata of the population, including among the population living within the Russian Federation. Dental morbidity among the child population does not have a downward trend, either. Its prevalence and intensity progress with the child’s age and entail complications in other body organs and systems. The existing prevention programs do not provide any lasting reduction in the prevalence of major dental diseases among those at highest risk of their occurrence. When taking preventive measures, it is necessary to consider the age and type of the child’s family, since their domestic relations and family typology have a direct impact on the development of the child’s psychological and physical health. At the same time, the antenatal period is an important stage in the child’s intrauterine development, it is in this period where body organs and systems are evolving and formed. Unfavorable pregnancy course and the adverse effects of socio-hygienic risk factors lead to the development of pathology in the child, including dental pathologies, such as multiple dental caries, formation of dentoalveolar anomalies, and non-carious dental diseases. Aim. To analyze the results of medical and social prevention of dental caries in preschool children, depending on the type of family and on the impact of socio-hygienic risk factors. Materials and Methods. As part of the study, a family survey of women and children from different types of families was carried out, socio-hygienic factors of the antenatal period were found, and their impact by the type of family relations. Conclusions. The findings of the study demonstrate the influence of family relationship typology on the incidence of dental caries among preschool children, as well as on the impact of risk factors in the antenatal period. At the same time, we have obtained data on a decrease in the prevalence of dental caries after a prevention program, considering the type of the child’s family and the influence of socio-hygienic factors.
Keywords: medical and social prevention, preschool children, risk factors, dental caries, family type.
For citation: Khadyeva, M.N.; Galiullin, A.N.; Saleev, R.A.; et al. Scientific rationale for medico-social prevention of dental caries in preschool children by family type. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 82-89. DOI: 10.20969/VSKM.2026.19(2).82-89.
REFERENCES
1. Леонтьев В. К., Кисельникова Л.Р. Детская терапевтическая стоматология: Национальное руководство. – М.: ГЭОТАР–Медиа, 2017. – 952 с. Leont’yev VK, Kisel’nikova LR. Detskaya terapevticheskaya stomatologiya: Natsional’noye rukovodstvo [Pediatric therapeutic dentistry: National guidelines]. Moskva: GEOTAR–Media [Moscow: GEOTAR-Media]. 2017; 952 p. (In Russ.)
2. Tinanoff N, Baez RJ, Diaz Guillory C. Early childhood caries epidemiology, aetiology, risk assessment, societal burden, management, education, and policy: Global perspective. Int J Paediatr Dent. 2019; 29 (3): 238—248. DOI: 10.1111/ipd.12484
3. Хадыева М. Н. Особенности медико-социальной профилактики стоматологических заболеваний у детей дошкольного возраста // Казанский медицинский журнал. – 2025. – № 4. – С.145–147. Khadyeva MN. Osobennosti mediko-social’noj profilaktiki stomatologicheskih zabolevanij u detej doshkol’nogo vozrasta [Peculiarities of medical and social prevention of dental diseases in preschool-aged children]. Kazanskij medicinskij zhurnal [Kazan medical Journal]. 2025; 4: 145-147. (In Russ.) DOI: 10.17816/KMJ629569
4. Akhmedov A, Utesheva I, Ishanova M, et al. Prevalence, prophylaxis and treatment principles of primary teeth erosion in children. International Journal of Psychosocial Rehabilitation. 2020; 24 (4): 2073-2078. DOI: 10.37200/IJPR/V24I4/PR201317
5. Buldur B, Oguz E. Reliability and validity of the Turkish version of the Oral Health Literacy Assessment Task: Pathways between parental oral health literacy and oral health consequences in children. Int J Paediatr Dent. 2023; 33 (2): 101-112. DOI: 10.1111/ipd.13025
6. Lorna MD Macpherson, Graham EB, King P, et al. Wendy Gnich. Childsmile: the child oral health improvement programme in Scotland. Prim. Dent J. 2015; 4: 33. DOI: 10.1308/205016815816682236
7. Lumsden C, Wolf R, Contento I, Basch C, et al. Feasibility, Acceptability, and Short-term Behavioral Impact of the MySmileBuddy Intervention for Early Childhood Caries. J Health Care Poor. Underserved. 2019; 30 (1): 59-69. DOI: 10.1353/hpu.2019.0007
8. Федеральный закон Российской Федерации № 620-Ф3 от 30 декабря 2003 г. «Об утверждении протоколов ведения детей, страдающих стоматологическими заболеваниями» здоровья граждан Российской Федерации». Federal’nyj zakon Rossijskoj Federacii № 620-F3 ot 30 dekabrya 2003 goda «Ob utverzhdenii protokolov vedeniya detej, stradayushchih stomatologicheskimi zabolevaniyami» zdorov’ya grazhdan Rossijskoj Federacii [Federal Law of the Russian Federation No. 620-FZ of December 30, 2003 “On approval of protocols for the care of children suffering from dental diseases” of the health of citizens of the Russian Federation]. 2003. (In Russ.) Режим доступа [URL]: https://oblstomat32.ru/wp-content/uploads/prikaz620.pdf
9. Alzahrani AY, El Meligy O, Bahdila D, et al. The influence of parental oral health literacy on children’s oral health: a scoping review. J Clin Pediatr Dent. 2024; 48 (4):16-25. DOI: 10.22514/jocpd.2024.074
10. Jiangling S, Juanjuan Wu, Liming Ch, et all. Analysis of 5-year children’s oral health service utilization and influencing in Guizhou Province, China (2019-2020). BMC Oral Health. 2023; 23: 627. DOI: 10.1186/s12903-023-03350-y
11. Галиуллин А. Н., Хадыева М.Н., Якимова Ю.Ю. Моделирование стоматологической заболеваемости у детей дошкольного возраста с применением искусственного интеллекта // Kazan digital week – 2024 : сборник материалов Международного форума, Казань, 09–11 сентября 2024 года. – Казань: Научный центр безопасности жизнедеятельности, 2024. – С. 821-830. Galiullin AN, Khadyeva MN, Yakimova YuYu. Modelirovanie stomatologicheskoj zabolevaemosti u detej doshkol’nogo vozrasta s primeneniem iskusstvennogo intellekta; Kazan digital week – 2024: sbornik materialov Mezhdunarodnogo foruma, Kazan’, 09–11 sentyabrya 2024 goda [Modeling dental morbidity in preschool children using artificial intelligence; Kazan digital week – 2024: collection of materials from the International forum, Kazan, September 9–11, 2024]. Kazan’: Nauchnyj centr bezopasnosti zhiznedeyatel’nosti [Kazan: Scientific Center for Life Safety]. 2024; 821-830. (In Russ.)
12. Жаркова О.А. Образовательно-профилактическая программа «Здоровую улыбку детям» среди детских дошкольных учреждений и средних школ города Витебска // Стоматология. Эстетика. Инновации. – 2017. – №1. – С.103-110. ZHarkova OA. Obrazovatel’no-profilakticheskaya programma «Zdorovuyu ulybku detyam» sredi detskih doshkol’nyh uchrezhdenij i srednih shkol goroda Vitebska [Educational and preventive program “Healthy Smiles for Children” among preschool institutions and secondary schools in the city of Vitebsk]. Stomatologiya; Estetika; Innovacii [Dentistry; Aesthetics; Innovations]. 2017; 1: 103-110.
13. Терехова Т.Н., Шаковец Н.В., Мельникова Е.И. Эпидемиология стоматологических заболеваний у детского населения Республики Беларусь // Актуальные вопросы стоматологии детского возраста. 1-ая Всероссийская научно-практическая конференция: сб. науч. ст. – Казань, 2018. – С.250-254. Terekhova TN, SHakovec NV, Mel’nikova NL. Epidemiologiya stomatologicheskikh zabolevaniy u detskogo naseleniya Respubliki Belarus’ [Epidemiology of dental diseases in the child population of the Republic of Belarus]. Kazan’: Aktual’nyye voprosy stomatologii detskogo vozrasta; 1-aya Vserossiyskaya nauchno-prakticheskaya konferentsiya: sbornik nauchnykh statey [Kazan: Current issues in pediatric dentistry; 1st All-Russian scientific and practical conference: collection of scientific articles]. 2018; 250-254. (In Russ.)
14. Alshunaiber R, Alzaid H, Meaigel S. Early childhood caries and infant’s oral health; pediatricians’ and family physicians’ practice, knowledge and attitude in Riyadh city, Saudi Arabia. Saudi Dent J. 2019; 31: 96-105. DOI: 10.1016/j.sdentj.2019.01.006
15. Указ Президента Российской Федерации №875 от 22.11.2023 года о проведении в Российской Федерации Года Семьи – 2024. Ukaz Prezidenta Rossijskoj Federacii №875 ot 22/11/2023 goda o provedenii v Rossijskoj Federacii Goda Sem’i – 2024 [Decree of the President of the Russian Federation No 875 of November 22, 2023 on holding the Year of the Family in the Russian Federation – 2024]. URL: http://pravo.gov.ru/proxy/ips/?docbody=&firstDoc=1&lastDoc=1&nd=60611429
16. Naavaal S, Brickhouse TH, Hafidh S, Smith K. Factors Associated with Preventive Dental Visits Before and During Pregnancy. J Womens Health (Larchmt). 2019 Dec; 28(12): 1670-1678. DOI: 10.1089/jwh.2018.7509
17. Rai NK, Tiwari T. Parental Factors Influencing the Development of Early Childhood Caries in Developing Nations: A Systematic Review. Front Public Health. 2018; 6: 64. DOI: 10.3389/fpubh.2018.00064
18. Кузьмина В.А., Якубова И.М., Коркач Г.Н. Стоматологическое просвещение беременных как важное звено антенатальной профилактики кариеса временных зубов // Стоматологический журнал. – 2017. – № 1. – С.29-34. Kuz’mina VA, YAkubova IM, Korkach GN. Stomatologicheskoe prosveshchenie beremennyh kak vazhnoe zveno antenatal’noj profilaktiki kariesa vremennyh zubov [Dental education of pregnant women as an important link in antenatal prevention of dental caries in primary teeth]. Stomatologicheskij zhurnal [Dental Journal]. 2017; 1: 29-34. (In Russ.)
19. Гарина И.К., Капранова В.В. Взаимосвязь кариеса зубов у детей с осложненным течением беременности; Стоматология славянских государств: Сборник трудов ХI Международной научно-практической конференции. – Белгород: ИД «Белгород», 2018.—С.54-56. IK Garina, VV Kapranova. Vzaimosvyaz’ kariesa zubov u detej s oslozhnennym techeniem beremennosti; Stomatologiya slavyanskikh gosudarstv: Sbornik trudov KHI Mezhdunarodnoy nauchno-prakticheskoy konferentsii [The relationship between dental caries in children and complicated pregnancy; Dentistry of the Slavic States: Proceedings of the XI International Scientific and Practical Conference]. Belgorod: ID “Belgorod” [Belgorod: Belgorod Publishing House]. 2018; 54-56. (In Russ.)
20. Галиуллин А.Н., Шулаев А.В. Теоретические и методологические основы медико-социальной профилактики // Здоровье человека в XXI веке : IХ-я Российская научно-практическая конференция: сборник научных статей, Казань, 30–31 марта 2017 года. – Казань: Общество с ограниченной ответственностью «Издательско-полиграфическая компания «Бриг», 2017. – С. 440-444. Galiullin AN, SHulaev AV. Teoreticheskie i Metodologicheskie osnovy mediko-social’noj profilaktiki; Zdorov’e cheloveka v XXI veke: IH-ya Rossijskaya nauchno-prakticheskaya konferenciya: sbornik nauchnyh statej, Kazan’, 30–31 marta 2017 goda [Theoretical and methodological foundations of medical and social prevention; Human health in the 21st century: IX Russian scientific and practical conference: collection of scientific articles, Kazan, March 30–31, 2017]. Kazan’: Obshchestvo s ogranichennoj otvetstvennost’yu “Izdatel’sko-poligraficheskaya kompaniya “Brig” [Kazan: Limited Liability Company “Publishing and Printing Company “Brig”]. 2017; 440-444. (In Russ.)
21. Kamalova MK, Atavullaev MJ. Optimization of the prevention and treatment of dental caries in preschool children based on a comprehensive medical and social analysis. Journal of Biomedicine and Practice. 2020; Special issue: 719-725. DOI: 10.26739/2181-9300-2020-SI-86
22. Moynihan P, Tanner LM, Holmes RD. Systematic Review of Evidence Pertaining to Factors That Modify Risk of Early Childhood Caries. JDR Clin Trans Res. 2019 Jul; 4(3): 202-216. DOI: 10.1177/2380084418824262
23. Воронин Г.Л., Янак А.Л. Монородительские семьи: их типы и социальный портрет одинокого родителя // Женщина в российском обществе. – 2018. – №1(86). – С.53-66. Voronin GL, Yanak AL. Monoroditel’skiesem’i: ih tipyi social’nyj portret odinokogo roditelya [Mono-parent families: their types and social portrait of a single parent]. ZHenshchina v rossijskom obshchestve [A woman in Russian society]. 2018; 1(86): 53-66. (In Russ.). DOI: 10.21064/WinRS.2018.1.5
24. Lin YC, Chang CS, PS Ho. Immigrant⁻Native Differences in Sugar-Sweetened Beverage and Snack Consumption and Preventive Behaviors Associated with Severe Early Childhood Caries: A Large-Scale Survey in Taiwan. Int J Environ Res Public Health. 2019; 16: E1047. DOI: 10.3390/ijerph16061047
25. Badriddinovna DS, Makhsumova SS, Makhsumov SM, Maxsumova IS. Clinical Picture and Characteristics of the Course of Children’s Caries. Annals of the Romanian Society for Cell Biology. 2021; 25 (3): 6766-6771.
26. Спивачук З.В. Семья, типы семей, семейные отношения, межличностные отношения // Национальное здоровье. – 2016. – №3-4. – С.132-145. Spivachuk ZV. Sem’ya, tipy semej, semejnye otnosheniya, mezhlichnostnye otnosheniya [Family, types of families, family relationships, interpersonal relationships]. Nacional’noe zdorov’e [National Health]. 2016; 3-4: 132-145. (In Russ.).
REVIEWS
УДК: 614.2 DOI: 10.20969/VSKM.2026.19(2).90-99
Drug addict rehabilitation monitoring system: Key performance indicator (KPI) dashboard as a cybernetic control tool
Azis V. Akhokhova1,2, Aminat R. Bechelova1, Maria M. Thabisimova1, Salima R. Koichueva1, Yulia V. Chuvakina1, Dana A. Kardanova1, Farida A. Pshukova1, Tamila T. Kumakhova1
1 Kabardino-Balkarian State University named after Kh. M. Berbekov, 173 Chernyshevsky str., 360004 Nalchik, Kabardino-Balkarian Republic, Russia
2 Republican Clinical Center of Psychiatry and Narcology, 15 Naloev str., 360032 Nalchik, Kabardino-Balkarian Republic, Russia
Abstract. Introduction. In the context of the increasingly complex drug abuse situation and growing demands on the efficacy of rehabilitation programs, record-keeping systems based on retrospective reporting are proving insufficient for managerial decisions. Aim of this study is to present a cybernetically oriented dashboard of key performance indicators (KPIs) for monitoring drug user rehabilitation, enabling adaptive management at the service and throughout the region. Theoretically, the dashboard is based on S. Beer’s concept of the Viable System Model and W. Ashby’s law of requisite variety, allowing for the structuring of indicators across three management levels (L1–L3): Leading triggers, tactical retention indicators, and strategic clinical and social outcomes. Materials and Methods. Methodological framework includes a cohort design with a standardized index date, registry deduplication, watch time windows, censoring rules, and a flip-flop alert system. The digital implementation is represented by a three-layer architecture: A data layer based on FHIR events, a rule layer for calculating KPIs, and a web dashboard for displaying L1–L3 metrics. Results and Discussion. KPI dashboard is interpreted as a sensory circuit of a cybernetic system, doing the groundwork for predictive control and integrated into the PDCA (Plan–Do–Check–Act) cycle. Conclusions. The proposed model is shown to improve the manageability of the rehabilitation process, contribute to the reduction of blind spots in the care pathway, and it is consistent with international guidelines from the World Health Organization (WHO) and UNODC for monitoring the efficacy of drug addiction treatment and rehabilitation programs.
Keywords: cybernetic management, Viable System Model, law of requisite variety, drug rehabilitation, key performance indicators.
For citation: Akhokhova, A.V.; Bechelova, A.R.; Tkhabisimova, M.M.; et al. Drug addict rehabilitation monitoring system: Key performance indicator (KPI) dashboard as a cybernetic control tool. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 90-99. DOI: 10.20969/VSKM.2026.19(2).90-99.
REFERENCES
1. Beer S. The Brain of the Firm. Wiley. 1995; 432 p.
2. Kelly JF, Bergman B, Hoeppner BB, et al. Prevalence and pathways of recovery from drug and alcohol problems in the United States population. Drug Alcohol Depend. 2017; 181: 162-169. DOI: 10.1016/j.drugalcdep.2017.09.028
3. Zwitter A. Cybernetic governance: implications of technology convergence on governance convergence. Ethics Inf Technol. 2024; 26: 24. DOI: 10.1007/s10676-024-09763-9
4. Smedslund G, Wollscheid S, Fang L, et al. Motivational interviewing for substance abuse. Cochrane Database Syst Rev. 2011; (5): CD008063. DOI: 10.1002/14651858.CD008063.pub2
5. McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness. JAMA. 2000; 284 (13): 1689-1695. DOI: 10.1001/jama.284.13.1689
6. Timko C, Schultz NR, Britt J, Cucciare MA. Transitioning from detoxification to substance use disorder treatment: Facilitators and barriers. J Subst Abuse Treat. 2016; 70: 64-72. DOI: 10.1016/j.jsat.2016.07.010
7. Connery HS. Medication-assisted treatment for opioid use disorder. Harv Rev Psychiatry. 2015; 23 (2): 63-75. DOI: 10.1097/HRP.0000000000000075
8. Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal overdose and association with mortality. Ann Intern Med. 2018; 169 (3): 137-145. DOI: 10.7326/M17-3107
9. Verma AA. Toward the Rigorous Evaluation of Early Warning Scores. JAMA Netw Open. 2024; 7 (10): e2438986. DOI: 10.1001/jamanetworkopen.2024.38986
10. Wong DCW, Bonnici T, Gerry S, et al. Effect of Digital Early Warning Scores on Hospital Vital Sign Observation Protocol Adherence: Stepped-Wedge Evaluation. J Med Internet Res. 2024; 26: e46691. DOI: 10.2196/46691
11. Smith MEB, Chiovaro J, O’Neil M, et al. Early Warning System Scores: A Systematic Review. VA-ESP Report. 2014. URL: https://pubmed.ncbi.nlm.nih.gov/25506953/
12. Harris AH, Humphreys K, Bowe T, Tiet Q. Treatment retention and outcomes in substance use disorder services. Adm Policy Ment Health. 2010; 37: 254-264. DOI: 10.1007/s10488-009-0233-x
13. Blanco C, Wall MM, Okuda M, et al. Generalizability of clinical trials for cannabis dependence to community samples. Drug Alcohol Depend. 2014; 137: 80-86. DOI: 10.1016/j.drugalcdep.2014.01.019
14. Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016; 374 (4): 363-371. DOI: 10.1056/NEJMra151148
15. Mainz J. Defining and classifying clinical indicators. Int J Qual Health Care. 2003; 15 (6): 523-530. DOI: 10.1093/intqhc/mzg081
16. Arah OA, Westert GP, Hurst J, Klazinga NS. A conceptual framework for health system performance assessment. Soc Sci Med. 2006; 63: 2223-2242. DOI: 10.1016/j.socscimed.2006.04.027
17. Campbell SM, Roland MO, Buetow SA. Defining quality of care. Soc Sci Med. 2000; 51: 1611-1625. DOI: 10.1016/S0277-9536(00)00057-5
18. Pronovost PJ, Lilford R. A road map for improving the measurement of quality in health care. BMJ. 2011; 342: d2538. DOI: 10.1136/bmj.d2538
19. Kruse CS, Stein A, Thomas H, Kaur H. The use of electronic health records to support population health: A scoping review. J Med Syst. 2018; 42 (11): 214. DOI: 10.1007/s10916-018-1077-6
20. Ben-Assuli O. Electronic health records, adoption, quality of care, legal and financial aspects. Health Policy. 2015; 119 (3): 287-294. DOI: 10.1016/j.healthpol.2014.10.009
21. Krumholz HM. Big data and new knowledge in medicine. BMJ. 2014; 348: g3721. DOI: 10.1136/bmj.g3721
22. Fujita K, Chiyoda S, Hayashi K. Dashboard monitoring systems improve clinical governance. Int J Med Inform. 2021; 151: 104468. DOI: 10.1016/j.ijmedinf.2021.104468
23. Urbanoski K. Performance measurement in mental health and addiction: A conceptual and empirical review. J Stud Alcohol Drugs Suppl. 2019; 18: 114-128. DOI: 10.15288/jsads.2019.s18.114
24. Meadows DH. Thinking in Systems. Chelsea Green. 2008. DOI: 10.1201/9780429494611
25. Tabak YP, Sun X, Nunez CM, Johannes RS. Early readmission risk prediction using EHR data. Int J Med Inform. 2016; 84 (12): 1048-1056. DOI: 10.1016/j.ijmedinf.2015.08.003
26. Marafino BJ, Huesch MD, Chou EA, Dudley RA. Clinical utility of predictive models for targeting quality improvement interventions. JAMA Netw Open. 2021; 4 (5): e2114739. DOI: 10.1001/jamanetworkopen.2021.14739
27. Lakshman P, et al. Digital Early Warning and Remote Monitoring for Chronic Care Management: A Systematic Review. J Med Progn. 2025; 6 (1): 1-15. DOI: 10.3390/jmp6010009
28. Bar-Yam Y. Multiscale variety in complex systems. Complexity. 2004; 9 (4): 37-45. DOI: 10.1002/cplx.20029
29. Hollnagel E, Woods DD, Leveson N. Resilience Engineering. CRC Press. 2006; 397 p. DOI: 10.1201/9781315605685
30. CDC. Chronic Disease Indicators (CDI). Atlanta: US HHS. 2024. URL: https://www.cdc.gov/cdi/
31. Brenner M, O’Neill A, Breatnach C, et al. Development of the key performance indicators for digital health: A scoping review. Digit Health. 2023; 9: 1-16. DOI: 10.1177/20552076231152160
32. Sreedharan J, Subbarayalu AV. Key Performance Indicators: A Framework for Allied Healthcare Educational Institutions. J Taibah Univ Med Sci. 2024; 19 (2): 247-258. DOI: 10.1016/j.jtumed.2024.01.006
33. Garnick DW, Horgan CM, Acevedo A, et al. Performance measures for substance use disorders. Addict Sci Clin Pract. 2012; 7 (18): 1-11. DOI: 10.1186/1940-0640-7-18
34. Henderson C, Klimas J, Dunne C, et al. Key performance indicators for mental health and substance use disorders: A literature review. Ment Health Subst Use. 2014; 7 (4): 407-419.
DOI: 10.1080/17523281.2014.901402
35. Bassin LA, Greenhalgh D, Tiffin PA. Evaluating a digital early warning score system: mixed-methods. BMJ Health Care Inform. 2023; 30 (1): e100683. DOI: 10.1136/bmjhci-2022-100683
36. Blanchet K, Nam SL, Ramalingam B, Pozo-Martin F. Governance and health: An ecosystems perspective. PLoS Med. 2017; 14 (12): e1002464. DOI: 10.1371/journal.pmed.1002464
37. Kruk ME, Ling EJ, Bitton A, et al. Building resilient health systems. Lancet. 2017; 389: 1021-1035. DOI: 10.1016/S0140-6736(17)30374-6
38. Peters DH. The application of systems thinking in health. Health Res Policy Syst. 2014; 12: 51. DOI: 10.1186/1478-4505-12-51
39. Nahum-Shani I, Smith SN, Spring BJ, et al. Just-in-Time Adaptive Interventions. Ann Behav Med. 2018; 52 (6): 446-462. DOI: 10.1007/s12160-016-9830-8
40. Barnett ML, Olenski AR, Jena AB. Opioid-prescribing patterns of emergency physicians. N Engl J Med. 2017; 376: 663-673. DOI: 10.1056/NEJMsa1610524
41. Borghmans F, Van Hooft S, Reniers G, et al. Applying the Viable System Model to improve integrated care. Health Syst. 2021; 10 (3): 207-227. DOI: 10.1080/20476965.2020.1767069
42. Bickel WK, Moody L, Quisenberry A. Digital therapeutics for addiction. Curr Psychiatry Rep. 2019; 21: 109. DOI: 10.1007/s11920-019-1091-2
43. Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales. Sydney: Psychology Foundation. 1996; 42 p.
44. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): Construct validity and normative data in a large non-clinical sample. Br J Clin Psychol. 2005; 44 (2): 227-239. DOI: 10.1348/014466505X29657
45. Nahum-Shani I, Hekler EB, Spruijt-Metz D. Building health behavior models to guide the development of Just-In-Time Adaptive Interventions: A pragmatic framework. Health Psychol. 2015; 34 (Suppl): 1209-1219. DOI: 10.1037/hea0000306
46. Huckvale K, Torous J, Larsen ME. App-based digital health interventions: effectiveness. Lancet Digit Health. 2019; 1 (6): e250-e260. DOI: 10.1016/S2589-7500(19)30100-7
47. Rojas JC, Manis DR, Vivek S, et al. ML-based prediction of readmission. NPJ Digit Med. 2022; 5: 109. DOI: 10.1038/s41746-022-00643-0
48. Ахохова А.В., Тлакадугова М.Х., Агнокова Т.Х., [и др.]. Прогнозирование рисков дебюта и рецидива наркопотребления: оценочный чеклист и матрица построения индивидуального профилактического маршрута // Менеджер здравоохранения. – 2025. – № 10. – С. 54-62. Akhokhova AV, Tlakadugova MH, Agnokova TH, et al. Prognozirovanie riskov debiuta i retsidiva narkopotrebleniia: otsenochnyi cheklist i matritsa postroeniia individual’nogo profilakticheskogo marshruta [Prediction of debut and relapse risks of drug use: An assessment checklist and a matrix for constructing an individual preventive pathway]. Menedzher zdravookhraneniia [Healthcare Manager]. 2025; 10: 54-62. (In Russ.) DOI: 10.21045/1811-0185-2025-10-54-62
49. Ахохова А.В., Тлакадугова М.Х., Бетуганов Р.Р., [и др.]. Региональный опыт реализации внутреннего контроля качества в медицинской организации по профилю «Психиатрия и наркология»: селективный поиск лучшего решения (часть II) // Менеджер здравоохранения. – 2025. – № 7. – С. 26-35. Akhokhova AV, Tlakadugova MH, Betuganov RR, et al. Regional’- nyi opyt realizatsii vnutrennego kontrolia kachestva v meditsinskoi organizatsii po profiliu “Psikhiatriia i narkologiia”: selektivnyi poisk luchshego resheniia (chast’ II) [Regional experience in implementing internal quality control in a medical organization in the field of psychiatry and narcology: A selective search for the best solution (part II)]. Menedzher zdravookhraneniia [Healthcare Manager]. 2025; 7: 26-35. (In Russ.) DOI: 10.21045/1811-0185-2025-7-26-35
50. Naumann RB, Guynn I, Clare HM, Lich KH. System dynamics in addiction research: a scoping review. Drug Alcohol Depend. 2022; 231: 109237. DOI: 10.1016/j.drugalcdep.2021.109237
51. Canty T, Lootens MR, Sabounchi NS, et al. System dynamics modeling for community-based opioid overdose prevention. Front Public Health. 2025; 13: 1616032. DOI: 10.3389/fpubh.2025.161603
52. Richards TAD, Kirkham J, Lorenzetti DL, Seitz DP. Quality indicators for substance use disorder care: a scoping review protocol. BMJ Open. 2025; 15 (3): e085216. DOI: 10.1136/bmjopen-2024-085216
53. Ashby WR. An Introduction to Cybernetics. Chapman & Hall. 1956; 432 p.
54. Alegría M, Falgas-Bague I, Fukuda M, et al. Performance metrics of SUD care among Medicaid enrollees. JAMA Health Forum. 2022; 3 (7): e221771. DOI: 10.1001/jamahealthforum.2022.1771
55. WHO. Guidelines for the Treatment of Drug Dependence. Geneva: WHO. 2023.
УДК 616.36-002 DOI: 10.20969/VSKM.2026.19(2).100-108
Liver transplantation in autoimmune liver diseases
Evgenia S. Bodryagina1, Dilyara R. Akberova1, Alfiya Kh. Odintsova2, Aigul R. Kirshina2, Polina I. Levanova2, Anastasiya O. Koval1, Sufiya F. Ishkina1
1 Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia
2 Republican Clinical Hospital, 138 Orenburg Tract str., 420124 Kazan, Russia
Abstract. Introduction. In autoimmune liver diseases, liver is transplanted in cases where conservative treatment is ineffective, and the disease leads to the liver function decompensation or to the development of liver cirrhosis of the liver with complications. Liver transplantation is one of the radical treatment options. Aim. To study the features of liver transplantation in autoimmune liver diseases. Materials and Methods. Literature sources were reviewed on liver transplantation in autoimmune diseases of various origins. Results and Discussion. Etiological factors of liver damage can be autoimmune, vascular, congenital, metabolic, tumor-induced, viral, and nutritional. Autoimmune liver diseases are the fourth most common indication for liver transplantation worldwide. These include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, and overlap syndrome (a combination of autoimmune and cholestatic liver diseases). Indications for transplantation are severe liver failure (increased MELD score); irreversible complications of liver cirrhosis, such as ascites, portal hypertension, and hepatic encephalopathy; resistance to immunosuppressive therapy; and severe cholestasis. The patient’s immune profile requires carefully choosing the immunosuppression methods after surgery to reduce the recurrence risk of the autoimmune process. Recurrence of the disease in the transplanted liver is possible, but less pronounced with proper treatment. Conclusions. Liver transplantation in patients with autoimmune liver diseases often improves the quality of life and prolongs it, but requires constant monitoring and support from a hepatologist and a transplantologist.
Keywords: liver transplantation, autoimmune liver diseases.
For citation: Bodryagina, E.S.; Akberova, D.R.; Odintsova, A.Kh.; et al. Liver transplantation in autoimmune liver diseases. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 100-108. DOI: 10.20969/VSKM.2026.19(2).100-108.
REFERENCES
1. Samuel D, De Martin E, Berg T et al. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol. 2024 Dec; 81(6): 1040-1086. DOI: 10.1016/j.jhep.2024.07.032
2. Венцловайте Н.Д., Ефремова Н.А., Горячева Л.Г., Герасимова О.А. Трансплантация печени у детей: опыт последних десятилетий, актуальные проблемы и пути их решения // Детские инфекции. – 2020. – Т.19(2). – С.52-57. Venclovajte ND, Efremova NA, Goryacheva LG, Gerasimova OA. Transplantaciya pecheni u detej: opyt poslednih desyatiletij, aktual’nye problemy i puti ih resheniya [Liver transplantation in children: the experience of last decades, current problems and solutions]. Detskie infekcii [Children’s Infections]. 2020; 19(2): 52-57. (In Russ.) DOI: 10.22627/2072-8107-2020-19-2-52-57
3. Shah YR, Nombera-Aznaran N, Guevara-Lazo D, et al. Liver transplant in primary sclerosing cholangitis: Current trends and future directions. World J Hepatol. 2023 Aug 27; 15(8): 939-953. DOI: 10.4254/wjh.v15.i8.939
4. Global Observatory on Donation and Transplantation. International reports on organ donation and transplantation activities 2021. Available at: www.transplant-observatory.org (2022). Accessed 2 Jan 2023.
5. Terrault NA, Francoz C, Berenguer M, et al. Liver Transplantation 2023: Status Report, Current and Future Challenges. Clin Gastroenterol Hepatol. 2023 Jul; 21(8): 2150-2166. DOI: 10.1016/j.cgh.2023.04.005
6. Dababneh Y, Mousa OY. Liver Transplantation. [Updated 2025 Jun 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559161/
7. Kamath PS, Kim WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology. 2007 Mar; 45(3): 797-805. DOI: 10.1002/hep.21563
8. Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006 May; 130(6): 1652-60. DOI: 10.1053/j.gastro.2006.02.010
9. Кляритская И.Л., Мошко Ю.А., Шелихова Е.О., Максимова Е.В. Новые аспекты трансплантации печени // Крымский терапевтический журнал. – 2016. – №2(29). – С.36-45. Klyaritskaya IL, Moshko YuA, Shelihova EO, Maksimova EV. Novye aspekty transplantacii pecheni [Modern aspects of liver transplantation]. Krymskij terapevticheskij zhurnal [Crimean journal of internal diseases]. 2016; 2(29): 36-45. (In Russ.)
10. Готье С.В., Хомяков С.М. Донорство и трансплантация органов в Российской Федерации в 2023 году. XVI сообщение регистра Российского трансплантологического общества // Вестник трансплантологии и искусственных органов. – 2024. – Т.XXVI. – №3. – С.8-31. Gautier SV, Khomyakov SM. Donorstvo i transplantaciya organov v Rossijskoj Federacii v 2023 godu. XVI soobshchenie registra Rossijskogo transplantologicheskogo obshchestva [Organ donation and transplantation in the Russian Federation in 2023 16th Report from the Registry of the Russian Transplant Society]. Vestnik transplantologii i iskusstvennyh organov [Russian Journal of Transplantology and Artificial Organs]. 2024; XXVI, 3: 8-31. (In Russ.) DOI: 10.15825/1995-1191-2024-3-8-31
11. Battistella S, D’Arcangelo F, Grasso M, et al. Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management. Clin Mol Hepatol. 2023 Feb; 29(Suppl): S286-S301. DOI: 10.3350/cmh.2022.0392
12. Bittermann T, Lewis JD, Levy C, Goldberg DS. Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis. Hepatology. 2023 Feb 1; 77(2): 367-378.
3. Battistella S, Grasso M, Catanzaro E, et al. Evolution of Liver Transplantation Indications: Expanding Horizons. Medicina (Kaunas). 2024 Feb 28; 60(3): 412. DOI: 10.3390/medicina60030412
14. Montano-Loza AJ, Corpechot C, Burra P, et al. Recurrence of autoimmune liver diseases after liver transplantation: Review and expert opinion statement. Liver Transpl. 2025 Mar 1; 31(3): 369-383. DOI: 10.1097/LVT.0000000000000419
15. Chazouilleres O, Beuers U, Bergquist A, et al. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022 Sep; 77(3): 761-806. DOI: 10.1016/j.jhep.2022.05.011
16. Martínez Casas OY, Díaz Ramírez GS, Marín Zuluaga JI, et al. Autoimmune hepatitis - primary biliary cholangitis overlap syndrome. Long-term outcomes of a retrospective cohort in a university hospital. Gastroenterol Hepatol. 2018 Nov; 41(9): 544-552. English, Spanish. DOI: 10.1016/j.gastrohep.2018.05.019
17. Zeng Q, Zhao L, Wang C, et al. Relationship between autoimmune liver disease and autoimmune thyroid disease: a cross-sectional study. Scand J Gastroenterol. 2020 Feb; 55(2): 216-221. DOI: 10.1080/00365521.2019.1710766
18. Kulkarni AV, Parthasarathy K, Kumar P, et al. Early liver transplantation after COVID-19 infection: The first report. Am J Transplant. 2021 Jun; 21(6): 2279-2284. DOI: 10.1111/ajt.16509
19. Murillo Perez CF, Ivanics T, Claasen MPAW, et al. Trends in liver transplantation for autoimmune liver diseases: a Canadian study. Can J Surg. 2022 Oct 12; 65(5): E665-E674. DOI: 10.1503/cjs.012121
20. Mercado LA, Gil-Lopez F, Chirila RM, Harnois DM. Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview. Diagnostics (Basel). 2024 Feb 9; 14(4): 382. DOI: 10.3390/diagnostics14040382
21. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol. 2015 Oct; 63(4): 971-1004. DOI: 10.1016/j.jhep.2015.06.030
22. Galaski J, Weiler-Normann C, Schakat M, et al. Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. J Hepatol. 2021 Feb; 74(2): 312-320. DOI: 10.1016/j.jhep.2020.07.032
23. Hahn JW, Yang HR, Moon JS, et al. Global incidence and prevalence of autoimmune hepatitis, 1970-2022: a systematic review and meta-analysis. EClinicalMedicine. 2023 Oct 17; 65: 102280. DOI: 10.1016/j.eclinm.2023.102280
24. Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020 Aug; 72(2): 671-722. DOI: 10.1002/hep.31065
25. Muratori L, Lohse AW, Lenzi M. Diagnosis and management of autoimmune hepatitis. BMJ. 2023 Feb 6; 380: e070201. DOI: 10.1136/bmj-2022-070201
26. Flikshteyn B, Amer K, Tafesh Z, Pyrsopoulos NT. Diagnosis of Autoimmune Hepatitis. Clin Liver Dis. 2024 Feb; 28(1): 37-50. DOI: 10.1016/j.cld.2023.06.004
27. Sirbe C, Simu G, Szabo I, et al. Pathogenesis of Autoimmune Hepatitis – Cellular and Molecular Mechanisms. Int J Mol Sci. 2021 Dec 17; 22(24): 13578. DOI: 10.3390/ijms222413578
28. Pape S, Snijders RJALM, Gevers TJG, et al. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol. 2022 Apr; 76(4): 841-849. DOI: 10.1016/j.jhep.2021.12.041
29. Andrade RJ, Aithal GP, de Boer YS, et al. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report. J Hepatol. 2023 Sep; 79(3): 853-866. DOI: 10.1016/j.jhep.2023.04.033
30. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011 Apr; 56(4): 958-76. DOI: 10.1007/s10620-011-1611-4
31. Stephens C, Robles-Diaz M, Medina-Caliz I, et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. J Hepatol. 2021 Jul; 75(1): 86-97. DOI: 10.1016/j.jhep.2021.01.029
32. van Gerven NM, Verwer BJ, Witte BI, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014 Oct; 49(10): 1245-54. DOI: 10.3109/00365521.2014.946083
33. Михайлова Е.А., Лапина Н.С. Случай поздней диагностики первичного билиарного холангита // Медицинский альманах. – 2023. – №1(74). – С.83-90. Mikhailova EA, Lapina NS. Sluchaj pozdnej diagnostiki pervichnogo biliarnogo holangita [A case of late diagnosis of primary biliary cholangitis]. Medicinskij al’manah [Medical almanac]. 2023; 1(74): 83-90. (In Russ.)
34. Трухан Д.И. Первичный билиарный холангит: новая дефиниция заболевания, актуальные аспекты диагностики и лечения. Обзор литературы // Клинический разбор в общей медицине. – 2023. – Т.4(2). – С.48–59. Trukhan DI. Pervichnyj biliarnyj holangit: novaya definiciya zabolevaniya, aktual’nye aspekty diagnostiki i lecheniya. Obzor literatury [Primary bilial cholangitis: a new definition of the disease, current aspects of diagnosis and treatment. Literature review]. Klinicheskij razbor v obshchej medicine [Clinical review for general practice]. 2023; 4 (2): 48–59. (In Russ.) DOI: 10.47407/kr2023.4.2.00204
35. Сюткин В.Е., Салиенко А.А., Олисов О.Д., Новрузбеков М.С. Возврат аутоиммунных болезней после трансплантации печени // Трансплантология. – 2022. – T.14(4). – C.421-431. Syutkin VE, Salienko AA, Olisov OD, Novruzbekov MS. Vozvrat autoimmunnyh boleznej posle transplantacii pecheni [Relapse of autoimmune diseases after liver transplantation]. Transplantologiya [The Russian Journal of Transplantation]. 2022; 14(4): 421–431. (In Russ.) DOI: 10.23873/2074-0506-2022-14-4-421-431
36. Goet JC, Murillo Perez CF, Harms MH, et al. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. Am J Gastroenterol 2021; 116 (7): 1514-22. DOI: 10.14309/ajg.0000000000001285
37. Egawa H, Ueda Y, Ichida T, et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry. Am J Transplant. 2011;11(3):518-27. DOI: 10.1111/j.1600-6143.2010.03402.x
38. Mehta TI, Weissman S, Fung BM, et al. Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and meta-analysis. Liver Int. 2021; 41: 2418–2426. DOI: 10.1111/liv.15007
39. Andersen IM, Fosby B, Boberg KM, et al. Indications and outcomes in liver transplantation in patients with primary sclerosing cholangitis in Norway. Transplant Direct. 2015; 1(9): e39. DOI: 10.1097/TXD.0000000000000548
40. Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg. 1997; 225(5):472-81; discussion 481-3. DOI: 10.1097/00000658-199705000-00004
41. Одинцова А.Х., Акберова Д.Р., Садыкова Л.Р., [и др.] Тринадцатилетнее наблюдение за пациенткой с циррозом печени в исходе синдрома перекреста аутоиммунного гепатита и первичного билиарного холангита: тяжелый COVID-19 и трансплантация печени // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2024. – Т.34, №1. – С.76-84. Odincova AH, Akberova DR, Sadykova LR, et al. Trinadcatiletnee nablyudenie za pacientkoj s cirrozom pecheni v iskhode sindroma perekresta autoimmunnogo gepatita i pervichnogo biliarnogo holangita: tyazhelyj COVID-19 i transplantaciya pecheni [Thirteen-Year Follow-Up of a Patient with Liver Cirrhosis Resulting from the Overlap Syndrome of Autoimmune Hepatitis and Primary Biliary Cholangitis: Severe COVID-19 and Liver Transplantation]. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2024; 34,№1: 76-84. (In Russ.) DOI: 10.22416/1382-4376-2024-34-1-76-84
42. Sohal A, Nikzad N, Kowdley KV. Overlap syndromes in autoimmune liver disease: a review. Transl Gastroenterol Hepatol. 2025 Apr 15; 10: 33. DOI: 10.21037/tgh-24-140.
43. Filipovic B, Marjanovic-Haljilji M, Blagojevic D, et al. A Closer Look into Autoimmune Liver Diseases. Int J Mol Sci. 2025 Feb 21; 26(5): 1863. DOI: 10.3390/ijms26051863
44. Poudel S, Gupta S, Saigal S. Basics and Art of Immunosuppression in Liver Transplantation. J Clin Exp Hepatol. 2024 May-Jun; 14(3): 101345. DOI: 10.1016/j.jceh.2024.101345
45. Forde JJ, Bhamidimarri KR. Management of Biliary Complications in Liver Transplant Recipients. Clin Liver Dis. 2022 Feb; 26(1): 81-99. DOI: 10.1016/j.cld.2021.08.008
46. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001 Mar; 33(3): 544-53. DOI: 10.1053/jhep.2001.22131
47. Czaja AJ. Cholestatic phenotypes of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2014 Sep; 12(9): 1430-8. DOI: 10.1016/j.cgh.2013.08.039
48. Донова Л.В., Новрузбеков М.С., Магомедов К.М. Эхография при трансплантации печени: обзор литературы // Вестник медицинского института «Реавиз». Реабилитация, Врач и Здоровье. – 2021. – Т.1(49). – С.87-96. Donova LV, Novruzbekov MS, Magomedov KM. Ekhografiya pri transplantacii pecheni: obzor literatury [Echography in liver transplantation: a literature review]. Vestnik medicinskogo instituta «Reaviz»: Reabilitaciya, Vrach i Zdorov’e [Bulletin of the Medical Institute Reaviz: Rehabilitation, Doctor and Health]. 2021; 1(49): 87-96. (In Russ.) DOI: 10.20340/vmi-rvz.2021.1.TX.2
49. Sağlam O, Harputluoğlu MMM, Bilgiç Y, et al. Liver Transplantation for Autoimmune Hepatitis: 20 Years of Tertiary Centre Experience. Turk J Gastroenterol. 2024 Dec 16; 36(3): 145-151. DOI: 10.5152/tjg.2024.24464
50. Harputluoglu M, Caliskan AR, Akbulut S. Autoimmune hepatitis and liver transplantation: Indications, and recurrent and de novo autoimmune hepatitis. World J Transplant. 2022 Mar 18; 12(3): 59-64. DOI: 10.5500/wjt.v12.i3.59
УДК: 616.988-022.7-036.2:314.44 DOI: 10.20969/VSKM.2026.19(2).109-116
Herpesvirus infections: Global epidemiology, clinical and social consequences, and control issues
Ekaterina B. Kasymova1, Olga A. Bashkina1, Vera V. Kulagina2
1 Astrakhan State Medical University, 121 Bakinskaya str., 414000 Astrakhan, Russia
2 Samara Medical University – Reaviz, 227 Chapaevskaya str., 443001 Samara, Russia
Abstract. Introduction. Herpesvirus infections remain a serious global health problem due to their ubiquity and ability to cause a wide range of pathologies, from labial herpes through cancer. Eight types of human herpesviruses have a unique ability to latency and reactivation, which significantly complicates controlling them, despite advances in diagnostics and therapy. Aim. To comprehensively analyze contemporary epidemiological data on herpesvirus infections, assess their clinical manifestations and socio-economic burden, and arrange the key issues hindering the development of effective epidemiological control strategies. Materials and Methods. The study was based on a comprehensive analysis of the scientific literature selected from PubMed, Scopus, and Web of Science over the past 15 years. Priority was given to large-scale epidemiological studies, relevant clinical guidelines, and meta-analyses. Results and Discussion. Herpesvirus infections demonstrate global distribution with high seroprevalence (herpes simplex virus type 1 was detected in 67-98% of the individuals examined, while Epstein-Barr virus and cytomegalovirus were found in 90-98% of them). Regional differences are marked for herpes simplex virus type 2 (15–80%) and human herpes virus type 8 (2–30%). The key problem is the ability to reactivate during immunosuppression (the risk increases by 2.1–3.8 times for herpes simplex virus when taking glucocorticoids and up to 68–72% for cytomegalovirus during cytostatic therapy). Herpesvirus infections are associated with oncopathology, neonatal infections, and decreased quality of life. Conclusions. Main difficulties in controlling are the lack of effective vaccines (except for that aimed at preventing from chickenpox virus), ineffective therapy for latent forms, and imperfect diagnostics. Promising approaches include the development of new treatment strategies, improved diagnostics, and international cooperation in the creation of vaccines and drugs.
Keywords: herpesvirus infections, epidemiology, medical and social significance, epidemiological control issues
For citation: Kasymova, E.B.; Bashkina, O.A.; Kulagina, V.V. Herpesvirus infections: Global epidemiology, clinical and social consequences, and control issues. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 109-116. DOI: 10.20969/VSKM.2026.19(2).109-116.
REFERENCES
1. James C, Harfouche M, Welton NJ, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020; 98 (5): 315-329. DOI: 10.2471/BLT.19.237149
2. Zhang I, Hsiao Z, Liu F. Development of Genome Editing Approaches against Herpes Simplex Virus Infections. Viruses. 2021; 13 (2): 338. DOI: 10.3390/v13020338
3. Looker KJ, Magaret AS, May MT, et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS One. 2015; 10 (10): e0140765. DOI: 10.1371/journal.pone.0140765
4. Ayoub HH, Chemaitelly H, Abu-Raddad LJ. Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions. BMC Med. 2019; 17 (1): 57. DOI: 10.1186/s12916-019-1285-x
5. Хрянин А.А. Герпес под подушкой. Распространенность вируса простого герпеса в Российской популяции: многолетний мониторинг // Status Praesens. – 2014. – Т. 6, №17. – С. 67-74. Khryanin AA. Gerpes pod podushkoy; Rasprostranennost’ virusa prostogo gerpesa v Rossiyskoy populyatsii: mnogoletniy monitoring [Herpes under the pillow; Prevalence of herpes simplex virus in the Russian population: long-term monitoring]. Status Praesens [Status Praesens]. 2014; 6 (17): 67–74. (In Russ.)
6. Ho DY, Enriquez K, Multani A. Herpesvirus Infections Potentiated by Biologics. Infect Dis Clin North Am. 2020; 34 (2):3 11-339. DOI: 10.1016/j.idc.2020.02.006
7. Honore PM, Barreto Gutierrez L, Kugener L, et al. SARS-CoV-2 infection as a risk factor for herpesviridae reactivation: consider the potential influence of corticosteroid therapy. Crit Care. 2020; 24 (1): 530. DOI: 10.1186/s13054-020-03349-9
8. Osterman A, Ruf VC, Domingo C, et al. Travel-associated neurological disease terminated in a postmortem diagnosed atypical HSV-1 encephalitis after high-dose steroid therapy – a case report. BMC Infect Dis. 2020; 20 (1): 150. DOI: 10.1186/s12879-020-4859-5
9. Heininger A, Haeberle H, Fischer I, et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care. 2011; 15 (2): R77. DOI: 10.1186/cc10069
10. Raouf MME, Ouf NM, Elsorady MAS, et al. Human herpesvirus-6 in hematopoietic stem cell transplant recipients: a prospective cohort study in Egypt. Virol J. 2023; 20 (1): 20. DOI: 10.1186/s12985-023-01980-w
11. Шамгунова Б.А., Демидов А.А., Заклякова Л.В., [и др.] Лекарственно-индуцированная реакция гиперчувствительности (DRESS-синдром), ассоциированная с реактивацией герпесвирусной инфекции (клиническое наблюдение) // Современные проблемы науки и образования. – 2020. – №. 4. – С. 169. Shamgunova BA, Demidov AA, Zaklyakova LV, et al. Lekarstvenno-indutsirovannaya reaktsiya giperchuvstvitel’nosti (DRESS-sindrom), assotsiirovannaya s reaktivatsiey gerpesvirusnoy infektsii (klinicheskoe nablyudenie) [Drug-induced hypersensitivity reaction (DRESS syndrome) associated with reactivation of herpesvirus infection (clinical case)]. Sovremennye problemy nauki i obrazovaniya [Modern Problems of Science and Education]. 2020; (4): 169. (In Russ.) DOI: 10.17513/spno.30054
12. Zong Y, Kamoi K, Miyagaki M, et al. Applications of Biological Therapy for Latent Infections: Benefits and Risks. Int J Mol Sci. 2024; 25 (17): 9184. DOI: 10.3390/ijms25179184
13. Honore PM, Mugisha A, Kugener L, et al. Acyclovir for ventilator-associated pneumonia refractory to antibiotics and with high viral herpes simplex load: we are not sure. Crit Care. 2020; 24 (1): 262. DOI: 10.1186/s13054-020-02868-9
14. Hansen R, Thomson JM, El-Omar EM, Hold GL. The role of infection in the aetiology of inflammatory bowel disease. J Gastroenterol. 2010; 45 (3): 266-76. DOI: 10.1007/ s00535–009–0191-y
15. Mikaeloff Y, Kezouh A, Suissa S. Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft tissue complications in patients with varicella or zoster disease. Br J Clin Pharmacol. 2008; 65 (2): 203–209. DOI: 10.1111/j.1365-2125.2007.02997.x
16. Rostgaard K, Balfour HH Jr, Jarrett R, et al. Primary Epstein-Barr virus infection with and without infectious mononucleosis. PLoS One. 2019; 14 (12): e0226436. DOI: 10.1371/journal.pone.0226436
17. Xu F, Schillinger JA, Sternberg MR, et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis. 2002; 185: 1019-1024. DOI: 10.1086/340041
18. Smith JS, Robinson NJ. Age-Specific Prevalence of Infection with Herpes Simplex Virus Types 2 and 1: A Global Review. J Infect Dis. 2002; 186: 3–28. DOI: 10.1086/343739
19. Sherrard J, Wilson J, Donders G, et al. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018; 29 (13): 1258–1272. DOI: 10.1177/0956462418785451
20. Yousuf W, Ibrahim H, Harfouche M, et al. Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions. BMJ Glob Health. 2020; 5 (7): e002388. DOI: 10.1136/bmjgh-2020-002388 21. Debrah O, Agyemang-Yeboah F, Asmah RH, et al. SERO-prevalence of herpes simplex virus type 1 and type 2 among women attending routine Cervicare clinics in Ghana. BMC Infect Dis. 2018; 18 (1): 378. DOI: 10.1186/s12879-018-3288-1
22. Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol. 2007; 57 (5): 737–766. DOI: 10.1016/j.jaad.2007.06.027
23. Del Romero J, Moreno Guillén S, Rodríguez-Artalejo FJ, et al. Sexually transmitted infections in Spain: Current status. Rev Esp Quimioter. 2023; 36 (5):4 44-465. DOI: 10.37201/req/038.2023
24. Smith JS, Herrero R, Muñoz N, et al. Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines. Sex Transm Dis. 2001; 28 (4):1 87-194. DOI: 10.1097/00007435-200104000-00001
25. Issakwisa HM, Mbwile GR, Mbwanji GF, et al. Seroprevalence of herpes simplex virus type 1 among people living with HIV in Mbeya, Tanzania. BMC Infect Dis. 2020; 20 (1): 577. DOI: 10.1186/s12879-020-05301-2
26. Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM. Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect. 2007; 83 (1): 16-22. DOI: 10.1136/sti.2006.020966
27. Schiffer JT, Gottlieb SL. Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development. Vaccine. 2019; 37 (50): 7363-7371. DOI: 10.1016/j.vaccine.2017.09.044
28. Woestenberg PJ, Tjhie JHT, de Melker HE, et al. Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period. BMC Infect Dis. 2016; 16: 364. DOI: 10.1186/s12879-016-1707-8
29. Chaiyakunapruk N, Lee SWH, Kulchaitanaroaj P, et al. Estimated global and regional economic burden of genital herpes simplex virus infection among 15–49 year-olds in 2016. BMC Global Public Health. 2024; 2: 42. DOI: 10.1186/s44263-024-00053-6
30. Орадовская И.В., Викулов Г.Х., Колобухина Л.В. [и др.]. Герпесвирусные инфекции у взрослых жителей г. Москвы: заболеваемость, распространенность, нозологические формы и алгоритм ведения // Инфекционные болезни. – 2022. – Т. 4, № 20. – С. 125–142. Oradovskaya IV, Vikulov GK, Kolobukhina LV, et al. Gerpesvirusnye infektsii u vzroslykh zhiteley g. Moskvy: zabolevaemost’, rasprostranennost’, nozologicheskie formy i algoritm vedeniya [Herpesvirus infections in adult residents of Moscow: morbidity, prevalence, nosological forms and management algorithm]. Infektsionnye bolezni [Infectious Diseases]. 2022; 20 (4): 125–142. (In Russ.) DOI: 10.20953/1729-9225-2022-4-125-142
31. Жебрун А.Б., Куляшова Л.Б., Ермоленко К.Д. [и др.]. Распространенность герпесвирусных инфекций у детей и взрослых в Санкт-Петербурге по данным сероэпидемиологического исследования //Журнал микробиологии, эпидемиологии и иммунобиологии. – 2013. – №6. – С. 30-36. Zhebrun AB, Kulyashova LB, Ermolenko KD, et al. Rasprostranennost‘ gerpesvirusnykh infektsiy u detey i vzroslykh v Sankt-Peterburge po dannym seroepidemiologicheskogo issledovaniya [Prevalence of herpesvirus infections in children and adults in St. Petersburg according to seroepidemiological study]. Zhurnal mikrobiologii, epidemiologii i immunobiologii [Journal of Microbiology, Epidemiology and Immunobiology]. 2013; (6): 30–36. (In Russ.).
32. Baker DA. Consequences of herpes simplex virus in pregnancy and their prevention. Curr Opin Infect Dis. 2007; 20 (1): 73–76. DOI: 10.1097/QCO.0b013e328013cb19
33. Samies NL, James SH, Kimberlin DW. Neonatal Herpes Simplex Virus Disease: Updates and Continued Challenges. Clin Perinatol. 2021; 48 (2): 263-274. DOI: 10.1016/j.clp.2021.03.003
34. Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections. Semin Perinatol. 2018; 42 (3): 168-175. DOI: 10.1053/j.semperi.2018.02.004
35. Teutsch S, Berkhout A, Raynes-Greenow C, et al. Characteristics of neonatal herpes simplex central nervous system disease in Australia (1997-2020). J Clin Virol. 2023; 165: 105526. DOI: 10.1016/j.jcv.2023.105526
36. Koshy E, Mengting L, Kumar H, Jianbo W. Epidemiology, treatment and prevention of herpes zoster: A comprehensive review. Indian J Dermatol Venereol Leprol. 2018; 84 (3): 251–262. DOI: 10.4103/ijdvl.IJDVL_1021_16
37. Johnson BH, Palmer L, Gatwood J, et al. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis. 2015; 15: 502. DOI: 10.1186/s12879-015-1262-8
38. Lim DZJ, Tey HL, Salada BMA, et al. Herpes Zoster and Post-Herpetic Neuralgia-Diagnosis, Treatment, and Vaccination Strategies. Pathogens. 2024; 13 (7): 596. DOI: 10.3390/pathogens13070596
39. Касымова Е.Б., Башкина О.А., Галимзянов Х.М. [и др.]. Клинико-эпидемиологические аспекты Эпштейн-Барр вирусной инфекции // Астраханский медицинский журнал. – 2017. – Т. 12, № 3. – С. 6–12. Kasymova EB, Bashkina OA, Galimzyanov KhM, et al. Kliniko-epidemiologicheskie aspekty Epshteyn-Barr virusnoy infektsii [Clinical and epidemiological aspects of Epstein-Barr virus infection]. Astrakhanskiy meditsinskiy zhurnal [Astrakhan Medical Journal]. 2017; 12 (3): 6–12. (In Russ.).
40. Касымова Е.Б., Башкина О.А., Галимзянов Х.М. [и др.]. Динамика герпесвирусных инфекций у детей Астраханской области по данным ПЦР-диагностики // Астраханский медицинский журнал. – 2012. – Т. 7, № 2. – С. 116-119. Kasymova EB, Bashkina OA, Galimzyanov KhM, et al. Dinamika gerpesvirusnykh infektsiy u detey Astrakhanskoy oblasti po dannym PTsR-diagnostiki [Dynamics of herpesvirus infections in children of the Astrakhan region according to PCR diagnostics]. Astrakhanskiy meditsinskiy zhurnal [Astrakhan Medical Journal]. 2012; 7 (2): 116–119. (In Russ.)
41. Касымова Е.Б., Башкина О.А., Галимзянов Х.М. Ключевые вопросы диагностики и лечения инфекционного мононуклеоза // Астраханский медицинский журнал. – 2016. – № 3 (11). – С. 38-44. Kasymova EB, Bashkina OA, Galimzyanov KhM. Klyuchevye voprosy diagnostiki i lecheniya infektsionnogo mononukleoza [Key issues of diagnosis and treatment of infectious mononucleosis]. Astrakhanskiy meditsinskiy zhurnal [Astrakhan Medical Journal]. 2016; 11 (3): 38–44. (In Russ.)
42. Попкова М.И., Уткин О.В. Генетическое разнообразие вируса Эпштейна-Барр: современный взгляд на проблему // Журнал микробиологии, эпидемиологии и иммунобиологии. – 2022. – Т. 1, № 99. – С. 93–108. Popkova MI, Utkin OV. Geneticheskoye raznoobraziye virusa Epshteyna-Barr: sovremennyy vzglyad na problemu [Genetic diversity of Epstein-Barr virus: modern view on the problem]. Zhurnal mikrobiologii, epidemiologii i immunobiologii [Journal of Microbiology, Epidemiology and Immunobiology]. 2022; 99(1): 93–108. (In Russ.) DOI: 10.36233/0372-9311-228
43. Гурцевич В.Э., Смирнова К.В., Ботезату И.В. [и др.]. Полиморфизм онкогена LMP-1 вируса Эпштейна-Барр в двух этнических группах России, татар и славян, и его влияние на развитие некоторых злокачественных опухолей // Инфекция и иммунитет. – 2020. – Т. 10, №2. – С. 347–358. Gurtsevich VE, Smirnova KV, Botezatu IV, et al. Polimorfizm onkogena LMP-1 virusa Epshteyna-Barr v dvukh etnicheskikh gruppakh Rossii, tatar i slavyan, i yego vliyaniye na razvitiye nekotorykh zlokachestvennykh opukholey [Polymorphism of LMP-1 oncogene of Epstein-Barr virus in two ethnic groups of Russia, Tatars and Slavs, and its influence on development of some malignant tumors]. Infektsiya i immunitet [Infection and Immunity]. 2020; 10 (2): 347–358. (In Russ.) DOI: 10.15789/2220-7619-EBV-1162
44. Griffiths P, Lumley S. Cytomegalovirus. Curr Opin Infect Dis. 2014; 27 (6): 554–559. DOI: 10.1097/QCO.0000000000000107
45. Moseley P, Klenerman P, Kadambari S. Indirect effects of cytomegalovirus infection: Implications for vaccine development. Rev Med Virol. 2023; 33 (1): e2405. DOI: 10.1002/rmv.2405
46. Ковалык В.П., Владимирова Е.В., Колиева Г.Л. [и др.]. Цитомегаловирус, вирус Эпштейна-Барр и вирус герпеса 6 типа в качестве инфекций, передаваемых половым путем: обзор литературы // Современные проблемы здравоохранения и медицинской статистики. – 2023. – № 2. – С. 50–65. Kovalyk VP, Vladimirova EV, Kolieva GL, et al. Tsitomegalovirus, virus Epshteyna-Barr i virus gerpesa 6 tipa v kachestve infektsiy, peredavayemykh polovym putem: obzor literatury [Cytomegalovirus, Epstein-Barr virus and herpesvirus type 6 as sexually transmitted infections: literature review]. Sovremennye problemy zdravookhraneniya i meditsinskoy statistiki [Modern Problems of Healthcare and Medical Statistics]. 2023; (2): 50–65. (In Russ.) DOI: 10.24412/2312-2935-2023-2-50-65
47. Yamanishi K, Kondo T, Kondo K, et al. Exanthem subitum and human herpesvirus 6 (HHV-6) infection. Adv Exp Med Biol. 2014; 278: 29–37. DOI: 10.1007/978-1-4684-5853-4_4
48. LaCroix S, Stewart JA, Thouless ME, Black JB. An immunoblot assay for detection of immunoglobulin M antibody to human herpesvirus 6. Clin Diagn Lab Immunol. 2000; 7 (5): 823–827. DOI: 10.1128/CDLI.7.5.823-827.2000
49. Kosuge H. HHV-6, 7 and their related diseases. J Dermatol Sci. 2000; 22 (3): 205-212. DOI: 10.1016/s0923-1811(99)00086-9
50. Ablashi DV, Berneman ZN, Kramarsky B, et al. Human herpesvirus-7 (HHV-7): current status. Clin Diagn Virol. 2001; 4 (1): 1–13. DOI: 10.1016/0928-0197(95)00005-s
51. Caselli E, Di Luca D. Molecular biology and clinical associations of Roseoloviruses human herpesvirus 6 and human herpesvirus 7. New Microbiol. 2007; 30 (3): 173–187.
52. Keshavarz M, Ghasemi S, Arjeini Y, et al. Frequency eva luation and molecular characterization of HHV-6 and HHV-7 among children under 5 years with fever and skin rash. J Med Virol. 2023; 95 (3): e28608. DOI: 10.1002/jmv.28608
53. Ngalamika O, Munsaka S. Cells of the Innate and Adaptive Immune Systems in Kaposi’s Sarcoma. J Immunol Res. 2020; 2020: 8852221. DOI: 10.1155/2020/8852221
54. Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi’s sarcoma. J Natl Cancer Inst. 2002; 94 (22): 1712–1718. DOI: 10.1093/jnci/94.22.1712
УДК: 613.25:577.21 DOI: 10.20969/VSKM.2026.19(2).117-126
Key aspects of metabolically healthy obesity
Inna V. Korol1, Liudmila A. Ivanova1, Yuliya S. Kovalenko1
1 Kuban State Medical University, 4 Mitrofan Sedin str., 350063 Krasnodar, Russia
Abstract. Introduction.Currently, there are many publications dealing with the metabolic phenotypes of obesity. They are classified as metabolically healthy and unhealthy obesity. There are also metabolically healthy and unhealthy normal weights. Аim. To examine and analyze literary data on the problem of metabolically healthy obesity. Materials and Methods. Open-access publications were systematically searched for in the PubMed and Scopus databases, using the “metabolic healthy obesity” query. Data from reviews, original studies, and meta-analyses were included. The study identified the key aspects of metabolically healthy obesity causes, classification, diagnostic criteria, clinical characteristics, and treatment principles.Results and Discussion. An increase in one’s body mass index does not always correlate with a decline in cardiometabolic health. Fat accumulation and metabolic patterns vary based on genetic and acquired factors.The main healthy-obesity development principle is the preserved ability of the subcutaneous adipose tissue to accumulate triglycerides, preventing ectopic accumulation of fat.The core scientific vectors are aimed at identifying the predictors of transitioning from a metabolically favorable form of obesity to an unfavorable one, as well as at studying the relationship between obesity phenotypes and various diseases. Conclusions. Metabolically healthy obesity is a transient phenotype followed by the development of metabolically unhealthy obesity. It is important to prolong the patient’s metabolic health for as long as possible and to address factors that contribute to metabolic deterioration to reduce or prevent the risk of transition to a metabolically unfavorable state.
Keywords: metabolically healthy obesity, obesity phenotypes.
For citation: Korol, I.V.; Ivanova, L.A.; Kovalenko, Yu.S. Key aspects of metabolically healthy obesity. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 117-126. DOI: 10.20969/VSKM.2026.19(2).117-126.
REFERENCES
1. Okunogbe A, Nugent R, Spencer G, et al. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health. 2022; 7 (9): 1-17. DOI: 10.1136/bmjgh-2022-009773
2. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002; 347 (5): 305-313. DOI: 10.1056/NEJMoa020245
3. Lavie CJ, Laddu D, Arena R, et al. Healthy Weight and Obesity Prevention: JACC Health Promotion Series. J Am Coll Cardiol. 2018; 72 (13): 1506-1531. DOI: 10.1016/j.jacc.2018.08.1037
4. Blüher М. Metabolically Healthy Obesity. Endocrine Reviews. 2020; 41 (bnaa004): 1-49. DOI 10.1210/endrev/bnaa004
5. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. 1956; 4 (1): 20-34. DOI: 10.1093/ajcn/4.1.20
6. Eckel N, Li Y, Kuxhaus O, et al. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018; 6 (9): 714-724. DOI: 10.1016/S2213-8587(18)30137-2
7. Van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014; 14: 9. DOI: 10.1186/1472-6823-14-9
8. Metspalu A. Estonian Genome Project--before the take-off and take-off. Bioinformatics. 2002; 18 (2): 152. DOI: 10.1093/bioinformatics/18.suppl 2.s152
9. Inouye M, Kettunen J, Soininen P, et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol. 2010; 6: 441. DOI: 10.1038/msb.2010.93
10. Aromaa A, Koskinen S. Baseline results of the population health survey Health 2000: health and functional capacity in Finland. National Institute of Public Health Publications B12/2004. 2004; 148 p.
11. Wichmann HE, Gieger C, Illig T. MONICA/KORA Study Group. KORA-gen--resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen. 2005; 1: 26-30. DOI: 10.1055/s-2005-858226
12. Pattaro C, Marroni F, Riegler A, et al. The genetic study of three population microisolates in South Tyrol (MICROS): study design and epidemiological perspectives. BMC Med Genet. 2007; 8: 29. DOI: 10.1186/1471-2350-8-29
13. Pinto-Sietsma SJ, Janssen WMT, Hillege HL, et al. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol. 2000; 11 (10): 1882-1888. DOI: 10.1681/ASN.V11101882
14. Krokstad S, Langhammer A, Hveem K, et al. Cohort Profile: the HUNT Study, Norway. Int J Epidemiol. 2013; 42 (4): 968-77. DOI: 10.1093/ije/dys095
15. Power C, Elliott J. Cohort profile: 1958 British birth cohort (National Child Development Study). Int J Epidemiol. 2006; 35 (1): 34-41. DOI: 10.1093/ije/dyi183
16. Caleyachetty R, Thomas GN, Toulis KA, et al. Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3,5 Million Men and Women. J Am Coll Cardiol. 2017; 70 (12): 1429-1437. DOI: 10.1016/j.jacc.2017.07.763
17. Баланова Ю.А., Имаева А.Э., Куценко В.А. и др. Метаболический синдром и его ассоциации с социально-демографическими и поведенческими факторами риска в российской популяции 25-64 лет. Кардиоваскулярная терапия и профилактика. – 2020. – 19 (4). С. 45-47. Balanova YuA, Imaeva AE, Kutsenko VA, et al. Metabolicheskiy sindrom i yego assotsiatsii s sotsial’no-demograficheskimi i povedencheskimi faktorami riska v rossiyskoy populyatsii 25-64 let [Metabolic syndrome and its associations with socio-demographic and behavioral risk factors in the Russian population aged 25-64 years]. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2020; 19 (4): 45-57. (In Russ.) DOI: 10.15829/1728-8800-2020-2600
18. Iozzo P. Myocardial, perivascular, and epicardial fat. Diabetes Care. 2011; 34 (2): 371-379. DOI: 10.2337/dc11-s250
19. Cinti S. Anatomy and physiology of the nutritional system. Mol Aspects Med. 2019; 68: 101-107. DOI: 10.1016/j.mam.2019.04.001
20. Bartelt A, Heeren J. Adipose tissue browning and metabolic health. Nat Rev Endocrinol. 2014; 10 (1): 24-36. DOI: 10.1038/nrendo.2013.204
21. Schulze MB, Stefan N. Metabolically healthy obesity: from epidemiology and mechanisms to clinical implications. Nat Rev Endocrinol. 2024; 20 (11): 633-646. DOI: 10.1038/s41574-024-01008-5
22. Amato MC, Giordano C, Galia M, et al. AlkaMeSy Study Group. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010; 33 (4): 920-922. DOI: 10.2337/dc09-1825
23. McQuaid SE, Hodson L, Neville MJ, et al. Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition? Diabetes. 2011; 60 (1): 47-55. DOI: 10.2337/db10-0867
24. Eckel N, Meidtner K, Kalle-Uhlmann T, Stefan N, Schulze MB. Metabolically healthy obesity and cardiovascular events: A systematic review and meta-analysis. Eur J Prev Cardiol. 2016; 23 (9): 956-966. DOI: 10.1177/2047487315623884
25. Roberson LL, Aneni EC, Maziak W, et al. Beyond BMI: The “Metabolically healthy obese” phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality - a systematic review. BMC Public Health. 2014; 14: 14. DOI: 10.1186/1471-2458-14-14
26. Sesha Satya Sagar VV, Acharya S, Kumar S, et al. Echo cardiographic Assessment in Various Obesity Phenotypes: A Cross-Sectional Study. Cureus. 2025; 17 (2): 78716. DOI: 10.7759/cureus.78716
27. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008; 168 (15): 1609-1616. DOI: 10.1001/archinte.168.15.1609
28. Chang Y, Jung HS, Cho J, et al. Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2016; 111 (8): 1133-1140. DOI: 10.1038/ajg.2016.178
29. Ampuero J, Aller R, Gallego-Durán R, et al. HEPAmet Registry. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018; 48 (11-12): 1260-1270. DOI: 10.1111/apt.15015
30. Zheng J, Li X, Zhang Y, Miao Y, et al. Hyperuricemia as an effect modifier of the association between metabolic phenotypes and nonalcoholic fatty liver disease in Chinese population. J Transl Med. 2023; 21 (1): 39. DOI: 10.1186/s12967-022-03850-5
31. Koliaki C, Dalamaga M, Kakounis K, et al. Metabolically Healthy Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Navigating the Controversies in Disease Development and Progression. Curr Obes Rep. 2025; 14 (1): 46. DOI: 10.1007/s13679-025-00637-9
32. Su Z, Efremov L, Mikolajczyk R. Differences in the levels of inflammatory markers between metabolically healthy obese and other obesity phenotypes in adults: A systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2024; 34 (2): 251-269. DOI: 10.1016/j.numecd.2023.09.002
33. Wani K, Emam O, Kumar B, et al. Exploring inflammation and adipose tissue dysfunction in metabolically healthy versus unhealthy obesity among Arab adults. Diabetol Metab Syndr. 2025; 17 (1): 244. DOI: 10.1186/s13098-025-01836-z
34. Dagpo TD, Nolan CJ, Delghingaro-Augusto V. Exploring Therapeutic Targets to Reverse or Prevent the Transition from Metabolically Healthy to Unhealthy Obesity. Cells. 2020; 9 (7): 1596. DOI: 10.3390/cells9071596
35. Otto TC, Lane MD. Adipose development: from stem cell to adipocyte. Crit Rev Biochem Mol Biol. 2005; 40 (4): 229-242. DOI: 10.1080/10409230591008189
36. Wang QA, Tao C, Gupta RK, et al. Tracking adipogenesis during white adipose tissue development, expansion and regeneration. Nat Med. 2013; 19 (10): 1338-1344. DOI: 10.1038/nm.3324
37. Ntambi JM, Young-Cheul K. Adipocyte differentiation and gene expression. J Nutr. 2000; 130 (12): 3122S-3126S. DOI: 10.1093/jn/130.12.3122S
38. Clemente-Postigo M, Queipo-Ortuño MI, Fernandez-Garcia D, et al. Adipose tissue gene expression of factors related to lipid processing in obesity. PLoS One. 2011; 6 (9): e24783. DOI: 10.1371/journal.pone.0024783
39. Tinahones FJ, Garrido-Sanchez L, Miranda M, et al. Obesity and insulin resistance-related changes in the expression of lipogenic and lipolytic genes in morbidly obese subjects. Obes. Surg. 2010; 20: 1559–1567. DOI: 10.1007/s11695-010-0194-z
40. He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U.S.A. 2003; 100 (26): 15712-15717. DOI: 10.1073/pnas.2536828100
41. Sugii S, Olson P, Sears D. PPARγ activation in adipocytes is sufficient for systemic insulin sensitization, Proc. Natl. Acad. Sci. U.S.A. 2009; 106 (52): 22504-22509. DOI: 10.1073/pnas.0912487106(2009)
42. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50 (9): 2094-2099. DOI: 10.2337/diabetes.50.9.2094
43. Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol. 2014; 220 (2): 47-59. DOI: 10.1530/JOE-13-0339
44. Telle-Hansen VH, Halvorsen B, Dalen KT, et al. Altered expression of genes involved in lipid metabolism in obese subjects with unfavourable phenotype. Genes Nutr. 2013; 8 (4): 425-434. DOI: 10.1007/s12263-012-0329-z
45. Wernstedt Asterholm I, Tao C, Morley TS, et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 2014; 20 (1): 103-118. DOI: 10.1016/j.cmet.2014.05.005
46. Lee YS, Kim JW, Osborne O, et al. Increased adipocyte oxygen consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesity. Cell. 2014; 157: 1339–1352. DOI: 10.1016/j.cell.2014.05.012
47. Strissel KJ, Stancheva Z, Miyoshi H, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes. 2007; 56 (12): 2910-2918. DOI: 10.2337/db07-0767
48. Lawler HM, Underkofler CM, Kern PA, et al. Adipose Tissue Hypoxia, Inflammation, and Fibrosis in Obese Insulin-Sensitive and Obese Insulin-Resistant Subjects. J. Clin. Endocrinol. Metab. 2016; 101: 1422–1428. DOI: 10.1210/jc.2015-4125
49. Лясникова М.Б., Белякова Н.А., Цветкова И.Г. [и др.], Риски развития выраженного алиментарно-конституционального ожирения и метаболических нарушений: интервенционное сравнительное исследование // Кубанский научный медицинский вестник. – 2023. – Т. 30 (1). – С. 49–57. Lyasnikova MB, Belyakova NA, Tsvetkova IG, et al. Riski razvitiya vyrazhennogo alimentarno-konstitutsionalnogo ozhireniya i metabolicheskikh narusheniy: interventsionnoye sravnitelnoye issledovaniye [Risks of developing severe alimentary-constitutional obesity and metabolic disorders: an interventional comparative study]. Kubanskiy nauchnyy meditsinskiy vestnik [Kuban Scientific Medical Bulletin]. 2023; 30 (1): 49-57. (In Russ.) DOI: 10.25207/1608-6228-2023-30-1-49-57
50. Ионов А.Ю., Кузнецова Е.А., Киндалёва О.Г. [и др.], Клиническое значение эндокринных нарушений в развитии синдрома раннего сосудистого старения у мужчин с абдоминальным ожирением и сопутствующей артериальной гипертензией: обсервационное когортное исследование // Кубанский научный медицинский вестник. – 2024. – Т. 31 (1). С 74-87. Ionov AYu, Kuznetsova YeA., Kindalova OG, et al. Klinicheskoye znacheniye endokrinnykh narusheniy v razvitii sindroma rannego sosudistogo stareniya u muzhchin s abdominal’nym ozhireniyem i soputstvuyushchey arterial’noy gipertenziyey: observatsionnoye kogortnoye issledovaniye [Clinical significance of endocrine disorders in the development of early vascular aging syndrome in men with abdominal obesity and concomitant arterial hypertension: an observational cohort study]. Kubanskiy nauchnyy meditsinskiy vestnik [Kuban Scientific Medical Bulletin]. 2024; 31 (1): 74-87. (In Russ.) DOI: 10.25207/1608-6228-2024-31-1-74-87
51. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А. [и др.]. Ожирение. Клинические рекомендации // Consilium Medicum. – 2021. – Т. 23 (4). – С. 311–325. Dedov II, Mokrysheva NG, Melnichenko GA, et al. Ozhireniye. Klinicheskiye rekomendatsii [Obesity. Clinical guidelines]. Consilium Medicum [Consilium Medicum]. 2021; 23 (4): 311–325. (In Russ.) DOI: 10.26442/20751753.2021.4.200832
52. Moholdt T, Lavie CJ, Nauman J. Sustained Physical Activity, Not Weight Loss, Associated With Improved Survival in Coronary Heart Disease. J Am Coll Cardiol. 2018; 71 (10): 1094-1101. DOI: 10.1016/j.jacc.2018.01.011
53. Ojalehto Lindfors E, De Oliveira TL, Reynolds CA, et al. Genetic influences, lifestyle and psychosocial aspects in relation to metabolically healthy obesity and conversion to a metabolically unhealthy state. Diabetes Obes Metab. 2025; 27 (1): 207-214. DOI: 10.1111/dom.16004
54. Estruch R, Ros E, Salas-Salvadó J, et al. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013; 368 (14): 1279-1290. DOI: 10.1056/NEJMoa1200303
55. Han E, Lee YH. Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases. Diabetes Metab J. 2017; 41 (6): 430-437. DOI: 10.4093/dmj.2017.41.6.430
56. Gilardini L, Zambon A, Soranna D, et al. Predictors of the transition from metabolically healthy obesity to unhealthy obesity. Eat Weight Disord. 2018; 23 (6): 739-744. DOI: 10.1007/s40519-018-0600-4
57. Zhang H, Tang X, Hu D, et al. Transition patterns of metabolism-weight phenotypes over time: A longitudinal study using the multistate Markov model in China. Front Public Health. 2022; 10: 1026751. DOI: 10.3389/fpubh.2022.1026751
58. Zimmet P, Alberti KG, Stern N, et al. The Circadian Syndrome: is the Metabolic Syndrome and much more! J Intern Med. 2019; 286 (2): 181-191. DOI: 10.1111/joim.12924
59. Matsui K, Komada Y, Okajima I, et al. A Cross-Sectional Study of Evening Hyperphagia and Nocturnal Ingestion: Core Constituents of Night Eating Syndrome with Different Background Factors. Nutrients. 2021; 13 (11): 4179. DOI: 10.3390/nu13114179
УДК: 577.21:616-008.9:613.24 DOI: 10.20969/VSKM.2026.19(2).127-134
Impact of epigenetic factors on the development of Yo-Yo syndrome. “Obesity memory” issue
Maxim A. Makarov1, Anastasia A. Korneeva1, Rumiya R. Karimova1, Aida R. Sadykova1,2, Ramziya T. Khabibullina3, Elena V. Moiseenko3
1 Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia
2 City Clinical Hospital No. 7, 54 Chuykov str., 420132 Kazan, Russia
3 City Clinical Hospital No. 11, 34/24 Maximov str., 420127 Kazan, Russia
Abstract. Introduction. Weight loss in obesity is the main tactic for patient management. However, according to statistics, weight fluctuations occur in 80% of people. This rebound phenomenon can be caused by various factors, but recently there has been an increasing number of studies on the relationship between epigenetic changes and weight fluctuations. Aim. To analyze scientific literature on the influence of epigenetic factors on the development of Yo-Yo syndrome. Materials and Methods. Analysis of research on the relationship between epigenetic factors and the development of Yo-Yo syndrome. Sources: PubMed, ResearchGate, eLibrary, and CyberLeninka. Results and Discussion. One of the key genes is POMC that regulates appetite through producing alpha-melanocyte-stimulating hormone. The methylation level of its promoter, especially in the ventromedial hypothalamus (VMH), correlates with body mass index and ability to maintain weight loss. Low methylation at positions +136 bp and +138 bp is associated with successful weight loss, while hypomethylation of the NPY promoter increases the risk of weight regain. The ghrelin (stimulates hunger) and leptin (suppresses appetite) hormones regulate energy balance through interaction with POMC and NPY neurons. Obesity often leads to leptin resistance, while epigenetic changes, particularly the leptin gene promoter modifications, such as methylation and acetylation, reduce its expression, promoting weight regain. In adipogenesis, transcription factor PPARγ plays a central role regulated epigenetically via histone modifications, chromatin dynamics, and non-coding RNA action. Protein PRDM16 suppresses myogenesis (through hypermethylation of MyoD and myogenin), directing cells towards adipogenesis. Patients with obesity also exhibit the TNFα promoter hypomethylation, enhancing their inflammatory response. After bariatric surgery, gene methylation (PPARGC1A, IL1B, IL6, TNF) temporarily normalizes but returns to baseline levels after 12 months, particularly in PDK4 promoters and pro-inflammatory genes. Studies have found a link between DNA methylation profile and anthropometric measures: Overweight individuals show the reduced methylation of MRTFA, PLEKHO1, and TNFAIP8L2, which activate these genes. Conclusion. Despite adherence to all dietary rules, such cyclical weight behavior may be genetically justified, thus creating a problem maintaining normal body mass. Understanding these mechanisms opens opportunities for developing biomarkers of recurrence risk and personalized prevention and treatment strategies, including prenatal period.
Keywords: obesity, epigenetics, DNA methylation, Yo-Yo syndrome, rebound effect, weight cycling
For citation: Makarov, M.A.; Korneeva, A.A.; Karimova, R.R.; et al. Impact of epigenetic factors on the development of Yo-Yo syndrome. “Obesity memory” issue // The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 127-134. DOI: 10.20969/VSKM.2026.19(2).127-134.
REFERENCES
1. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., [и др.]. Клинические рекомендации «Ожирение» Минздрава России. Версия 2024 года // Вестник репродуктивного здоровья. — 2025. — Т. 4. — No2. — С. 14-30. Dedov II, Mokry`sheva NG, Mel`nichenko GA, et al. Klinicheskiye rekomendatsii «Ozhireniye» Minzdrava Rossii: Versiya 2024 goda [Clinical Guidelines “Obesity” of the Russian Ministry of Health: 2024 Version]. Vestnik reproduktivnogo zdorov’ya [Bulletin of Reproductive Health]. 2025;4(2): 14-30. (in Russ.) DOI: 10.14341/brh12763
2. Баланова Ю.А., Шальнова С.А., Деев А.Д., [и др.]. Ожирение в российской популяции — распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний // Российский кардиологический журнал. – 2018. – №6. – С.123-130. Balanova YuA, Shal`nova SA, Deev AD, et al. Ozhirenie v rossijskoj populyacii – rasprostranennost` i associacii s faktorami riska xronicheskix neinfekcionny`x zabolevanij. [Obesity in the Russian population: prevalence and associations with risk factors for chronic noncommunicable diseases]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2018; 6: 123-130. (in Russ.) DOI: 10.15829/1560-4071-2018-6-123-130
3. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 году: Государственный доклад. – М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2020.– 299 с. O sostoyanii sanitarno-e`pidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federacii v 2019 godu: Gosudarstvenny`j doklad [On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2019: State report]. Moskva: Federal`naya sluzhba po nadzoru v sfere zashhity` prav potrebitelej i blagopoluchiya cheloveka [Moscow: Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing]. 2020; 299 p. (in Russ.)
4. Баланова Ю.А., Драпкина О.М., Куценко В.А., [и др.]. Ожирение в российской популяции в период пандемии COVID-19 и факторы, с ним ассоциированные. Данные исследования ЭССЕ-РФ3 // Кардиоваскулярная терапия и профилактика. – 2023. – Т.22. № 8S. – C.80-91. Balanova YuA, Drapkina OM, Kucenko VA, et al. Ozhirenie v rossijskoj populyacii v period pandemii COVID-19 i faktory`, s nim associirovanny`e; Danny`e issledovaniya E`SSE-RF3. [Obesity in the Russian population during the COVID-19 pandemic and associated factors; Data from the ESSE-RF3 study]. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention] 2023; 22(8S): 80-91. (in Russ.) DOI: 10.15829/1728-8800-2023-3793. EDN: SBUNIG
5. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr. 2001; 21: 323–41. DOI: 10.1146/annurev.nutr.21.1.323
6. Mehta T, Smith DL Jr, Muhammad J, Casazza K. Impact of weight cycling on risk of morbidity and mortality. Obes Rev. 2014 Nov;15(11):870-81. DOI: 10.1111/obr.12222
7. Brownell KD. The LEARN program for weight control: lifestyle, exercise, attitudes, relationships, nutrition. LEARN Education Center — 7th ed. Dallas, Tex: American Health Pub. Co., Address orders to the LEARN Education Center. 1997; 250 p.
8. Phuong-Nguyen K, McGee SL, Aston-Mourney K, et al. Post-Obesity Weight Loss, and Their Relationship with Gut Health. Nutrients. 2024; 16 (18): 3170. DOI: 10.3390/nu16183170
9. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39(8):1188-1196. DOI: 10.1038/ijo.2015.59
10. Самсонова Г.О., Языкова Т.А., Агасаров Л.Г. Психологи ческие аспекты алиментарного ожирения (обзор ли те ра туры) // Вестник новых медицинских технологий. Электронное издание. –
2018. – №3. – С. 133-139. Samsonova GO, Yazy`kova TA, Agasarov LG. Psixologicheskie aspekty` alimentarnogo ozhireniya (obzor literatury`) [Psychological aspects of alimentary obesity (literature review)]. Vestnik novy`x medicinskix texnologij: E`lektronnoe izdanie [Bulletin of new medi cal techno logies: Electronic publication]. 2018; 3: 133-139. (in Russ.) DOI: 10.24411/2075-4094-2018-16027
11. Contreras RE, Schriever SC, Pfluger PT. Physiological and Epigenetic Features of Yoyo Dieting and Weight Control. Front Genet. 2019; 10: 1015. DOI: 10.3389/fgene.2019.01015
12. Елиашевич С.О., Дадаева В.А., Драпкина О.М. Снижение и «удержание» массы тела – известное неравенство в рамках профилактики хронических неинфекционных заболеваний // Профилактическая медицина. – 2022. – №25(3). – С. 85-91. Eliashevich SO, Dadaeva VA, Drapkina OM. Snizhenie i «uderzhanie» massy` tela – izvestnoe neravenstvo v ramkax profilaktiki xronicheskix neinfekcionny`x zabolevanij [Weight loss and weight maintenance are well-known inequalities in the prevention of chronic non-communicable diseases]. Profilakticheskaya medicina [Preventive Medicine]. 2022;25(3): 85-91. (in Russ.) DOI: 10.17116/profmed20222503185
13. Anderson JW, Konz EC, Frederich RC, et al. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001 Nov; 74(5):579-84. DOI: 10.1093/ajcn/74.5.579
14. Weiss EC, Galuska DA, Kettel Khan, et al. Weight regain in U.S. adults who experienced substantial weight loss, 1999-2002. Am J Prev Med. 2007 Jul; 33(1):34-40. DOI: 10.1016/j.amepre.2007.02.040
15. Wing RR, Phelan S. Long-term weight loss main te nan ce. Am J Clin Nutr. 2005 Jul; 82(1 Suppl): 222-25. DOI: 10.1093/ajcn/82.1.222S
16. Bond DS, Phelan S, Leahey TM, et al. Weight-loss maintenance in successful weight losers: surgical vs non-surgical methods. Int J Obes (Lond). 2009 Jan; 33(1):173-80. DOI: 10.1038/ijo.2008.256
17. Садыкова А.Р., Сафиуллина К.Р., Нуриахметова К.Р., [и др.]. Роль эпигенетических факторов в развитии и диагностике ишемической болезни сердца // Вестник современной клинической медицины. – 2023. – № 16. – С. 123-129. Sady`kova AR, Safiullina KR, Nuriaxmetova KR, et al. Rol` e`pigeneticheskix faktorov v razvitii i diagnostike ishemicheskoj bolezni serdcza. [The role of epigenetic factors in the development and diagnosis of coronary heart disease]. Vestnik sovremennoj klinicheskoj mediciny` [Bulletin of Modern Clinical Medicine]. 2023; 16:123-129. (in Russ.) DOI: 10.20969/VSKM.2023.16(6).123-129
18. Seki Y, Williams L, Vuguin PM, et al. Minireview: epigenetic programming of diabetes and obesity: animal models. Endocrinology. 2012 Mar; 153(3):1031-8. DOI: 10.1210/en.2011-1805
19. Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004 May 27; 429(6990):457-63. DOI: 10.1038/nature02625
20. Dalgaard K, Landgraf K, Heyne S, et al. Trim28 Haploinsufficiency Triggers Bi-stable Epigenetic Obesity Cell. 2016 Jan;164(3):353-64. DOI: 10.1016/j.cell.2015.12.025
21. Heijmans BT, Tobi EW, Stein AD, et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A. 2008 Nov; 105(44):17046-9. DOI: 10.1073/pnas.0806560105
22. Lumey LH, Stein AD, Kahn HS, et al. Cohort Profile: The Dutch Hunger Winter families study. Int J Epidemiol. 2007 Dec; 36(6):1196-204. DOI: 10.1093/ije/dym126
23. Heijmans BT, Tobi EW, Stein AD, et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci USA. 2008;105(44):17046-49. DOI: 10.1073/pnas.0806560105.
24. Ravelli AC, van der Meulen JH, Michels RP et al. Glucose tolerance in adults after prenatal exposure to famine. Lancet.1998 Jan 17;351(9097):173-7. DOI: 10.1016/s0140-6736(97)07244-9
25. Millington GW. The role of proopiomelanocortin (POMC) neurones in feeding behaviour. Nutr Metab (Lond). 2007 Sep 1;4:18. DOI: 10.1186/1743-7075-4-18
26. Kühnen P, Handke D, Waterland RA, et al. Interindividual Variation in DNA Methylation at a Putative POMC Metastable Epiallele Is Associated with Obesity. Cell Metab. 2016 Sep; 24(3):502-509. DOI: 10.1016/j.cmet.2016.08.001
27. Crujeiras AB, Campion J, Díaz-Lagares A, et al. Association of weight regain with specific methylation levels in the NPY and POMC promoters in leukocytes of obese men: a translational study. Regul Pept. 2013 Sep; 186: 1-6. DOI: 10.1016/j.regpep.2013.06.012
28. Frago LM, Baquedano E, Argente J, et al. Neuroprotective actions of ghrelin and growth hormone secretagogues. Front Mol Neurosci. 2011 Sep 28; 4: 23. DOI: 10.3389/fnmol.2011.00023
29. Farooqi IS, O’Rahilly S. Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity. Nat Clin Pract Endocrinol Metab. 2008 Oct; 4(10):569-77. DOI: 10.1038/ncpendmet0966
30. Fried SK, Ricci MR, Russell CD, Laferrère B. Regulation of leptin production in humans. J Nutr. 2000 Dec; 130(12):3127-31. DOI: 10.1093/jn/130.12.3127S
31. Shen W, Wang C, Xia L, et al. Epigenetic modification of the leptin promoter in diet-induced obese mice and the effects of N-3 polyunsaturated fatty acids. Sci Rep. 2014 Jun; 4: 5282. DOI: 10.1038/srep05282
32. Löffler G, Hauner H. Adipose tissue development: the role of precursor cells and adipogenic factors. Part II: The regulation of the adipogenic conversion by hormones and serum factors. Klin Wochenschr. 1987 Sep 1; 65(17): 812-7. DOI: 10.1007/BF01727475
33. Berry R, Rodeheffer MS. Characterization of the adipocyte cellular lineage in vivo. Nat Cell Biol. 2013 Mar; 15(3): 302-8. DOI: 10.1038/ncb2696
34. Seale P, Bjork B, Yang W, et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature. 2008 Aug; 454 (7207): 961-7. DOI: 10.1038/nature07182
35. Seale P, Conroe HM, Estall J, et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest. 2011;121(1):96-105. DOI: 10.1172/JCI44271
36. Rosen ED, Hsu C-H, Wang X, et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 2002 Jan;16(1):22-6. DOI: 10.1101/gad.948702
37. Li X, Wang J, Jiang Z, et al. Role of PRDM16 and its PR domain in the epigenetic regulation of myogenic and adipogenic genes during transdifferentiation of C2C12 cells. Gene. 2015;570(2):191-8. DOI: 10.1016/j.gene.2015.06.017
38. Lee JE, Ge K. Transcriptional and epigenetic regulation of PPARγ expression during adipogenesis. Cell Biosci. 2014 May;4:29. DOI: 10.1186/2045-3701-4-29
39. Lee JE, Wang C, Xu S, et al. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. Elife. 2013 Dec;2:e01503. DOI: 10.7554/eLife.01503
40. Lizcano F, Romero C, Vargas D. Regulation of adipogenesis by nuclear receptor PPARγ is modulated by the histone demethylase JMJD2C. Genet Mol Biol. 2011;34(1):19-24. DOI: 10.1590/S1415-47572010005000105
41. Okuno Y, Ohtake F, Igarashi K, et al. Epigenetic regulation of adipogenesis by PHF2 histone demethylase. Diabetes. 2013;62(5):1426-34. DOI: 10.2337/db12-0628
42. Salma N, Xiao H, Mueller E, et al. Temporal recruitment of transcription factors and SWI/SNF chromatin-remodeling enzymes during adipogenic induction of the peroxisome proliferator-activated receptor gamma nuclear hormone receptor. Mol Cell Biol. 2004; 24(11):4651-63. DOI: 10.1128/mcb.24.11.4651-4663.2004
43. Sakamoto H, Kogo Y, Ohgane J, et al. Sequential changes in genome-wide DNA methylation status during adipocyte differentiation. Biochem Biophys Res Commun. 2008 Feb 8;366(2):360-6. DOI: 10.1016/j.bbrc.2007.11.137
44. Barres R, Kirchner H, Rasmussen M, et al. Weight loss after gastric bypass surgery in human obesity remodels promoter methylation. Cell Rep. 2013 Apr;3(4):1020-7. DOI: 10.1016/j.celrep.2013.03.018
45. Hermsdorff HH, Mansego ML, Campión J, et al. TNF-alpha promoter methylation in peripheral white blood cells: relationship with circulating TNFα, truncal fat and n-6 PUFA intake in young women. Cytokine. 2013 Oct;64(1):265-71. DOI: 10.1016/j.cyto.2013.05.028
46. Sala P, de Miranda Torrinhas RSM, Fonseca DC, et al. Tissue-specific methylation profile in obese patients with type 2 diabetes before and after Roux-en-Y gastric bypass. Diabetol Metab Syndr. 2017 Feb; 9: 15. DOI: 10.1186/s13098-017-0214-4
47. Milagro FI, Gómez-Abellán P, Campión J, et al. CLOCK, PER2 and BMAL1 DNA methylation: association with obesity and metabolic syndrome characteristics and monounsaturated fat intake. Chronobiol Int. 2012 Nov; 29(9): 1180-94. DOI: 10.3109/07420528.2012.719967
48. Multhaup ML, Seldin MM, Jaffe AE, et al. Mouse-human experimental epigenetic analysis unmasks dietary targets and genetic liability for diabetic phenotypes. Cell Metab. 2015 Jan;21(1):138-49. DOI: 10.1016/j.cmet.2014.12.014
49. Huang YT, Maccani JZJ, Hawley NL, et al. Epigenetic patterns in successful weight loss maintainers: a pilot study. Int J Obes (Lond). 2015; 39 (5): 865-868. DOI: 10.1038/ijo.2014.213
50. Milagro FI, Campión J, Cordero P, et al. A dual epigenomic approach for the search of obesity biomarkers: DNA methylation in relation to diet-induced weight loss. FASEB J. 2011 Apr; 25(4):1378-89. DOI: 10.1096/fj.10-170365
51. Rönn T, Volkov P, Davegårdh C, et al. A six months exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue. PLoS Genet. 2013 Jun; 9(6):e1003572. DOI: 10.1371/journal.pgen.1003572
52. van Dijk SJ, Molloy PL, Varinli H, et al. Epigenetics and human obesity. Int J Obes (Lond). 2015 Jan;39(1):85-97. DOI: 10.1038/ijo.2014.34
УДК: 616.89-008.454.4-053.2:577.1 DOI: 10.20969/VSKM.2026.19(2).135-143
Imbalance of trace elements in autism
Andrey A. Skalny1, Irini Rapushi2,3, Sofiya R. Marchenko1, Daria P. Safonova1
1 Peoples’ Friendship University of Russia named after Patrice Lumumba, 6 Miklukho-Maklay str., 117198 Moscow, Russia
2 University of Rome Tor Vergata, Via Orazio Raimondo, 18 – 00173 Rome, Italy
3 Ismail Qemali University of Vlor, Rruga Kosova, 9401, Vlor, Albania
Abstract. Introduction. Autism spectrum disorders are a group of neuropsychiatric conditions with complex pathogenesis involving genetic, epigenetic, and metabolic factors. One of the key elements actively studied in recent years is the balance of trace elements. Disruptions in this balance may contribute to the development of neuroinflammatory and oxidative processes characteristic of autism spectrum disorders. Aim. To analyze current scientific literature on trace element metabolism disorders in autism and assess their contribution to the pathogenesis of autism spectrum disorders. Materials and Methods. A literature search was conducted in databases, such as PubMed, Scopus, eLibrary, and Google Scholar, covering the period from 2014 to 2025. The selection included original studies containing data on the concentrations of zinc, copper, selenium, magnesium, iron, as well as lead, cadmium, mercury, and arsenic in children with autism spectrum disorders. Differences between autism spectrum disorders and control groups were assessed, along with potential clinical correlations. Results and Discussion. Cumulative data indicate a consistent decrease in zinc, magnesium, selenium, and iron levels in children with autism spectrum disorders. The most reproducible biomarker appears to be a reduced Zn/Cu ratio, which is associated with the severity of autistic symptoms. Data on toxic metals are inconsistent, i.e., some studies show increased levels, others report decreased urinary excretion, potentially indicating impaired detoxification and elimination processes. Correlational analyses in several studies revealed associations between trace element imbalance and symptom severity in autism spectrum disorders. Conclusions. The available evidence supports the involvement of trace element imbalance in the pathogenesis of autism spectrum disorders. Altered levels of zinc, copper, and antioxidant elements, as well as the specific patterns of accumulation and elimination of toxic metals, may act as additional biomarkers and targets for personalized intervention. It is still a promising trend to perform prospective multicenter studies with standardized methodologies for assessing trace element balance.
Keywords: autism spectrum disorders; trace element imbalance; Zn/Cu ratio; toxic metals; magnesium; neurometabolism.
For citation: Skalny, A.A.; Rapushi, I.; Marchenko, S.R.; Safonova, D.P. Imbalance of trace elements in autism. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 135-143. DOI: 10.20969/VSKM.2026.19(2).135-143.
REFERENCES
1. Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014; 383(9920): 896–910. DOI: 10.1016/S01406736(13)615391
2. Lord C, Elsabbagh M, Baird G, et al. Autism spectrum disorder. Lancet. 2018; 392(10146): 508–526. DOI: 10.1016/S01406736(18)311292
3. Tremblay MW, Jiang YH. DNA methylation and susceptibility to autism spectrum disorder. Annual Review of Medicine. 2019; 70: 151–166. DOI: 10.1146/annurev-med-041217-011431
4. Ladd-Acosta C, Hansen KD, Briem E, et al. Common DNA methylation alterations in autism. Molecular Psychiatry. 2014; 19(8): 862–871. DOI: 10.1038/mp.2013.114
5. Zhou Y, Kaiser T, Monteiro P, et al. Shank3 mutations and ASD. Neuron. 2016; 89(1): 147–162. DOI: 10.1016/j.neuron.2015.11.023
6. Pfaender S, Sauer AK, Hagmeyer S, et al. Zinc deficiency in SHANK3 mutations. Scientific Reports. 2017; 7: 45190. DOI: 10.1038/srep45190
7. Sayehmiri F, Babaknejad N, Bahrami S, et al. Zn/Cu levels in autism: meta-analysis. Iranian Journal of Child Neurology. 2015; 9(4): 1–9. DOI: 10.22037/ijcn.v9i4.6780
8. Zhao G, Liu SJ, Gan XY, et al. Trace elements in ASD children. Biol Trace Elem Res. 2023; 201(2): 627–635. DOI: 10.1007/s12011-022-03134-0
9. do Nascimento PKDSB, Oliveira Silva DF, de Morais TLSA, et al. Zinc status in ASD. Nutrients. 2023; 15(16): 3663. DOI: 10.3390/nu15163663
10. Rafi’i MR, Ja’afar MH, Abd Wahil MS, et al. Urine trace elements in ASD. PeerJ. 2024; 12: e17660. DOI: 10.7717/peerj.17660
11. Długosz A, Wróblewski M, Błaszak B, et al. Trace elements in ASD pathophysiology. Int J Mol Sci. 2025; 26(2): 808. DOI: 10.3390/ijms26020808
12. Abd Wahil MS, Ja’afar M, Md Isa Z. Urinary lead and trace elements in ASD. Int J Environ Res Public Health. 2022; 200(1): 97–121. DOI: 10.1007/s12011-021-02654-w
13. Baj J, Flieger W, Flieger M, et al. Trace elements imbalance in ASD. Neurosci Biobehav Rev. 2021; 129: 117–132. DOI: 10.1016/j.neubiorev.2021.07.029
14. Ipsiroglu OS, Pandher PK, Poilblanc M, et al. Iron deficiency in neurodevelopmental disorders. Nutrients. 2024; 16(18): 3064. DOI: 10.3390/nu16183064
15. Awadh SM, Yaseen ZM, AlSuwaiyan MS. Environmental toxicants and autism. Ecotoxicol Environ Saf. 2023; 251: 114785. DOI: 10.1016/j.ecoenv.2023.114561
16. Rahbar MH, Ibrahim SH, Azam SI, et al. Heavy metals in ASD. Int J Environ Res Public Health. 2021; 18(16): 8625. DOI: 10.3390/ijerph18168625
17. Feng J, Shan L, Miao C, et al. Zinc, copper and ASD symptoms. BMC Pediatrics. 2023; 23(1): 173. DOI: 10.1186/s12887-023-03987-2
18. Demircan K, Chillon TS, Jensen RC, et al. Maternal selenium deficiency and autism. Free Radic Biol Med. 2024; 220: 324–332. DOI: 10.1016/j.freeradbiomed.2024.05.001
19. Ding M, Shi S, Qie S, et al. Heavy metals and autism: meta-analysis. Front Pediatr. 2023; 11: 1169733. DOI: 10.3389/fped.2023.1169733
20. Zhang Y, Xie F, Li S, et al. Serum elements and ASD. Autism Research. 2025; 18(2): 427–436. DOI: 10.1002/aur.3302
21. Zhu Q, Zhang T, Sun Y, et al. Metallic elements and telomere length in ASD. PeerJ. 2025; 13: e19174. DOI: 10.7717/peerj.19174
22. Wu J, Liu DJ, Shou XJ, et al. Element profile in ASD children. Autism Res. 2018; 11(6): 834–845. DOI: 10.1002/aur.1949
23. Zhou Q, Huang D, Xu C, et al. Hair metal levels in ASD. J Trace Elem Med Biol. 2021; 66: 126748. DOI: 10.1016/j.jtemb.2021.126748
24. Botturi A, Ciappolino V, Delvecchio G, et al. Magnesium in mental disorders. Nutrients. 2020; 12(6): 1661. DOI: 10.3390/nu12061661
25. Genovese A, Butler MG. Autism spectrum: genetic associations. Genes. 2023; 14(3): 677. DOI: 10.3390/genes14030677
26. Skogheim TS, Weyde KVF, Engel SM, et al. Metals exposure and ASD risk. Environ Int. 2021; 152: 106468. DOI: 10.1016/j.envint.2021.106468
27. Amorós R, Murcia M, González L, et al. Maternal selenium and neurodevelopment. Environ Res. 2018; 166: 215–222. DOI: 10.1016/j.envres.2018.06.002
28. Siddiqi UR, Begum S, Shahjadi S, et al. Zn/Cu levels in ASD children. Heliyon. 2023; 9(8): e18624. DOI: 10.1016/j.heliyon.2023.e18624
29. Curtin P, Austin C, Curtin A, et al. Zinc–copper cycles and ASD. Sci Adv. 2018; 4(5): eaat1293. DOI: 10.1126/sciadv.aat1293
30. Fiore M, Barone R, Copat C, et al. Metals and autism severity. J Trace Elem Med Biol. 2020; 57: 126409. DOI: 10.1016/j.jtemb.2019.126409
31. Conti MV, Santero S, Luzzi A, Cena H. Zinc deficiency in autism spectrum disorder: a review. Nutr Res Rev. 2024; 37(2): 287–295. DOI: 10.1017/S0954422423000215
32. Botturi A, Ciappolino V, Delvecchio G, et al. Magnesium in mental disorders. Nutrients. 2020; 12(6): 1661. DOI: 10.3390/nu12061661
33. Genovese A, Butler MG. Autism spectrum: genetic associations. Genes. 2023; 14(3): 677. DOI: 10.3390/genes14030677
34. Skogheim TS, Weyde KVF, Engel SM, et al. Metals exposure and ASD risk. Environ Int. 2021; 152: 106468. DOI: 10.1016/j.envint.2021.106468
35. Amorós R, Murcia M, González L, et al. Maternal selenium status and neurodevelopment. Environ Res. 2018; 166: 215–222. DOI: 10.1016/j.envres.2018.06.002
36. Bakian AV, Bilder DA, Korgenski EK, Bonkowsky JL. Neonatal magnesium and ASD. Child Neurol Open. 2018; 5: 2329048X18800566. DOI: 10.1177/2329048X18800566
37. Siddiqi UR, Begum S, Shahjadi S, et al. Zinc, copper and ceruloplasmin in ASD. Heliyon. 2023; 9(8): e18624. DOI: 10.1016/j.heliyon.2023.e18624
38. Curtin P, Austin C, Curtin A, et al. Zinc–copper cycles and ASD. Sci Adv. 2018; 4(5): eaat1293. DOI: 10.1126/sciadv.aat1293
39. Anastasescu CM, Stoicănescu E, Badea O, Popescu F. Micronutrients in ASD. Curr Health Sci J. 2023; 49(3): 409–415. DOI: 10.12865/CHSJ.49.03.14
40. Amorós R, Murcia M, González L, et al. Maternal copper and neurodevelopment. Int J Hyg Environ Health. 2019; 222(3): 503–512.
DOI: 10.1016/j.ijheh.2019.01.007
41. Rezaei M, Rezaei A, Esmaeili A, et al. Urine trace elements and ASD. Environ Sci Pollut Res. 2022; 29(38): 57287–57295. DOI: 10.1007/s11356-022-19933-1
42. Tabatadze T, Zhorzholiani L, Kherkheulidze M, et al. Hair trace elements in ASD. Georgian Med News. 2015; (248): 77–82.
43. Fiore M, Barone R, Copat C, et al. Metals and autism severity. J Trace Elem Med Biol. 2020; 57: 126409. DOI: 10.1016/j.jtemb.2019.126409
44. Pilić S, Selović A, Sulejmanović J. Metallomic profiling in ASD. Biol Trace Elem Res. 2025. DOI: 10.1007/s12011-025-04541-0
45. Amadi CN, Orish CN, Frazzoli C, Orisakwe OE. Toxic metals and autism: review. Pharmacol Biochem Behav. 2022; 212: 173313. DOI: 10.1016/j.pbb.2021.173313
46. Ding M, Shi S, Qie S, et al. Heavy metals and autism: meta-analysis. Front Pediatr. 2023; 11: 1169733. DOI: 10.3389/fped.2023.1169733
47. Dickerson AS, Rotem RS, Christian MA, et al. Sex differences, metals and ASD. Curr Environ Health Rep. 2017; 4(4): 405–414. DOI: 10.1007/s40572-017-0164-x
48. Behl S, Mehta S, Pandey MK. Selenoproteins in neurodevelopment and ASD. Front Mol Neurosci. 2023; 16: 1130922. DOI: 10.3389/fnmol.2023.1130922
49. Bjørklund G, Meguid NA, El-Bana MA, et al. Oxidative stress in ASD. Mol Neurobiol. 2020; 57(5): 2314–2332. DOI: 10.1007/s12035-019-01742-2
50. Das AM. Urea cycle defects and neuropsychiatric disorders. Metab Brain Dis. 2025; 40(5): 192. DOI: 10.1007/s11011-025-01619-5
51. Yehia A, Melhuish Beaupre LM, Ho MC, et al. Ferroptosis and psychiatric disorders. Transl Psychiatry. 2025; 15(1): 205. DOI: 10.1038/s41398-025-03429-w
52. Zhou X, Xia X, Li L, et al. Hair elements and ASD severity. Biol Trace Elem Res. 2025. DOI: 10.1007/s12011-025-04588-z
PRACTICAL EXPERIENCE
УДК 616.36-004.5 DOI: 10.20969/VSKM.2026.19(2).144-151
A clinical case of cardiogenic liver cirrhosis in a patient with congenital heart disease
Dilyara R. Akberova1, Evgenia S. Bodryagina1, Adilya R. Garafutdinova1, Liana V. Chebulaeva1, Alfiya Kh. Odintsova2, Natalia A. Cheremina2, Leila R. Sadycova2, Alina Iu. Khasanshina2
1 Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia
2 Republican Clinical Hospital, 138 Orenburg Tract str., 420124 Kazan, Russia
Abstract. Introduction. Liver cirrhosis can develop resulting from chronic heart failure, which can be caused by various heart defects. This condition is called “cardiogenic cirrhosis.” There are types of palliative surgery for congenital heart defects. Blalock operation is a surgical procedure used to correct certain congenital heart defects. It involves creating a shunt between the artery that exits the heart and the pulmonary artery to improve blood supply to the lungs. Fontan procedure is used to surgically treat certain types of congenital heart defects, especially those associated with right-sided cardiac flow; it is conventionally used in children with conditions, such as tetralogy of Fallot or single-chamber heart. However, these interventions can lead to chronic venous hypertension, which often causes severe complications, including liver damage with progressive fibrosis. Aim. To present a clinical case of a patient with cardiogenic liver cirrhosis. Materials and Methods. Patient A., 39 years old, female, was hospitalized in the gastroenterology department of the Republican Clinical Hospital of Kazan with a diagnosis of liver cirrhosis of mixed etiology. It became known from the medical history that the patient has a congenital heart defect corrected by surgical interventions in her childhood (Blalock, Fontan). Considering the increasing edema and pronounced weakness, the patient was admitted for examination and therapy correction based on the interdisciplinary approach. Results and Discussion. This clinical case demonstrates the dynamics of clinical manifestations and laboratory and instrumental findings in a patient with congenital heart disease and advanced liver cirrhosis over several years. Conclusions. The case presented demonstrates the need for lifelong multidisciplinary monitoring of liver function in patients after surgery for congenital heart disease.
Keywords: congenital heart disease, Fallot’s tetralogy, cardiogenic liver cirrhosis, Blalock operation, Fontan procedure.
For citation: Akberova, D.R.; Bodryagina, E.S.; Garafutdinova, A.R.; et al. A clinical case of cardiogenic liver cirrhosis in a patient with congenital heart disease. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 144-151. DOI: 10.20969/VSKM.2026.19(2).144-151.
REFERENCES
1. Клинические рекомендации. Цирроз и фиброз печени. 2025. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/715_2 Klinicheskie rekomendacii; Cirroz i fibroz pecheni [Clinical guidelines; Liver cirrhosis and fibrosis]. 2025. URL: https://cr.minzdrav.gov.ru/view-cr/715_2. (In Russ.)
2. Tsoris A, Marlar CA. Use Of The Child Pugh Score In Liver Disease. 2023 Mar 13. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
3. Dewi NNGK, Mariadi IK, Dewi NLPY, et al. A Novel Predictor Compared to the Model for End-Stage Liver Disease (MELD) and Child-Turcotte-Pugh (CTP) Scores for Predicting 30-Day Mortality in Patients With Liver Cirrhosis. Cureus. 2025; 17(3): e81446. DOI: 10.7759/cureus.81446
4. Дудов Т.Р., Корой П.В., Ягода А.В. Осложнения цирроза печени и матриксные металлопротеиназы: клинические взаимосвязи // Медицинский вестник Северного Кавказа. – 2023. – №18(4). – С.363-367. Dudov TR, Koroy PV, Yagoda AV. Oslozhneniya cirroza pecheni i matriksnye metalloproteinazy: klinicheskie vzaimosvyazi [Complications of liver cirrhosis and matrix metalloproteinases: clinical relationships]. Medicinskij vestnik Severnogo Kavkaza [Medical News of North Caucasus]. 2023; 18(4): 363-367. (In Russ.) DOI: 10.14300/mnnc.2023.18086
5. Береговский Д.А., Филин Я.А., Шапиева А.Ш., [и др.]. Современные подходы к визуализации тетрады Фалло // Российский журнал персонализированной медицины. – 2024. – №4(4). – С.348-354. Beregovskii DA, Filin YaA, Shapieva ASh, et al. Sovremennye podhody k vizualizacii tetrady Fallo [Modern methods of visualization of the tetralogy of Fallot]. Rossijskij zhurnal personalizirovannoj mediciny [Russian Journal for Personalized Medicine]. 2024; 4(4):348-354. (In Russ.) DOI: 10.18705/2782-3806-2024-4-4-348-354
6. Hammett O, Griksaitis MJ. Management of tetralogy of Fallot in the pediatric intensive care unit. Frontiers in pediatrics. 2023; 11: 1104533. DOI: 10.3389/fped.2023.1104533
7. Bailliard F, Anderson RH. Tetralogy of fallot. Orphanet journal of rare diseases. 2009; 4 (1): 2. DOI: 10.1186/1750-1172-4-2
8. Бурая В.Ю. Нечаева Е.М., Королев Д.В. [и др.]. Врожденные пороки сердца: тетрада Фалло //Международный научно-исследовательский журнал. – 2024. – №. 4 (142). – С. 16. Buraya VYU, Nechaeva EM, Korolev DV, et al. Vrozhdennye poroki serdca: tetrada Fallo [Congenital heart defects: tetralogy of Fallot]. Mezhdunarodnyj nauchno-issledovatel’skij zhurnal [International research journal]. 2024; 4(142): 16. (In Russ.) DOI: 10.23670/IRJ.2024.142.48
9. Чепурных Е.Е., Григорьев Е.Г. Врожденные пороки сердца // Байкальский медицинский журнал. – 2014. – Т.126. – №.3. – С.121-127. CHepurnyh EE, Grigor’ev EG. Vrozhdennye poroki serdca [Congenital heart defects]. Bajkal’skij medicinskij zhurnal [Baikal Medical Journal]. 2014. 126(3): 121-127. (In Russ.)
10. Ляпин А.А., Халивопуло И.К., Тарасов Р.С. Поэтапное хирургическое лечение новорожденных с тетрадой Фалло с использованием современных паллиативных методов. Комплексные проблемы сердечнососудистых заболеваний. – 2021. – №10(2S). – С.50-53. Lyapin AA, Halivopulo IK, Tarasov RS. Poetapnoe hirurgicheskoe lechenie novorozhdennyh s tetradoj Fallo s ispol’zovaniem sovremennyh palliativnyh metodov [The features of step-by-step surgical approach for correction of tetralogy Fallot using modern palliative methods]. Kompleksnye problemy serdechnososudistyh zabolevanij [Complex Issues of Cardiovascular Diseases]. 2021;10(2S): 50-53. (In Russ.) DOI: 10.17802/2306-1278-2021-10-2S-50-53
11. Wu FM, Kogon B, Earing MG, et al. Liver health in adults with Fontan circulation: A multicenter cross-sectional study. J Thorac Cardiovasc Surg. 2017; 153(3): 656-664. DOI: 10.1016/j.jtcvs.2016.10.060
12. Shin YR, Kim SU, Lee S, et al. Noninvasive surrogates are poor predictors of liver fibrosis in patients with Fontan circulation. J Thorac Cardiovasc Surg. 2022 Oct; 164(4): 1176-1185.e3. DOI: 10.1016/j.jtcvs.2021.12.028
13. Egbe AC, Miranda WR, Veldtman GR, et al. Hepatic Venous Pressure Gradient in Fontan Physiology Has Limited Diagnostic and Prognostic Significance. CJC Open. 2020 May 4; 2(5): 360-364. DOI: 10.1016/j.cjco.2020.04.011
616.24-002.5:616-08 DOI: 10.20969/VSKM.2026.19(2).152-157
Proven experience of surgical treatment of a multimorbid patient with a complicated course of the chronic tuberculous process
Zhanna A. Laushkina1, Sergei S. Skliuev1, Elaman M. Nurdinov1, Elena M. Zhukova1, Pavel S. Morozov1
1 Novosibirsk Tuberculosis Research Institute, 81a Okhotskaya str., 630040 Novosibirsk, Russia
Abstract. Introduction. The problem of eliminating tuberculosis infection remains highly relevant worldwide. Despite significant progress in tuberculosis chemotherapy at the present stage, surgical treatment continues to be an integral part of the complex therapy for this disease. Its significance is particularly high in case of destructive forms of tuberculosis, drug-resistant mycobacteria, and/or pronounced residual changes in the lungs. Aim. To demonstrate the potential of surgical treatment in a patient with a complicated course of chronic tuberculosis. Materials and Methods. A case of successful complex treatment is analyzed and described, involving a multimorbid female patient with a long tuberculosis history, following complicated surgical interventions for pulmonary tuberculosis with pre-extensively drug-resistant pathogens, in combination with HIV infection, chronic viral hepatitis C, alcohol dependence syndrome, and low treatment adherence. The patient underwent completion pneumonectomy with simultaneous thoracomyoplasty, which was performed without any complications. Results and Discussion. The presented clinical observation demonstrates the surgery capabilities in the most challenging cohort of patients. Modern approaches to surgical treatment can significantly improve the effectiveness of complex therapy in patients with chronic forms of pulmonary tuberculosis and high comorbidity. Conclusions. Patients with fibro-cavernous pulmonary tuberculosis represent a challenging population for achieving positive treatment outcomes. Surgical intervention for pulmonary tuberculosis remains a relevant and effective treatment method, especially in cases of extensively multidrug-resistant tuberculosis, as well as when conservative therapy is ineffective.
Keywords: pulmonary tuberculosis; drug resistance; surgical treatment; comorbidity; HIV infection; chronic hepatitis C.
For citation: Laushkina, J.A.; Sklyuyev, S.V.; Nurdinov, E.M.; et al. Proven experience of surgical treatment of a multimorbid patient with a complicated course of the chronic tuberculous process. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 152-157. DOI: 10.20969/VSKM.2026.19(2).152-157.
REFERENCES
1. Гиллер Д.Б., Саенко С.С., Герасимов А.Н., [и др.]. Эффективность хирургического лечения МЛУ и ШЛУ деструктивного туберкулеза легких в отдаленный период // Медицинский альянс. – 2024. – № 4. – С. 45–54. Giller DB, Saenko SS, Gerasimov AN, et al. Effektivnost’ hirurgicheskogo lecheniya MLU i ShLU destruktivnogo tuberkuleza legkih v otdalennyj period [The effectiveness of surgical treatment of MDR and XDR destructive pulmonary tuberculosis in the long term]. Medicinskij al’yans [Medical Alliance]. 2024; 4: 45-54. (In Russ.) DOI: 10.36422/23076348-2024-12-4-45-54
2. Минздрав России. Клинические рекомендации: Туберкулез у взрослых. – 2024. Minzdrav Rossii [The Ministry of Health of Russia]. Klinicheskie rekomendacii: Tuberkulez u vzroslyh [Clinical recommendations: Tuberculosis in adults]. 2024. (In Russ.) Режим доступа [URL]: https://obolezny.online/2024/06/26/klinicheskie-rekomendaczii-tuberkulez-u-vzroslyh-2024
3. Wang Y, Zhang R, Lee S. Surgical outcomes and predictors of post-TB lung disease: a cohort study. International Journal of Tuberculosis and Lung Disease. 2024; 28(3): 177–183. DOI: 10.5588/ijtld.24.0123
4. Riskiyev A, Ciobanu A, Hovhannesyan A, et al. Characteristics and Treatment Outcomes of Patients with Tuberculosis Receiving Adjunctive Surgery in Uzbekistan. Int J Environ Res Public Health. 2021; 18(12): 6541. DOI: 10.3390/ijerph18126541
5. Склюев С. В., Петренко Т.И. Эффективность установки эндобронхиального клапана при комплексной терапии больных неэффективно леченным деструктивным инфильтративным туберкулёзом лёгких // Туберкулез и болезни легких. – 2013. – Т. 90, № 7. – С.11-15. Skliuev, SV, Petrenko TI. Effektivnost’ ustanovki endobronhial’nogo klapana pri kompleksnoj terapii bol’nyh neeffektivno lechennym destruktivnym infil’trativnym tuberkulyozom lyogkih [The effectiveness of endobronchial valve installation in the complex therapy of patients with inefficiently treated destructive infiltrative pulmonary tuberculosis]. Tuberkulez i bolezni legkih [Tuberculosis and lung diseases]. 2013; 90(7): 11-15. (In Russ.) Режим доступа [URL]: https://elibrary.ru/download/elibrary_20658840_71972176.pdf
6. Романова М.И., Гайда А.И., Абрамченко А.В., [и др.] Эффективность хирургического лечения больных деструктивным туберкулезом легких (метаанализ). Туберкулез и болезни легких. – 2024. – Т. 102, вып. 2. – С.52-61. Romanova MI, Gayda AI, Abramchenko AV, et al. Effektivnost’ khirurgicheskogo lecheniya bol’nykh destruktivnym tuberkulezom legkikh (metaanaliz) [Effectiveness of surgical treatment of patients with destructive pulmonary tuberculosis (meta-analysis)]. Tuberkulez i bolezni legkikh [Tuberculosis and Lung Diseases]. 2024; 102 (2): 52–61. (In Russ.) DOI: 10.58838/2075-1230-2024-102-2-52-61
7. Суздальницкий А.Е., Петров С.И., Петухов В.П., [и др.]. Ближайшие и отдаленные результаты хирургического лечения туберкулеза у пациентов с ВИЧ-инфекцией // Туберкулез и болезни легких – 2021 – Т.99, вып. 5. – С.43-50. Suzdalnitskiy AE, Petrov SI, Petukhov VP, et al. Blizhajshie i otdalennye rezul’taty hirurgicheskogo lecheniya tuberkuleza u pacientov s VICh-infekciej [Immediate and postponed results of surgery of tuberculosis in patients with HIV infection]. Tuberkulez i bolezni legkih [Tuberculosis and Lung Diseases]. 2021; 99(5): 43-50. (In Russ.) DOI: 10.21292/2075-1230-2021-99-5-43-50.
8. Рогожкин П.В., Бородулина Е.А., Пискун В.В., Еременко. Е.П. Хирургическое лечение туберкулеза у ВИЧ-инфицированных пациентов // Новости хирургии. – Т 30, № 2. – с. 207-213. Rogozhkin PV, Borodulina EA, Piskun VV, Eremenko. EP. Hirurgicheskoe lechenie tuberkuleza u VICh-inficirovannyh pacientov [Surgical treatment of tuberculosis in HIV-infected patients]. Novosti hirurgii [Surgery News]. 30(2): 207-213. (In Russ)
9. Рогожкин П.В., Колсанов А.В., Бородулина Е.А. Хирургическое лечение больных туберкулезом легких в XXI веке. Хирургия. Журнал им. Н.И. Пирогова. – 2020. – Т. 6. – С.104-108. Rogozhkin PV, Kolsanov AV, Borodulina EA. Hirurgicheskoe lechenie bol’nyh tuberkulezom legkih v XXI veke [Surgical treatment of pulmonary tuberculosis]. Hirurgiya; Zhurnal imeni NI Pirogova [Pirogov Russian Journal of Surgery]. 2020; 6: 104-108. (In Russ.) DOI: 10.17116/hirurgia2020061104
10. Krasnov DV, Skliuev SV, Petrova YaK, et al. Modern Collapse Therapy for Pulmonary Tuberculosis. Thoracic Surgery Clinics. 2019; 29 (1): 47-58. DOI: 10.1016/j.thorsurg.2018.09.005
11. Гиллер Д.Б., Глотов А.А., Кесаев О.Ш., [и др.]. Пневмонэктомия в лечении рецидивов туберкулеза в резецированном легком. Вестник хирургии имени И.И. Грекова. – 2020. Т. 179, вып. 2. – С.11-19. Giller DB, Glotov AA, Kesaev OSh, et al. Pnevmonektomiya v lechenii recidivov tuberkuleza v rezecirovannom legkom [Pneumonectomy in the treatment of tuberculosis relapse in a previously resected lung]. Vestnik hirurgii imeni I.I. Grekova [Grekov’s Bulletin of Surgery]. 2020; 179 (2): 11-19. (In Russ.) DOI: 10.24884/0042-4625-2020-179-2-11-19
DURING THE IMPOSING OF THE NUMBER
УДК: 613.95:612.017.2 DOI: 10.20969/VSKM.2026.19(2).158-165
Health status of children during their adaptation to the microsocial conditions of educational institutions
Qahramon M. Yusupov1, Abdurayim Sh. Arzikulov1, Maria A. Daminova2, Maxpora M. Mirzaeva1, Dilnoza A. Melieva1, Zemfira B. Khafizova1
1 Andijan State Medical Institute, 1 Atabekov str., 170100 Andijan, Uzbekistan
2 Institute of Biology and Fundamental Medicine, Kazan Federal University, 74 Karl Marx str., 420012 Kazan, Russia
Abstract. Introduction. Currently, the problem of diagnosing health disorders in children during their adaptation to the microsocial conditions of educational institutions (preschool and general education organizations) has evolved into a fundamental multidisciplinary field. It is at the intersection of clinical pediatrics, developmental physiology, child and adolescent hygiene, and educational psychology. Aim. To determine the age-specific clinical manifestations of adaptation syndrome and develop diagnostic criteria for adaptation disorders in children upon their admission to cooperative education institutions. Material and Methods. The study involved 299 children divided into three groups: 109 infants and toddlers (aged 7 months to 3 years), 85 preschool children (aged 4–7 years), and 105 primary school students (aged 7 years). The children were examined prior to their being admitted, throughout their entire adaptation period, and one year after its completion. The following health indicators were analyzed: Physical development; neuropsychological development (using the Rostock test for infants/toddlers, the L.A. Wenger and V.V. Kholmovskaya method for preschoolers, and an adapted Wechsler Intelligence Scale for first graders); morbidity rates based on medical consultations and individual analyses; neuropsychiatric health status based on pediatric psychiatric consultations and parental surveys; and a comprehensive health assessment. Results and Discussion. First graders’ school adaptation period was accompanied by more significant changes in neuropsychiatric health compared to the younger age groups. Neurotic reactions were characterized by polymorphic clinical symptoms and were recorded in 74 of 105 first graders (70.4 %). Notably, no single form of disorder was dominant. Asthenic manifestations were diagnosed most frequently (53.3%). Hyperdynamic syndrome was observed in 41 students (39%), characterized by motor restlessness, fidgeting, and episodic aggressiveness. Conclusions. We were the first in the pediatric practice of Central Asia to determine the age-specific features of the adaptation syndrome patterns in relation to children’s health status through a multidisciplinary medical and pedagogical approach. The study identified the predominant forms of adaptation disorders for various age periods and established clinical criteria for diagnosing them in children entering new social environments.
Keywords: adaptation, children, morbidity, health, school, school-related diseases.
For citation: Yusupov, Q.M.; Arzikulov, A.Sh.; Daminova, M.A.; et al. Health status of children during their adaptation to the microsocial conditions of educational institutions. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (2), 158-165. DOI: 10.20969/VSKM.2026.19(2).158-165.
REFERENCES
1. Pshenichnikova II, Shkolnikova MA, Zaharova IN, Tvorogova TM. Adaptation of children to studying in various institutions: the influence of vegetative homeostasis and personal adaptive resources. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2018; 63 (5): 81-91. (In Russ.) DOI: 10.21508/1027-4065-2018-63-5-81-91
2. Кучма В. Р. Медико-профилактические основы достижения ожидаемых результатов мероприятий десятилетия детства на период до 2027 года // Вопросы школьной и университетской медицины и здоровья. – 2021. - № 1. – С.11–23. Kuchma VR. Mediko-profilakticheskiye osnovy dostizheniya ozhidayemykh rezul’tatov meropriyatiy desyatiletiya detstva na period do 2027 goda [Medical and preventive foundations for achieving the expected results of the activities of the Decade of Childhood for the period up to 2027]. Voprosy shkol’noy i universitetskoy meditsiny i zdorov’ya [Issues of school and university medicine and health]. 2021; 1: 11–23. (In Russ.) URL: http://schoolshealth.ru/docs/1-2021/KuchmaVR_1_2021_11-23.pdf
3. WHO. Noncommunicable diseases. 2025. URL: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
4. Красникова Т.В. Адаптация младших школьников в школе: факторы, уровни, показатели, этапы. – Ялта: Крымский федеральный университет имени В.И. Вернадского, 2020. – №68-2. – С. 434-437. Krasnikova TV. Adaptatsiya mladshikh shkol’nikov v shkole: faktory, urovni, pokazateli, etapy [Adaptation of primary school students at school: factors, levels, indicators, stages]. Yalta: Krymskiy federal’nyy universitet imeni VI Vernadskogo [Yalta: Crimean Federal University named after VI Vernadsky]. 2020; 68-2: 434-437. (In Russ.)
5. Кривичева Ю.В., Ткаченко И.В. Психическое развитие младшего школьника как фактор успешной адаптации к школьному обучению. – Армавир: АГПУ, 2022. – №22. – С. 70-75. Krivicheva YuV, Tkachenko IV. Psikhicheskoye razvitiye mladshego shkol’nika kak faktor uspeshnoy adaptatsii k shkol’nomu obucheniyu [Mental development of primary school students as a factor in successful adaptation to school education]. Armavir: AGPU [Armavir: ASPU]. 2022; 22: 70-75. (In Russ.)
6. Álvarez-García D, Núñez Pérez JC, Dobarro González A, Pérez CR. Risk factors associated with cybervictimization in adolescence. International Journal of Clinical and Health Psychology. 2015; 15(3): 226–235. DOI: 10.1016/j.ijchp.2015.03.002
7. Editorial. Growing up in a digital world: benefits and risks. The Lancet Child & Adolescent Health. 2018; 2 (2): 79. DOI: 10.1016/S2352-4642(18)30002-6 URL: https://www.thelancet.com/action/showPdf?pii=S2352-4642%2818%2930002-6
8. Miller DP, Chang J. Parental Work Schedules and Child Overweight or Obesity: Does Family Structure Matter? J Marriage Fam. 2015; 77: 1266-1281. DOI: 10.1111/jomf.12215
9. WHO child growth standards and the identification of severe acute malnutrition in infants and children: A Joint Statement. World Health Organization: United Nations Children’s Fund. 2009; 11 p. URL: https://www.who.int/publications/i/item/9789241598163
10. Табачкова А.С. Распространенность заболеваний желудочно-кишечного тракта среди школьников // Социосфера. – 2021. – № 2. – С.98-102. Tabachkova AS. Rasprostranennost’ zabolevaniy zheludochno-kishechnogo trakta sredi shkol’nikov [Prevalence of gastrointestinal diseases among schoolchildren]. Sotsiosfera [Sociosphere]. 2021; 2: 98–102. (In Russ.)
11. Сетко Н.П. Современные подходы к оценке напряжённости учебного процесса в образовательных учреждениях различного типа // Оренбургский медицинский вестник. – 2018. – Т. VI. – № 2 (22). – С. 47–52. Setko NP. Sovremennyye podkhody k otsenke napryazhennosti uchebnogo protsessa v obrazovatel’nykh uchrezhdeniyakh razlichnogo tipa [Modern approaches to assessing the intensity of the educational process in educational institutions of various types]. Orenburgskiy meditsinskiy vestnik [Orenburg Medical Bulletin]. 2018; VI, 2 (22): 47-52. (In Russ.)
12. Баховиддинова З.М., Сахибова М.Д. Экологические факторы риска и состояние здоровья детей // Экономика и социум. – 2024. – № 3-2 (118). – С.541-546. Bakhoviddinova ZM, Sakhibova MD. Ekologicheskiye faktory riska i sostoyaniye zdorov’ya detey [Environmental risk factors and children’s health]. Ekonomika i sotsium [Economy and Society]. 2024; 3-2 (118): 541-546. (In Russ.)
13. Колягин В.В. Задержки психического развития, пограничные формы интеллектуальной недостаточности // Научное обозрение. Медицинские науки. – 2022. – № 3. – С.52-59. Kolyagin VV. Zaderzhki psikhicheskogo razvitiya, pogranichnyye formy moyey intellektual’noy dostatochnosti [Mental retardation, borderline forms of intellectual disability]. Nauchnoye obozreniye: Meditsinskaya nauka [Scientific Review: Medical Sciences]. 2022; 3: 52-59. (In Russ.)
14. Соколова, С.Б. Распространённость поведенческих факторов риска, определяющих здоровье среди обучающихся 7-8 и 10-11 классов города Москвы // Здоровье населения и среда обитания. – 2018. – № 8 (305). – С. 4–10. Sokolova SB. Rasprostranennost povedencheskikh faktorov riska, opredelyayushchikh zdorov’ye, sredi obuchayushchikhsya 7-8 i 10-11 klassov goroda Moskva [Prevalence of behavioral risk factors determining health among students in grades 7-8 and 10-11 in Moscow]. Zdorov’ye naseleniya i sreda obitaniya [Population health and habitat]. 2018; 8 (305): 4-10. (In Russ.)
15. Lu W. Adolescent Depression: National Trends, Risk Factors, and Healthcare Disparities. Am J Health Behav. 2019 Jan 1;43(1):181-194. DOI: 10.5993/AJHB.43.1.15
16. Комплект диагностических методик для психодиагностики детей, имеющих особенности развития : учебно-метод. пособие / сост. : Н. А. Разнадежина, Н. Н. Семенова. – Сургут : Изд-во бюджетного учреждения Ханты-Мансийского автономного округа – Югры «Методический центр развития социального обслуживания», 2017. – 44 с.
17. Raznadezhina NA, Semenova NN. Komplekt diagnosticheskikh metodik dlya psikhodiagnostiki detey, imeyushchikh osobennosti razvitiya: uchebno-metodicheskoe posobiye [A set of diagnostic methods for psychodiagnostics of children with special needs: a teaching aid]. Surgut: Izdatelstvo byudzhetnogo uchrezhdeniya Khanty-Mansiyskogo avtonomnogo okruga – Yugry «Metodicheskiy tsentr razvitiya sotsial’nogo obsluzhivaniya» [Surgut: Publishing house of the budgetary institution of the Khanty-Mansi Autonomous Okrug - Yugra “Methodological Center for the Development of Social Services»]. 2017; 44 p. (In Russ.)
18. Храмцов П.И. Физиолого-гигиенические предпосылки повышения здоровье-формирующей эффективности физического воспитания детей в образовательных организациях // Вопросы школьной и университетской медицины и здоровья. – 2017. – № 4. – С.15–20. Khramtsov PI. Fiziologo - gigiyenicheskiye predposylki povysheniya zdorov’ye-formiruyushchey effektivnosti fizicheskogo vospitaniya detey v obrazovatel’nykh organizatsiyakh [Physiological and hygienic prerequisites for increasing the health-forming effectiveness of physical education of children in educational organizations]. Voprosy shkol’noy i universitetskoy meditsiny i zdorov’ya [Issues of school and university medicine and health]. 2017; 4: 15–20. (In Russ.)







